Cancer incidence and mortality in Western Australia, 2009

A report of the Western Australian Cancer Registry

Data Collection and Analysis, Statutory & Non-Admitted Branch,
Data Integrity Directorate, Performance Activity & Quality Division
Department of Health
Perth, Western Australia

August 2011

Statistical Series Number 91

ISSN: 0816-2999

© 2011 Performance, Activity & Quality Division, Department of Health, Western Australia

Material in this publication may be reproduced and used, with acknowledgment, for genuine educational and health research purposes.

To ensure ongoing accuracy and proper context, it is recommended that electronic retrieval systems store only links to the original source rather than copies.

Contact regarding enquiries and additional information:

Principal Medical Officer/Manager Western Australian Cancer Registry Department of Health 1st Floor, C Block 189 Royal St East Perth WA 6004 AUSTRALIA

Fax: +61 (0)8 9222 4236 Phone: +61 (0)8 9222 4022

E-mail - wacanreg@health.wa.gov.au

(No "spam" or commercial offers; cancer-related enquiries only please.)

Internet - Department of Health home page

www.health.wa.gov.au

- Western Australian Cancer Registry home page - www.health.wa.gov.au/wacr/home

Cancer Registry Staff, 2004-2011

Timothy Threlfall Principal medical officer/ John Langley Analyst/programmer

Manager

Judith Thompson Medical officer/ Cathy Johnston Data quality officer coding advisor Colleen Kontor Data quality officer

coding advisor Colleen Kontor Data quality office

Data quality officer Nola Olsen Research officer

Charmaine Brewster Data quality officer

Citation

Kaye Garrod

The following citation is suggested in referring to this report:

Threlfall TJ, Thompson JR (2010). *Cancer incidence and mortality in Western Australia, 2009.* Department of Health, Western Australia, Perth. Statistical Series Number 91.

Contents

_			Page
Lis [°]		es for sections 1-3 es for sections 1-3	i ii ii iii
	knowledg	ments	iv
1	Overvie	w and Methods	1
	1.1	Overview	1
	1.2	General structure; how to find information	1
	1.3	Interpretation	1
	1.4	Methods	2
2	Cancer	in Western Australia, 2009	3
	2.1	All cancers	3
	2.2	Common cancers	4
	2.3	Cancer in different age groups	6
	2.4	Cancer trends and projections	11
3	Cancer	in Western Australia: Data and technical issues	13
	3.1	Basis of diagnosis	13
	3.2	Death Certificate and Hospital Morbidity Data System cases	13
	3.3	Registry enquiries	14
	3.4	"Non-counted" cancers	14
	3.5	Non-invasive neoplasms recorded	15
4	Referen	ices and list of Appendices	16
ΔΕ	PENDI	CES (list also on page 16)	
<i>,</i>		ut The Western Australian Cancer Registry	
	1A	Overview and technical issues	A1-1
	1B 2 Tech	Current issues nical and miscellaneous information	A1-6
	2 Teci	Glossary	A2-1
	2B	Statistical methods and formulae	A2-2
	2C	Populations and geographic areas	A2-4
	2D 2E	Confidentiality guidelines Cancer Notification Regulations	A2-6 A2-7
	2F	Cancer codes	A2-7
	2G	WACR publications	A2-11
	2H	Guide to tables in Appendix 3	A2-12
		cer incidence and mortality in Western Australia, 2007	40.4
	3A	Cancer incidence, Western Australia, 2009: numbers and rates by type, sex and age group	A3-1
	3B	Cancer mortality, Western Australia, 2009: numbers and rates by type, sex and age group	A3-11
	3C	Childhood cancer incidence, Western Australia, 2009: ICD-O 3rd Revision classification scheme	A3-21
	3D	Cancer incidence, Western Australia, 2009: leading types by sex and geographic area	A3-25
	3E	Cancer mortality, Western Australia, 2009: leading types by sex and geographic area	A3-30

Lis	t of tables	Page
1.	Cancer incidence and mortality, WA, 2009: leading types in males and females	5
2.	Cancer incidence, WA, 2009: leading types by sex and age group	9
3.	Cancer mortality, WA, 2009: leading types by sex and age group	10
4.	Trends and projections, all cancers and two most-common cancers, Western Australia, 2000-2019	12
5.	Cancer in Western Australia, 2009: Diagnosis methods	13
6.	Non-invasive neoplasms recorded in WA Cancer Registry, 2009	15
Lis	t of figures	Page
1	Cancer incidence, WA, 2009: common cancers	4
2	Cancer mortality, WA, 2009: common cancers	4
3	Cancer incidence, WA, 2009: common cancers in the 15 to 39 years age group	6
4	Cancer mortality, WA, 2009: common cancers in the 15 to 39 years age group	6
5	Cancer incidence, WA, 2009: common cancers in the 40 to 64 years age group	7
6	Cancer mortality, WA, 2009: common cancers in the 40 to 64 years age group	7
7	Cancer incidence, WA, 2009: common cancers in the 65 years & over age group	8
8	Cancer mortality, WA, 2009: common cancers in the 65 years & over age group	8
9	Death Certificate Only (DCO) and "DC & HMDS" cancers 2009: common types	13
10	Unresolved case enquiries - most common cancer types, 2009	14
11	"Non-counted" cancers 2009: common types	15

Summary - Cancer incidence and mortality in Western Australia, 2009

The Western Australian Cancer Registry has provided population-based cancer data since 1982 for use in the planning of health care services and the support of cancer-related research, at local, national and international levels. Most of this report is concerned with invasive tumours, or "cancers", using standardised reporting practices as used in other cancer registries in Australia and overseas. This report deals primarily with cancer incidence and cancer-related mortality in Western Australian residents, who comprise approximately 10% of the Australian population.

There were 10805 new cases of cancer recorded in Western Australians in 2009, 6291 (58%) occurring in males and 4514 in females. Age-standardised incidence rates were 378 per 100,000 males, and 264 per 100,000 females. The estimated lifetime risk of cancer to age 75 years was 1 in 3 for males, and 1 in 4 for females.

The most common cancers in males in 2009 were prostate and colorectal cancers, melanoma and lung cancer, while breast cancer predominated among females, followed by colorectal cancer, melanoma and lung cancer, patterns relatively stable in recent years.

Trend analysis based on the last ten years shows a continuing significant increase in the rate of prostate cancer in males (5.4% a year) but little change in colorectal, melanoma or lung cancer. In females, while annual incidence of breast cancer has declined slightly, a significant increase in lung cancer continues at an average of over 4% a year.

Among Western Australian residents, there were 3862 deaths due to cancer in 2009, 2158 in males and 1704 in females. All-cancers mortality rates for 2009 were 117 deaths per 100,000 males (similar to 2008) and 84 per 100,000 females (slightly increased). As usual in recent years, the most common causes of cancer-related death in males were lung, colorectal and prostate cancers, while lung, breast and colorectal cancers were the most common in females.

There were 61 children under the age of 15 years diagnosed with cancer in 2009 (ASR 18 per 100,000 in males and 11 in females), as well as a small number with other cancer-like conditions. There were 3 more cases than in 2008, but cancer at this age is a rare disease and annual variation in numbers and types is considerable.

Melanoma of the skin was - as in most years since 1982 - the most common cancer in males in the 15-39 years age range, however in 2008, melanoma was less common than breast cancer in females in the same age group. In persons over the age of 40 years, prostate and breast cancers, melanoma, colorectal and lung cancers, remain the most common incident cancers.

Based on 2009 data, one in 7 men would be expected to have a diagnosis of prostate cancer before the age of 75, and one in 11 women could be expected to develop breast cancer. One in 115 men could be expected to die from prostate cancer before age 75, and one in 66 women to die from breast cancer. However, as in recent years, lung cancer was the most common cause of cancer-related death for both males and females, killing one in 32 males and one in 53 females before age 75.

Acknowledgments

This report is based on data recorded and maintained by the staff of the Western Australian Cancer Registry, whose dedication and attention to detail are much appreciated.

We also wish to acknowledge the invaluable contribution of the Western Australian pathologists, haematologists and radiation oncologists who supply the vast majority of the Registry's primary notifications, and the health professionals and organisations who supply additional information in response to our enquiries.

The cooperation of other Australian Cancer Registries regarding procedures, coding, duplication and demarcation issues, and of staff of the Australian Cancer Database at AIHW, Canberra, is acknowledged as playing a vital part in ensuring data quality and comparability.

The Registry relies on a variety of supporting services in order to produce reports on cancer; these include population figures and projections, mapping, hospitalisation data, legal advice, computing services and general support and encouragement

1 Overview and Methods

1.1 This Report

Overview

This is the latest in this Registry's series of annual reports, and is devoted largely to Western Australian cancer incidence and mortality for 2009. The new report contains less commentary and interpretation, and less technical information and coverage of "special topics", than in the past, in the interest of producing a more timely publication. It is anticipated that more detailed discussion of particular issues will continue to be made available in other reports as the opportunity arises.

The Western Australian Cancer Registry (WACR) is a population-based cancer registry established in 1981, operating within the Department of Health (Western Australia). The main information sources are reports from pathologists, haematologists and radiation oncologists, supplemented by death registrations, hospital statistical discharge data systems, and information from hospital files and responses to enquiries directed at treating medical practitioners.

The WACR has acted with the delegated authority of the Executive Director of Public Health with respect to the Health (Notification of Cancer) Regulations 1981, until the commencement of the new Health (Western Australian Cancer Register) Regulations 2011 on 10 June 2011. These Regulations require the notification of *in situ* neoplasms and all non-melanoma skin cancers other than basal cell and squamous cell carcinomas, and all other invasive malignancies and benign CNS tumours, as well as a range of other neoplasms(see Appendix 2E). The new Regulations and a summary of changes can be seen at

http://www.health.wa.gov.au/wacr/home/regulations.cfm

1.2 General structure; how to find information

The major sections are based on cancers diagnosed, and deaths due to cancer, in 2009.

- Data for most common cancers are presented under headings based on incidence, mortality and age,
- Data for selected geographic areas are presented in Appendices 3D and 3E.
- Detailed data for all cancers for 2009 are found in the tables of Appendices 3A and 3B. The layout of those tables follows the coding system summarised in material available at www.health.wa.gov.au/wacr/home.

Readers seeking detailed information for particular cancers not shown in tables, should contact the Registry for further information.

Information from this report, and other WACR information, is available at -

http://www.health.wa.gov.au/wacr/statistics/stats_full.cfm

1.3 Interpretation

Western Australia is particularly polarised into metropolitan and rural areas, with huge differences in population density and there are likely to be some statistical biases due to the difficulties of transport and the location of services within the State. Throughout this report, readers should be aware that assessing the relevance of changes in cancer incidence and mortality is complex and depends on the underlying population sizes and their age structures. Caution is required in assessing changes on the basis of single rate comparisons.

The Cancer Registry database is continually updated in the light of the most recent available information. Accordingly, numbers in this report for earlier years may vary slightly from those in previous publications, as some Western Australian cases are found to have been diagnosed elsewhere, or in earlier years, and case-counts necessarily rise and fall as new information arrives. Mortality information, in particular, often sheds new light on a person's cancer history.

As a guide, while total cancers for 2008 were quoted at 10408 in our previous report,¹ the total currently recorded for 2008 is 10536, an increase of about 1.2%. Mortality data are much more stable, but the benefits of more timely incidence reporting must be weighed against the apparent stability of the data as time passes.

1.4 Methods

Statistics from the Registry commonly fall into one of two major groups: **incidence** is reported for all malignancies except primary squamous cell and basal cell skin cancers (SCC and BCC), and **mortality** for all malignancies and certain other tumours or tumour-like conditions. The usual statistics calculated for both types of report are briefly discussed below; formulae and relevant details are in Appendix 2B.

Rates are calculated separately for males and females, expressed as events (diagnoses or deaths) per 100,000 person-years:

Age-specific rates (ASPR) are based on five-year age groups and are calculated by dividing the numbers of cases by the population of the same sex and age group. Whole-population data come from the ABS and indigenous data from the Epidemiology Branch. Age-standardised rates (ASR in Tables) are calculated by the direct method, as a summation of weighted age-specific rates. Tables show the 95% confidence interval (c.i.) for ASRs. When a subset of age groups (e.g. 15-39 years) is considered, the term age-adjusted rate is used instead of ASR.

The World Standard Population 1960² remains in routine use for ASR calculation, as in most cancer registries worldwide. However in some tables a second ASR and 95% c.i. are shown, using the Australian (2001)³ population standard, labelled "ASR2". These ASRs are usually quite different, and comparisons need to take note of which "standard" is being used.

Cumulative Incidence and Lifetime Risk are closely related. Cumulative incidence is an estimate of the proportion of persons, up to a specific age, who have been affected by a particular condition at some time. In Registry reports, this is expressed as a percentage.

Lifetime risk (LR) estimates the probability of having cancer (incidence) or dying of it (mortality), up to a specific age. This is derived from the relevant cumulative incidence figures, and calculated for ages 0 to 74 years (see Appendix 2B for formulae).

In this report, LR is expressed as a "1 in n" chance of diagnosis or death. As indicated in relevant tables, a "-" is used to indicate a lack of data (no cases), and a "*" to indicate no data for cases under 75 years of age, or a "risk" smaller than 1 in 10,000.

Person years of life lost (PYLL) is an estimate of the number of years of life lost due to specific causes, calculated to age 75 years; an index of premature death (see Appendix 2B).

Rates and risks: It should be noted that incidence and mortality rates and lifetime risks may not be in proportion to one another because of differences in the age structures of populations.

2. Cancer in Western Australia, 2009

2.1 All cancers

2.1.1 Incidence

In 2009, there were 10805 new diagnoses of cancer in Western Australia, 4% more than in 2008, however the all-cancers age-standardized rates, indicating risk, were increased by only 1.7% in males, and 0.7% in females. There were 6291 cancers diagnosed in males (ASR 378 per 100,000) and 4514 in females (ASR 264) (Table 1) These increased rates were not statistically-significant.

The estimated lifetime risk of cancer to age 75 years was 1 in 3 for males and 1 in 4 for females; the cumulative incidence of cancer (the proportion of persons in whom cancer had been diagnosed by age 75) was 45% for males and 29% for females. These measures are essentially un changed in recent years.

Cancer is generally more common in females than in males between ages 25 and 50 (mainly ovarian and breast cancers), but prostate cancer and lung cancer account for much of a male predominance in older ages.

The differences in cancer incidence rates across the age range can be seen for individual cancers and all cancers combined, in Appendix 3A.

2.1.2 Mortality

Among Western Australian residents in 2009 there were 3862 due to cancer (2158 in males, 1704 in females) (Table 1). Mortality ASRs were 117 deaths per 100,000 males and 84 per 100,000 females (unchanged in males, slightly increased in females). The estimated lifetime risk of death due to cancer before age 75 years was 1 in 8 for males and 1 in 11 for females. There was no significant change in the age-pattern of cancer mortality in 2009. Cancer death rates generally increased for both males and females from age 20. All-cancers death rates among males were consistently higher than in females at ages greater than 50 years.

These cancer deaths include 59 deaths due to non-melanocytic skin cancers, 72% of them in males. 44 (75%) of these were due to squamous or basal cell carcinomas, types that are not included in "cancer" incidence statistics. The annual number of non-melanoma skin-cancer related deaths continues to increase.

Other deaths that are not counted in these "cancer" mortality statistics include -

- 30 cancer-related deaths in persons not normally resident in Western Australia (19 Australian, 11 from overseas)
- 6 deaths due to benign tumours (all CNS tumours)
- 1 death due to "uncertain malignant potential" lymphohaematopoietic neoplasms
- 3 deaths due to "uncertain malignant potential" non-lymphohaematopoietic neoplasms 1767 deaths due to **non**-tumour-related causes among persons with a Registry tumour record (978 males, 789 females)
- 44 deaths of unresolved cause among persons with a tumour record (pending outcome of coronial investigations).


2.2 Common cancers - Incidence and Mortality

The most common incident cancer types in males and females are shown in summary form in Figure 1, with the detailed statistics in Table 1. There has been no recent change in the distribution of the most common types of cancer. Numbers and rates of breast and prostate cancers were both slightly reduced from 2008 levels but differences were not statistically significant.

For further breakdown by age group, and including the less common cancer types, see Appendix 3A; for incidence statistics from different Regions within W.A. see Appendix 3D.

Figure 1. Cancer incidence, Western Australia, 2009: common cancers

Males (6291) Females (4514)



The cancers most commonly causing mortality are shown in summary form in Figure 2, with the detailed statistics in Table 1. There have been only minor differences in the relative impact of these most common types in recent years. In females, lung cancer now Lung cancer has been the leading cause of cancer-related death in males for many years, and now appears firmly established as a more frequent cause of mortality in women than breast cancer.

For further breakdown by age group, and including the less common cancer types, see Appendix 3B; for mortality statistics from different Regions within W.A. see Appendix 3E.

Figure 2. Cancer mortality, Western Australia, 2009: common cancers




Table 1. Cancer incidence and mortality, Western Australia, 2009: leading types in males and females

Incidence											
Males	Coooo	%	ASR	05% a i	Diele	Females	Cases	%	ASR	OE9/ a i	Risk
Prostate	Cases 2030	32.3	121.4	95%c.i. 116-127	Risk 7	Breast		29.1		95%c.i. 77.1-86.3	11
Colorectal	739	11.7	43.2	40.0-46.4	20	Colorectal	1313 545	12.1	81.7 28.8	26.2-31.4	30
Colon	471	7.5	26.7	24.2-29.2	32	Colon	379	8.4	19.3	17.2-21.4	44
Rectum	266	4.2	16.3	14.3-18.3	50	Rectum	165	3.7	9.5	8.0-11.0	92
Melanoma (skin)	643	10.2	39.6	36.5-42.7	21	Melanoma (skin)	400	8.9	24.8	22.3-27.4	40
Lung	583	9.3	32.9	30.1-35.6	25	Lung	393	8.7	20.5	18.3-22.7	40
Lymphoma	255	4.1	16.2	14.1-18.3	59	Uterus	176	3.9	10.5	8.9-12.1	75
Lymphoma NOS	10	0.2	0.7	0.2-1.2	1370	Lymphoma	172	3.8	9.8	8.2-11.4	95
Hodgkin lymphoma	33	0.5	2.7	1.8-3.7	501	Lymphoma NOS	4	0.1	0.1	0.0-0.2	*
NHL	212	3.4	12.8	11.0-14.5	71	Hodgkin lymphoma	20	0.4	1.7	0.9-2.5	690
Bladder & urinary tract	191	3.0	10.4	8.9-11.9	90	NHL	148	3.3	8.0	6.6-9.4	110
Kidney	183	2.9	11.4	9.7-13.2	75	Thyroid gland	159	3.5	11.6	9.7-13.4	86
Leukaemia	169	2.7	11.6	9.7-13.4	82	Pancreas	131	2.9	6.5	5.3-7.7	140
Leukaemia NOS	5	0.1	0.2	0.0-0.4	6335	Ovary	117	2.6	7.3	5.9-8.7	116
Lymphoid leukaemia	91	1.4	6.8	5.3-8.3	127	Unknown primary	115	2.5	5.0	3.9-6.0	205
Myeloid leukaemia	73	1.2	4.6	3.5-5.7	238	Leukaemia	110	2.4	7.0	5.5-8.5	160
Leukaemia, other	0	2.0		0404	400	Leukaemia NOS	1	0.0	0.1	0 - 0.2	6593
Unknown primary Pancreas	138 128	2.2 2.0	7.7 7.3	6.4-9.1 6.0-8.6	133 127	Lymphoid leukaemia Myeloid leukaemia	61 48	1.4 1.1	3.9 3.0	2.8-5.1 2.0-3.9	287 383
Stomach	120	1.9	7.3 6.8	5.6-8.1	130	Leukaemia, other	40	1.1	3.0	2.0-3.9	303
Lip, gum & mouth	102	1.6	6.5	5.2-7.7	152	Kidney	93	2.1	5.8	4.6-7.1	157
Oesophagus	88	1.4	5.1	4.0-6.2	161	Cervix	92	2.0	6.7	5.3-8.0	160
Brain	85	1.4	5.8	4.5-7.1	178	Bladder & urinary tract	77	1.7	3.5	2.6-4.3	272
Mesothelioma	81	1.3	4.7	3.6-5.7	160	Brain	72	1.6	4.8	3.6-6.1	218
Liver	76	1.2	4.7	3.6-5.8	178	Myeloma	62	1.4	3.0	2.2-3.9	306
Testis	72	1.1	5.7	4.3-7.0	226	Stomach	46	1.0	2.5	1.7-3.2	351
Myeloma	70	1.1	4.0	3.0-4.9	206	Lip, gum & mouth	43	1.0	2.6	1.8-3.5	355
Pharynx	68	1.1	4.3	3.3-5.3	199	Oesophagus	38	0.8	1.7	1.1-2.2	680
Thyroid gland	64	1.0	4.3	3.2-5.3	234	Liver	33	0.7	1.9	1.2-2.7	508
Skin (NMSC exc. SCC/BCC)	47	0.7	2.6	1.8-3.4	399	Gallbladder / bile ducts	33	0.7	1.7	1.0-2.3	512
All cancers	6291	100.0	378.2	369-388	3	All cancers	4514	100.0	264.5	256-273	4
Mortality											
Mortality Males						Females					
Males	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Males	483	22.4	26.5	24.0-28.9	Risk 32	Lung	320	18.8	16.2	14.3-18.1	53
Males Lung Prostate	483 255	22.4 11.8	26.5 12.1	24.0-28.9 10.5-13.6	Risk 32 115	Lung Breast	320 248	18.8 14.6	16.2 13.7	14.3-18.1 11.8-15.5	53 66
Males Lung Prostate Colorectal	483 255 228	22.4 11.8 10.6	26.5 12.1 12.5	24.0-28.9 10.5-13.6 10.8-14.2	Risk 32 115 73	Lung Breast Colorectal	320 248 209	18.8 14.6 12.3	16.2 13.7 10.1	14.3-18.1 11.8-15.5 8.6-11.6	53 66 90
Males Lung Prostate Colorectal Colon	483 255 228 146	22.4 11.8 10.6 6.8	26.5 12.1 12.5 7.8	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1	Risk 32 115 73 124	Lung Breast Colorectal Colon	320 248 209 154	18.8 14.6 12.3 9.0	16.2 13.7 10.1 7.3	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6	53 66 90 131
Males Lung Prostate Colorectal Colon Rectum	483 255 228 146 82	22.4 11.8 10.6 6.8 3.8	26.5 12.1 12.5 7.8 4.7	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8	Risk 32 115 73 124 178	Lung Breast Colorectal Colon Rectum	320 248 209 154 55	18.8 14.6 12.3 9.0 3.2	16.2 13.7 10.1 7.3 2.8	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6	53 66 90 131 283
Males Lung Prostate Colorectal Colon Rectum Pancreas	483 255 228 146 82 92	22.4 11.8 10.6 6.8 3.8 4.3	26.5 12.1 12.5 7.8 4.7 5.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2	Risk 32 115 73 124 178 172	Lung Breast Colorectal Colon Rectum Pancreas	320 248 209 154 55 112	18.8 14.6 12.3 9.0 3.2 6.6	16.2 13.7 10.1 7.3 2.8 5.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1	53 66 90 131 283 186
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin)	483 255 228 146 82 92 89	22.4 11.8 10.6 6.8 3.8 4.3 4.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0	Risk 32 115 73 124 178 172 190	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary	320 248 209 154 55 112 94	18.8 14.6 12.3 9.0 3.2 6.6 5.5	16.2 13.7 10.1 7.3 2.8 5.1 4.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9	53 66 90 131 283 186 262
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary	483 255 228 146 82 92 89 88	22.4 11.8 10.6 6.8 3.8 4.3 4.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5	Risk 32 115 73 124 178 172 190 238	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary	320 248 209 154 55 112 94 63	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4	53 66 90 131 283 186 262 255
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract	483 255 228 146 82 92 89 88 86	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5	Risk 32 115 73 124 178 172 190 238 233	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma	320 248 209 154 55 112 94 63 63	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4	53 66 90 131 283 186 262
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach	483 255 228 146 82 92 89 88 86 81	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0 3.8	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4	Risk 32 115 73 124 178 172 190 238 233 232	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS	320 248 209 154 55 112 94 63 63 3	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2	53 66 90 131 283 186 262 255 435
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma	483 255 228 146 82 92 89 88 86	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0 3.8 3.7	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5	Risk 32 115 73 124 178 172 190 238 233 232 176	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma	320 248 209 154 55 112 94 63 63 3	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6	53 66 90 131 283 186 262 255 435 *
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus	483 255 228 146 82 92 89 88 86 81 79	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0 3.8	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6	Risk 32 115 73 124 178 172 190 238 233 232	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS	320 248 209 154 55 112 94 63 63 3 4	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2	53 66 90 131 283 186 262 255 435
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma	483 255 228 146 82 92 89 88 86 81	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6	Risk 32 115 73 124 178 172 190 238 233 232 176 237	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NHL	320 248 209 154 55 112 94 63 63 3	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0	53 66 90 131 283 186 262 255 435 * 2976 509
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma	483 255 228 146 82 92 89 88 86 81 79 73 70	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9 3.8	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-6.6 3.0-4.8 2.9-4.8	Risk 32 115 73 124 178 172 190 238 233 232 176 237 231	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain	320 248 209 154 55 112 94 63 63 3 4 56	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5	53 66 90 131 283 186 262 255 435 * 2976 509 224
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS	483 255 228 146 82 92 89 88 86 81 79 73 70	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2	Risk 32 115 73 124 178 172 190 238 233 232 176 237 231	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin)	320 248 209 154 55 112 94 63 63 3 4 56 62 48	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4	53 66 90 131 283 186 262 255 435 * 2976 509 224 356
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma	483 255 228 146 82 92 89 88 86 81 79 73 70 1	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3	Risk 32 115 73 124 178 172 190 238 233 232 176 237 231 *	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia	320 248 209 154 55 112 94 63 63 3 4 566 62 48	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NHL	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9 3.8 0.1 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6	Risk 32 115 73 124 178 172 190 238 233 232 176 237 231 *	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia	483 255 228 146 82 92 88 86 81 79 73 70 1 2 67 65	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.2 0.0 0.1 3.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0-0.2 0-0.3 2.7-4.6	Risk 32 115 73 124 178 179 238 233 232 176 237 231 * 4622 248 255	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 2.8 0.1 0.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.5 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.5-6.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2	Risk 32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 48 2 13	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 2.8 0.1 0.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	483 255 228 146 82 92 98 88 86 81 79 73 70 1 2 67 65 2 17 46	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.2 0.0 0.1 3.1 3.0 0.1 0.1 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	Risk 32 115 73 124 178 1790 238 233 232 176 237 231 * 4622 248 255 6335 799 397 -	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach	320 248 209 154 55 112 94 63 63 3 4 566 2 48 48 2 13 33 0 0 38 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0	22.4 11.8 10.6 6.8 3.8 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	Risk 32 115 73 124 178 179 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain	483 255 228 146 82 92 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56	22.4 11.8 10.6 6.8 3.8 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-4.6 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4	Risk 32 115 73 124 178 1790 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 33 44 56 62 48 48 2	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.8 1.9 2.2 2.1 2.1 2.0	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney	483 255 228 146 82 92 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 59	22.4 11.8 10.6 6.8 3.8 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1 2.7 2.6 2.5	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4	Risk 32 115 73 124 178 179 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 33 44 56	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.6	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0-0.2 0-0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0-0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 59 56 54	22.4 11.8 10.6 6.8 4.3 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.1 0.1 0.2 2.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4	Risk 32 115 73 124 178 179 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 33 4 56 62 48 48 2 33 33 34 4 56 62 48 48 48 48 48 48 48 48 48 48 48 48 48	18.8 14.6 12.3 9.0 3.2 6.5 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.6 1.8 1.6 1.7	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0-0.2 0-0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0-0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.3 1.1-2.5	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC)	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 2.7 2.6 2.5 2.1 2.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.5 3.6 2.8 2.5 2.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0-0.2 0-0.3 2.7-4.6 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4	Risk 32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 317 426	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 36 36 37 38 38 38 38 38 38 38 38 38 38 38 38 38	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.8 1.7 1.8	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.5 0.9-2.1	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 647 534 643 502 586
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gall bladder / bile ducts	483 255 228 146 82 92 99 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 44 44 37	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.2 0.0 0.1 3.1 3.0 0.1 2.7 2.6 2.5 2.1 2.0 1.7	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5 2.4 2.0	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7	Risk 32 115 73 124 178 1790 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus	320 248 209 154 55 112 94 63 63 3 4 566 2 48 48 2 13 33 0 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7 0.2 0.2 3.3 6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.6 1.8 1.6 1.7 1.8	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1 0.8-1.8	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts Pharynx	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 44 43 72	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 2.7 2.6 2.5 2.1 2.0 1.7	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5 2.4 2.0 1.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-6.6 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7 0.8-2.0	Risk 32 115 73 124 178 1790 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384 488	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus Liver	320 248 209 154 55 112 94 63 63 3 4 566 2 48 48 2 13 33 0 38 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7 0.2 0.2 3.3 6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.7 1.4	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.6 1.7 1.8 1.5 1.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.5 0.9-2.1 0.8-1.8 0.6-1.6	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786 797
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts Pharynx Larynx	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 45 44 37 22 22	22.4 11.8 10.6 6.8 3.8 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.1 2.7 2.6 2.5 2.1 2.0 1.7 1.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 2.8 2.5 2.4 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-4.6 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7 0.8-2.0 0.8-1.9	Risk 32 115 73 124 178 179 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384 488 656	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus Liver Myelodysplastic diseases	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 36 36 37 38 38 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.8 1.7 1.4 1.2	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.6 1.7 1.8 1.5 1.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1 0.8-1.8 0.6-1.6 0.3-0.9	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786 797 8264
Males Lung Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts Pharynx	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 44 43 72	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.2 0.0 0.1 3.1 3.0 0.1 2.7 2.6 2.5 2.1 2.0 1.7 1.0 1.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5 2.4 2.0 1.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-6.6 2.9-4.8 0-0.2 0-0.3 2.7-4.6 0-0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7 0.8-2.0	Risk 32 115 73 124 178 1790 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384 488	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus Liver	320 248 209 154 55 112 94 63 63 3 4 566 2 48 48 2 13 33 0 38 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7 0.2 0.2 3.3 6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.7 1.4	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.6 1.7 1.8 1.5 1.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.5 0.9-2.1 0.8-1.8 0.6-1.6	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786 797

(NHL - Non-Hodgkin lymphoma; Refer to Statistical Methods, Section 1.4, for other terms & abbreviations used)

2.3 Cancer in different age groups

2.3.1 Cancer in children

Incidence: In children under the age of 15 years, there were 61 cases of cancer diagnosed in 2009, 38 males and 23 females. The most common types were leukaemias (22 cases) and brain tumours (11). Numbers and rates were similar to those of recent years.

Numbers and rates by age group may be found in Appendix 3A and Appendix 3B. The International Classification of Childhood Cancer (Version 3) table based on major diagnostic groups based primarily on tumour morphology is found in Appendix 3C. Note this table includes 71 cases, as the classification includes some additional conditions (non-malignant brain neoplasms) that are not tabulated elsewhere as "cancers".

2.3.2 Cancer in the 15-39 years age range

Incidence: In the 15 to 39 years age range, there were 614 cancer diagnoses in 2009, more than in 2007 or 2008. There were 62 cancer-related deaths in this age group in 2009, slightly fewer than in 2008.

The most common types are shown in summary form in Figures 3 and 4, with the detailed statistics in Table 2 and 3.

Figure 3. Cancer incidence, Western Australia, 2009: common cancers in the 15 to 39 years age group





Figure 4. Cancer mortality, Western Australia, 2009: common cancers in the 15 to 39 years age group



2.3.3 Cancer in the 40-64 years age range

There were 4389 new cancer cases in the age range 40 to 64 years, prostate and breast most common, with an overall risk of cancer occurring in this age range of 1 in 6 for males and 1 in 7 for females. There were 1021 cancer-related deaths in this age range, with mortality rates slightly higher than in 2008 for both males and females.

The most common types are shown in summary form in Figures 5 and 6, with the detailed statistics in Table 2 and 3.

Figure 5. Cancer incidence, Western Australia, 2009: common cancers in the 40 to 64 years age group





Figure 6. Cancer mortality, Western Australia, 2009: common cancers in the 40 to 64 years age group



2.3.4 Cancer in persons aged 65 and over

There were 5741 new cancer diagnoses in persons over the age of 65 years in 2009. In this age range, prostate cancer (1178 cases) outnumbered any other specific cancer type in either sex (Table 2) and accounted for 33% of diagnoses in males. Rates continue to rise in recent years, after major changes and unstable rates in the 1990s. Among females, breast cancer predominated (464 cases, 21%).

There were 2771 cancer-related deaths in this age range in 2009. Over the age of 65 years, lung cancer was the most common cause of cancer-related death, causing 598 deaths, almost 10% more than in 2008.

The most common types are shown in summary form in Figures 7 and 8, with the detailed statistics in Table 2 and 3.

Figure 7. Cancer incidence, Western Australia, 2009: common cancers in the 65 years & over age group




Figure 8. Cancer mortality, Western Australia, 2009: common cancers in the 65 years & over age group




Table 2. Cancer incidence, Western Australia, 2009: leading types by sex and age group (ASR: age-adjusted rate)

All cancers	3553	100.0	2724 4	2630-2813	4	All cancers	2188	100.0	1393 4	1330-1457	8
Leukaemia, other	0					Lymphoid leukaemia	33	1.5	19.0	11.8-26.2	674
Myeloid leukaemia	39	1.1	27.2	18.3-36.0	528	Leukaemia NOS	1	0.0	0.9	0 - 2.6	6593
Leukaemia NOS Lymphoid leukaemia	5 43	0.1 1.2	3.1 36.3	0.3-5.9 25.3-47.3	6335 221	Bladder & urinary tract Leukaemia	61 56	2.8 2.6	33.8 32.4	24.4-43.1 23.0-41.8	398 408
Leukaemia NOS	87	2.4	66.5	52.1-80.9	152	Uterus	80	3.7	56.5	43.1-69.8	168
Unknown primary	94	2.6	65.1	51.5-78.8	239	Pancreas	92	4.2	55.0	42.6-67.4	241
NHL	116	3.3	86.7	70.3-103	133	Unknown primary	95	4.3	50.5	39.2-61.7	287
Hodgkin lymphoma	1	0.0	0.6	0 - 1.8	*	NHL	91	4.2	57.3	44.4-70.2	205
Lymphoma NOS	121 4	3.4 0.1	90.4 3.1	73.7-107 0 - 6.3	3612	Lymphoma NOS Hodgkin lymphoma	4	0.2 0.1	1.4 2.3	0.0-2.7 0 - 4.9	3297
Bladder & urinary tract Lymphoma	142	4.0 3.4	101.8	84.3-119	135 128	Lymphoma NOS	98	4.5	60.9	47.7-74.1	193 *
Melanoma (skin)	317	8.9	248.2	220-276	41	Melanoma (skin)	137	6.3	83.6	68.2-98.9	140
Lung	416	11.7	312.4	281-344	37	Lung	270	12.3	173.6	151-196	64
Rectum	140	3.9	111.3	92.2-130	90	Rectum	81	3.7	53.0	40.4-65.7	208
Colon	315	8.9	232.6	206-259	49	Colon	264	12.1	161.3	140-183	71
Colorectal	456	12.8	344.5	312-377	32	Colorectal	346	15.8	214.7	190-239	53
Prostate	1178	33.2	938.8	95%C.I. 884-994	11	Breast	464	% 21.2	318.6	95%C.I. 287-350	32
Males	Cases	%	ASR	95%c.i.	Risk	Females	Cases	%	ASR	95%c.i.	Risk
65 years and over						Females					
All cancers	2437	100.0	644.3	619-670	6	All cancers	1952	100.0	536.6	513-560	7
Lip, gum & mouth	49	2.0	13.1	9.4-16.8	293	Leukaemia	33	1.7	9.0	5.9-12.1	415
Myeloid leukaemia Leukaemia, other	22 0	0.9	5.9	3.5-8.4	033	Kidney Pancreas	41 37	1.9	11.3 9.9	6.7-13.1	325 344
Lymphoid leukaemia	32	1.3 0.9	8.6 5.0	5.6-11.5 3.5-8.4	432 633	Cervix	45 41	2.3 2.1	12.7	9.0-16.4 7.8-14.8	322 325
Leukaemia NOS	0	1 2		5 G 11 E	420	NHL Candy	53 45	2.7	14.6	10.6-18.5	248
Leukaemia NOS	54	2.2	14.5	10.6-18.4	257	Hodgkin lymphoma	4	0.2	1.1	0.0-2.2	3173
Kidney	97	4.0	25.8	20.6-30.9	142	Lymphoma NOS	0	~ ~		0000	0.47
NHL	82	3.4	21.9	17.1-26.6	171	Lymphoma	57	2.9	15.7	11.6-19.7	230
Hodgkin lymphoma	11	0.5	3.1	1.3-4.9	1330	Ovary	57	2.9	15.7	11.6-19.8	230
Lymphoma NOS	5	0.2	1.3	0.2-2.5	2579	Thyroid gland	90	4.6	25.0	19.8-30.2	159
Lymphoma	98	4.0	26.3	21.1-31.5	143	Uterus	90	4.6	24.2	19.2-29.3	141
Lung	162	6.6	42.5	35.9-49.0	81	Lung	118	6.0	31.8	26.0-37.5	109
Melanoma (skin)	261	10.7	69.1	60.7-77.5	53	Rectum	75	3.8	20.2	15.6-24.7	180
Rectum	114	4.7	30.5	24.9-36.1	121	Colon	106	5.4	29.0	23.5-34.5	125
Color ectal	149	6.1	39.3	33.0-45.6	90	Colorectal	181	9.3	54.0 49.2	40.4-61.5	71
Prostate Colorectal	851 264	34.9 10.8	222.3 70.1	207-237 61.6-78.5	16 52	Breast Melanoma (skin)	764 196	39.1 10.0	211.4 54.0	196-226 46.4-61.5	19 71
Prostato	Cases	% 340	ASR	95%.i.	Risk	Prooct	Cases	% 20.1	ASR 211.4	95%c.i.	Risk
Males	•			0521	Б	Females				0521	
40 to 64 years											
All cancers	263	100.0	57.3	50.3-64.3	65	All cancers	351	100.0	79.3	70.9-87.7	46
Leukaemia, other Brain	0 11	4.2	2.6	1.1-4.2	1564	Leukaemia, other Ovary	0 10	2.8	2.4	0.9-3.9	1596
Myeloid leukaemia	10	3.8	2.4	0.9-4.0	1669	Myeloid leukaemia	10	2.8	2.4	0.9-4.0	1548
Lymphoid leukaemia	4	1.5	0.9	0.0-1.9	4260	Lymphoid leukaemia	3	0.9	0.7	0 - 1.6	5193
Leukaemia NOS	0		•			Leukaemia NOS	0		V. <u>-</u>		
Leukaemia	15	5.7	3.4	1.6-4.9	1125	Leukaemia	13	3.7	3.2	1.4-4.9	1193
Lip, gum & mouth Thyroid gland	16 15	5.7	3.4	1.7-5.1 1.6-4.9	1125	Hodgkin lymphoma NHL	13 4	3. <i>1</i> 1.1	3.5 0.9	0.0-1.9	4054
Rectum Lip, gum & mouth	12 16	4.6 6.1	2.5 3.4	1.1-3.9 1.7-5.1	1414 1058	Lymphoma NOS Hodgkin lymphoma	0 13	3.7	3.5	1.6-5.4	1203
Colon	7	2.7	1.7	0.4-2.9	2494	Lymphoma	17	4.8	4.4	2.3-6.5	928
Colorectal	19	7.2	4.2	2.3-6.0	903	Rectum	9	2.6	2.0	0.7-3.4	1761
NHL	12	4.6	2.6	1.1-4.1	1366	Colon	9	2.6	2.0	0.7-3.3	1769
Hodgkin lymphoma	20	7.6	4.8	2.7-7.0	848	Colorectal	18	5.1	4.0	2.1-5.9	883
Lymphoma NOS	0					Cervix	32	9.1	7.4	4.8-10.0	494
Lymphoma	32	12.2	7.4	4.8-10.0	524	Thyroid gland	45	12.8	10.7	7.6-13.9	352
Testis	42	24.7 16.0	13.4 9.4	6.5-12.3	259 404	Melanoma (skin)	85 67	24.2 19.1	17.7 14.9	11.3-18.4	237
Melanoma (skin)	Cases 65	% 24.7	13.4	95%C.I. 10.1-16.7	259	Breast	Cases 85	% 24.2	17.7	95%C.I. 13.9-21.4	Risk 190
	Coooo	%	ASR	95%c.i.	Risk	Females	Coooo	%	ASR	95%c.i.	Diele
Males											

Table 3. Cancer mortality, Western Australia, 2009: leading types by sex and age group (ASR: age-adjusted rate) $\frac{1}{2}$

15 to 39 years											
•											
Males						Females					-
	Deaths	%	ASR	95%c.i.		.	Deaths	%	ASR	95%c.i.	
Colorectal	7	26.9	1.6	0.4-2.8		Breast	8	22.2	1.7	0.5-3.0	
Colon Rectum	4	15.4 11.5	1.0	0.0-2.0 0 - 1.2		Colorectal Colon	4	11.1 8.3	1.0	0.0-1.9 0 - 1.5	
Brain	3		0.6			Rectum	3	0.3 2.8	0.7		3211
	4	15.4 11.5	0.9	0.0-1.9 0 - 1.4		Cervix	1	8.3	0.3	0 - 0.8 0 - 1.3	5240
Lung	3		0.6				3		0.6		
Melanoma (skin)	3 2	11.5	0.6	0 - 1.4 0 - 0.9		Unknown primary	3	8.3	0.7	0 - 1.4 0 - 1.6	
Lymphoma NOS	0	7.7	0.4	0 - 0.9	0040	Leukaemia Leukaemia NOS	3 0	8.3	0.8	0-1.0	3220
Lymphoma NOS Hodgkin lymphoma	1	3.8	0.2	0 - 0.6	*		0				-
NHL	1	3.8	0.2	0 - 0.6	*	Lymphoid leukaemia Myeloid leukaemia	3	8.3	0.8	0 - 1.6	5228
Leukaemia	2	7.7	0.2	0 - 1.4	90.94	Leukaemia, other	0	0.5	0.0	0 - 1.0	3220
Skin (NMSC inc. SCC/BCC	1	3.8	0.6	0 - 0.6	*	Stomach	2	5.6	0.4	0 - 1.0	7011
Connective/ soft tissues	1	3.8	0.2	0 - 0.7	*	Lung	2	5.6	0.4	0 - 1.0	
Kidney	1	3.8	0.2	0 - 0.6	*	Ovary	2	5.6	0.5	0 - 1.1	
Unknown primary	1	3.8	0.2	0 - 0.6	*	Brain	2	5.6	0.5	0 - 1.1	
Larynx	1	3.8	0.2	0 - 0.6	*	Lymphoma	2	5.6	0.5	0 - 1.1	
Laiyin	'	3.0	0.2	0-0.0		Lуттрпотпа	2	3.0	0.5	0-1.1	0070
All cancer deaths	26	100.0	5.8	3.5-8.1	645	All cancer deaths	36	100.0	8.1	5.4-10.8	446
40 to 64 years											
Males						Females					
	Deaths	%	ASR	95%c.i.			Deaths	%	ASR	95%c.i.	
Lung	111	20.5	29.2	23.7-34.6	119	Breast	110	22.9	30.0	24.4-35.7	124
Colorectal	60	11.1	16.0	12.0-20.1	217	Lung	89	18.5	24.2	19.2-29.2	147
Colon	33	6.1	8.7	5.7-11.7	393	Colorectal	52	10.8	14.3	10.4-18.2	258
Rectum	27	5.0	7.3	4.5-10.1	485	Colon	37	7.7	10.3	7.0-13.6	365
Stomach	38	7.0	10.1	6.9-13.3	350	Rectum	15	3.1	4.1	2.0-6.1	876
Pancreas	30	5.5	7.9	5.0-10.7	439	Ovary	26	5.4	7.1	4.4-9.9	509
Oesophagus	25	4.6	6.7	4.0-9.3	550	Brain	25	5.2	6.8	4.1-9.4	508
Melanoma (skin)	24	4.4	6.2	3.7-8.7	561	Pancreas	22	4.6	5.9	3.4-8.4	627
Mesotheliom a	23	4.3	6.1	3.6-8.6	571	Melanoma (skin)	21	4.4	5.7	3.3-8.2	651
Liver	22	4.1	5.8	3.4-8.2	605	Cervix	16	3.3	4.3	2.2-6.4	856
Prostate	21	3.9	5.6	3.2-8.0	603	Unknown primary	16	3.3	4.4	2.2-6.6	824
Brain	21	3.9	5.7	3.3-8.2	657	Leukaemia	11	2.3	3.0	1.2-4.8	1161
Lymphoma	20	3.7	5.3	3.0-7.6	674	Leukaemia NOS	0				-
Lymphoma NOS	1	0.2	0.3	0 - 0.8	*	Lymphoid leukaemia	2	0.4	0.6	0 - 1.3	6401
Hodgkin lymphoma	0				-	Myeloid leukaemia	9	1.9	2.5	0.8-4.1	1418
NHL	19	3.5	5.0	2.7-7.2	706	Leukaemia, other	0				-
Bladder & urinary tract	19	3.5	5.1	2.8-7.4	693	Lymphoma	10	2.1	2.8	1.1-4.6	1326
All cancer deaths	541	100.0	143.0	131-155	25	All cancer deaths	480	100.0	131.1	119-143	28
65 years and over											
Males						Females					
	Deaths	%	ASR	95%c.i.			Deaths	%	ASR	95%c.i.	
Lung	369	23.3	270.7	242-299	44	Lung	229	19.3	141.9	122-162	83
Prostate	234	14.7	152.5	132-173	143	Colorectal	153	12.9	88.3	72.8-104	142
Colorectal	161	10.1	113.3	95.1-132	115	Colon	114	9.6	64.0	51.0-76.9	212
Colon	109	6.9	75.2	60.5-89.9	189	Rectum	39	3.3	24.3	15.9-32.8	429
Rectum	52	3.3	38.1	27.3-48.9	295	Breast	130	11.0	78.5	63.5-93.5	152
Unknown primary	68	4.3	45.3	34.1-56.6	372	Pancreas	90	7.6	51.8	40.0-63.7	265
Bladder & urinary tract	67	4.2	46.5	34.9-58.2	351	Unknown primary	75	6.3	37.4	28.0-46.8	413
Pancreas	62	3.9	44.8	33.2-56.4	282	Lymphoma	51	4.3	25.5	17.8-33.1	702
Melanoma (skin)	61	3.8	42.9	31.7-54.2	309	Lymphoma NOS	3	0.3	1.0	0 - 2.2	*
Mesotheliom a	56	3.5	43.4	31.6-55.2	253	Hodgkin lymphoma	3	0.3	2.4	0 - 5.3	3667
Oesophagus	48	3.0	32.1	22.5-41.6	415	NHL	45	3.8	22.0	15.0-29.0	868
Lymphoma	48	3.0	34.2	24.1-44.2	367	Ovary	35	3.0	22.4	14.2-30.5	542
Lymphoma NOS	0				-	Bladder & urinary tract	35	3.0	19.2	12.1-26.3	734
Hodgkin lymphoma	1	0.1	0.9	0 - 2.7		Brain	34	2.9	21.9	13.9-29.8	434
NHL	47	3.0	33.3	23.4-43.2	390	Leukaemia	32	2.7	17.0	10.5-23.5	892
The state of the s	48	3.0	35.2	24.8-45.6	367						
Leukaemia	40										

2.4 Cancer trends and projections

2.4.1 Use and methods

Projections of cancer case numbers and rates may be somewhat unreliable, as discussed in previous reports. However, these are often requested for health service planning reasons, and are presented here as the best available basis for prediction of future need for medical services. These do not take into account unknown changes in risk factors or diagnostic practices, can be adversely affected by past events, and should be used with some caution. Reliance on any mathematical procedure (in isolation from knowledge of changes in medical practice and risk factors) is risky. Using an exponentially-weighted moving average method as described in *Cancer incidence and mortality in Western Australia 2002*, described projections for "All cancers" and the most common cancer type in males and in females, are presented here.

2.4.2 Trends and projections - incidence

While the incidence of all cancers combined tends to increase with time, differences are observed between trends for individual cancer types subject to particular influences. In particular, decreasing lung cancer incidence in males is commonly thought to be associated with a reduction in smoking prevalence, and increased prostate cancer incidence in the 1990s was thought to be associated with increased PSA testing.⁷

All cancers: Based on data for the last 10 years, incidence in males is increasing significantly by 0.71% per year with annual new cases expected to reach 7692 by 2014, with the incidence rate (ASR) rising from 378 to 382 per 100,000 per year (Table 4). In females there has been a non-significant decrease of 0.21% per year, and projection suggests little change in the incidence ASR.

Prostate cancer: Prostate cancer incidence doubled in 2 years in the early 1990s, then halved again in 2 years, and has since been on a less extreme but consistent increasing trend. Based on data for the last 10 years, incidence in males is increasing significantly by 5.46% per year, with annual new cases expected to reach 2715 by 2014 (Table 4). The incidence ASR is expected to increase only from 121 to 134 per 100,000 but case numbers are also increased by the increasing size and longevity of the population.

Breast cancer in females: Based on data for the last 10 years, breast cancer incidence in females is decreasing slightly by 0.48% per year, though this is not statistically significant. The incidence ASR is expected to fall from 82 to 81 per 100,000 per year by 2014, though annual case numbers can be expected to rise to 1501 in the same time (Table 4).

Trends in other common cancer types:

Colorectal cancer, males - decreasing by 1.7% per year (significant, p < .0001) Melanoma, males - decreasing by 1.5% per year (significant, p = .0009) Lung cancer, males - decreasing by 2.2% per year (significant, p = .0004)

Colorectal cancer, females - decreasing by 0.9 per year (not significant, p = .066) Melanoma, females - decreasing by 2.0% per year (significant, p = .0005) Lung cancer, females - increasing by 1.4% per year (significant, p = .0011)

Table 4. Trends and projections, all cancers and two most-common cancers, Western Australia, 2000-2019

	All cancers	s (males)						
Year	Cases	95% c.i.	ASR	95% c.i.	Cases	95% c.i.	ASR	95% c.i.
2000	4235	-	344.3	333.6-355.0	3455	-	261.7	252.4-271.0
2001	4329	-	339.8	329.4-350.3	3664	-	264.6	255.4-273.7
2002	4857	-	368.7	358.0-379.4	3926	-	278.9	269.6-288.3
2003	4952	-	364.1	353.6-374.6	3957	-	273.4	264.2-282.5
2004	5273	-	375.7	365.2-386.2	4102	-	277.6	268.5-286.6
2005	5303	-	364.7	354.5-374.8	4059	-	265.5	256.7-274.2
2006	5546	-	366.6	356.6-376.6	4301	-	272.3	263.6-281.1
2007	5676	-	364.4	354.6-374.2	4112	-	254.8	246.5-263.2
2008	6060	-	375.3	365.5-385.0	4457	-	264.6	256.3-272.9
2009	6291	-	378.2	368.6-387.9	4514	-	264.5	256.3-272.8
2010	6519	6396-6641	370.0	360.7-379.3	4783	4703-4863	266.1	258.0-274.2
2011	6795	6668-6923	373.0	363.8-382.2	4914	4831-4997	265.5	257.6-273.5
2012	7092	6964-7221	376.0	366.9-385.1	5052	4966-5137	264.9	257.1-272.7
2013	7390	7259-7520	379.1	370.1-388.0	5189	5101-5277	264.3	256.6-272.0
2014	7692	7560-7825	382.2	373.3-391.0	5329	5239-5420	263.7	256.1-271.4
2019	9338	9189-9486	397.9	389.4-406.5	6083	5982-6185	260.9	253.7-268.0

Trend: significant (P < .0001) 0.71% per year.

Trend: not significant (P = .606) -0.21% per year.

	Prostate c	ancer (males)						
Year	Cases	95% c.i.	ASR	95% c.i.	Cases	95% c.i.	ASR	95% c.i.
2000	830	-	66.0	61.4-70.6	1026	-	82.8	77.5-88.0
2001	965	-	75.4	70.5-80.3	1106	-	87.0	81.7-92.3
2002	1254	-	95.5	90.0-100.9	1149	-	87.4	82.2-92.7
2003	1271	-	92.8	87.6-98.1	1141	-	85.0	79.9-90.1
2004	1520	-	108.6	103.0-114.2	1150	-	82.9	77.9-87.8
2005	1495	-	101.9	96.6-107.2	1165	-	81.9	77.1-86.8
2006	1649	-	108.3	102.9-113.7	1251	-	85.6	80.7-90.5
2007	1813	-	115.7	110.3-121.2	1121	-	73.8	69.3-78.3
2008	1977	-	122.1	116.6-127.6	1344	-	86.4	81.7-91.2
2009	2030	-	121.4	116.0-126.8	1313	-	81.7	77.1-86.3
2010	1990	1815-2166	111.7	106.6-116.7	1377	1334-1419	82.3	77.8-86.8
2011	2158	1975-2340	117.1	112.1-122.2	1409	1365-1452	82.0	77.6-86.5
2012	2337	2149-2526	122.6	117.5-127.7	1440	1395-1484	81.6	77.2-86.0
2013	2523	2328-2718	128.1	123.0-133.2	1470	1425-1516	81.2	76.9-85.5
2014	2715	2513-2917	133.6	128.5-138.8	1501	1454-1547	80.8	76.5-85.0
2019	3806	3571-4041	161.8	156.5-167.1	1658	1604-1711	78.8	74.8-82.8

Trend: significant (P < .0001) 5.46% per year.

Trend: not significant (P = .129) -0.48% per year.

3. Cancer in Western Australia: Data and technical issues

3.1 Basis of diagnosis

Cancers may be diagnosed by a variety of methods, and many methods may be used in the same case, and cancer registries generally record a "best basis of diagnosis" as a guide to the specificity and reliability of the information. Generally "microscopic" methods (histology, cytology, haematology) are regarded as more reliable than clinical findings or imaging, and diagnoses based only on a death certificate are not generally well-regarded (see below). The contribution of the different methods is seen in Table 5, with a high 94% of cases based on a specific pathology test. The common cancers least likely to be based on a microscopic test, were liver cancers (59%), cancers of unknown primary site (66%) and pancreatic cancer (69%).

Table 5. Cancer in Western Australia, 2009: Diagnosis methods


Basis of diagnosis	Cases	%	Basis of diagnosis	Cases	%
Microscopic NOS	9	0.1	Surgery	6	0.1
Histology	8932	82.7	Necropsy	13	0.1
Cytology	1104	10.2	DCO	48	0.4
Haematology	135	1.2	DC & HMDS	53	0.5
Imaging	365	3.4	Unknown	42	0.4
Clinical	81	0.7			
Biochemical/Immunologic test	17	0.2	All "microscopic" bases	10182	94.2
			Total	10805	(100)

3.2 Death Certificate and Hospital Morbidity Data System cases

"Death certificate only" (DCO) cancer records are those based solely on a death notification's 'cause of death" text. In Western Australia, there were 48 DCO cancers recorded for 2009 (0.44% of all cases, reduced since 2007 and 2008) (Figure 9).

The Registry also uses hospital discharge statistics ("Hospital Morbidity Data System") to reduce letter-based enquiries and case note review, if data are consistent. There were 53 such "DC and HMDS" cases recorded for 2009 (Figure 9).

Figure 9. Death Certificate Only (DCO) and "DC & HMDS" cancers 2009: common types "DC & HMDS" (53) DCO (48 cases) Liver 17% Luna



Having a low proportion of DCO cases is widely regarded as an important index of data quality in a Cancer Registry. Although thought to be better than DCOs, reliability and specificity concerns limit the reliance placed on the "DC & HMDS" records. The combined total of these two types of records - 0.9% - is an indicator of a high standard in the Registry's data collection.

3.3 Registry enquiries

In search of better information on existing Cancer Registry cases, during 2009 and 2010 the Registry initiated 6213 "Enquiries", initiated via a hospital file request (3717) or a letter or call to a doctor or hospital (2487), and wrote 2435 individual letters. Not all such enquiries are successful, and not all can be resolved at the time of writing any report. In mid-2011, there were still 124 enquiries "outstanding" for 2009 cancer diagnoses, and 33 which had been abandoned. As might be expected, the related cancers were mainly unknown primaries, common cancers or those most often reported as "DCO" cases (Figure 10).




Figure 10. Unresolved case enquiries - most common cancer types, 2009 (124 cases)

3.4 "Non-counted" cancers


International standards for the reporting of cancer incidence dictate that new tumours should not be "counted" or reported in such statistics, if they represent a type that has previously been diagnosed in the same person. The effect is to reduce the numbers of cases that would otherwise be reported. The "type" of cancer depends on a combination of its anatomical site and/or cell type and follows a set of rules incorporated into the Registry's statistical reporting system; the source reference is available at the Internet URL http://www.iacr.com.fr/MPrules_july2004.pdf. As examples, a lung squamous cell carcinoma and a lung adenocarcinoma would both be counted; of two breast ductal carcinomas, only the first would be reported; but one would only count non-Hodgkin lymphoma once in a person irrespective of location in the body.

What follows in practice is that the Registry reports incidence using these standard rules, but can supply data including all known separate tumour occurrences, as an estimate of disease burden and workforce requirement, rather than disease risk.

The cancers that most commonly occur more than once in a person are the skin cancers, breast cancer, bladder and other urinary tract transitional cell carcinomas, and those occurring in colorectal polyps; the most common types are shown for males and females in Figure 11. The impact on incidence statistics if these were counted, would be an increase of approximately 5% - so effective data linkage and de-duplication is required to ensure the comparability of Cancer Registry statistics worldwide.

Figure 11. "Non-counted" cancers, 2009: common types

Males (260 cases) Females (230 cases)



3.5 Non-invasive neoplasms recorded

The Registry receives and records a considerable number of reports of benign neoplasms, neoplasms diagnosed at an early "pre-invasive" stage (*in situ* neoplasms), and others of types whose malignant potential or behaviour is uncertain such as "borderline" ovarian tumours or carcinoid tumours. In situ breast tumours are low in number compared with invasive ones. However, for some in situ tumours, the number of cases matches (melanoma) or even exceeds (cervix) the number of invasive cases defined as "cancers" and recorded elsewhere in this report (Table 6).

Table 6. Non-invasive neoplasms recorded in WA Cancer Registry, 2009

Туре	Males	Females	All
Benign CNS neoplasms	32	84	116
"Uncertain behaviour" or borderline neoplasms			
Ovary	0	36	36
CNS	15	19	34
Bowel	25	24	49
In situ neoplasms			
Breast	2	231	233
Colorectal	27	22	49
Cervix	0	945	945
Melanoma (skin)	678	451	1129
Non-melanoma (skin)	4	0	4
In situ SCC or BCC skin	43	22	65
Bladder	447	145	592
Urinary tract	10	4	14
Other	133	74	207

4. References

- 1 Threlfall TJ, Thompson JR (2010). *Cancer incidence and mortality in Western Australia, 2008.* Department of Health, Western Australia, Perth. Statistical series number 87.
- 2 Segi M (1960) *Cancer mortality for selected sites in 24 countries (1950-1957)*. Sendai, Japan, Tohoku University Press.
- 3 Population by age and sex. 2001 Census Edition Final. Australian Bureau of Statistics, Canberra, cat. 3201.0
- 4 Threlfall TJ, Thompson JR (2007). Cancer incidence and mortality in Western Australia, 2005. Department of Health, Western Australia, Perth. Statistical Series Number 81.
- World Health Organization (2000) *ICD-O: International classification of diseases for oncology* (Third Edition). WHO, Geneva.
- Threlfall TJ, Thompson JR (2004) Cancer incidence and mortality in Western Australia, 2002. Department of Health, Western Australia, Perth. Statistical series number 71.
- 7 Threlfall TJ, English DR, Rouse IL (1998) Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. *MJA* 169, 21-24.

LIST OF APPENDICES

About 7	The Western Australian Cancer Registry	
1A	Overview and technical issues	A1-1
1B	Current issues	A1-6
Techni	cal and miscellaneous information	
2A	Glossary	A2-1
2B	Statistical methods and formulae	A2-2
2C	Populations and geographic areas	A2-4
2D	Confidentiality guidelines	A2-6
2E	Cancer Notification Regulations	A2-7
2F	Cancer codes	A2-9
2G	WACR publications	A2-11
2H	Guide to tables in Appendix 3	A2-12
Cancer	incidence and mortality in Western Australia, 2007	
3A	Cancer incidence, Western Australia, 2009: numbers and rates by type, sex and age group	A3-1
3B	Cancer mortality, Western Australia, 2009: numbers and rates by type, sex and age group	A3-11
3C	Childhood cancer incidence, Western Australia, 2009: ICD-O 3rd Revision classification scheme	A3-21
3D	Cancer incidence, Western Australia, 2009: leading types by sex and geographic area	A3-25
3E	Cancer mortality, Western Australia, 2009: leading types by sex and geographic area	A3-30
	1A 1B Technic 2A 2B 2C 2D 2E 2F 2G 2H Cancer 3A 3B 3C 3D	Technical and miscellaneous information A Glossary Statistical methods and formulae C Populations and geographic areas C Confidentiality guidelines E Cancer Notification Regulations F Cancer codes WACR publications H Guide to tables in Appendix 3 Cancer incidence and mortality in Western Australia, 2007 A Cancer incidence, Western Australia, 2009: numbers and rates by type, sex and age group C Cancer mortality, Western Australia, 2009: numbers and rates by type, sex and age group C Childhood cancer incidence, Western Australia, 2009: lcD-O 3rd Revision classification scheme C Cancer incidence, Western Australia, 2009: leading types by sex and geographic area E Cancer mortality, Western Australia, 2009: leading types by sex and

Note: Appendix 3A now contains an incidence data summary for the most common cancers on page A3-10.

Appendix 1. About The Western Australian Cancer Registry

Appendix 1A. Overview and technical issues

History and role

The Western Australian Cancer Registry is a population-based cancer registry established in 1981. The Health (Notification of Cancer) Regulations 1981 require the reporting of cancers diagnosed by pathologists, haematologists and radiation oncologists; the current version can be found in **Appendix 2E**. The Registry was established in recognition of the potential importance of reliable population-based cancer data in the planning of services and in the prevention and treatment of cancer.

Surveillance of cancer extends beyond State and national boundaries and this Registry cooperates with other State registries and the Australian Institute of Health and Welfare (AIHW) who collate State information and manage the Australian Cancer Database in Canberra). Data are also provided to the International Agency for Research on Cancer in Lyon, France, for inclusion in Australian statistics published nationally and world-wide.

The Registry is a member of the Australasian Association of Cancer Registries (AACR) which includes all Territory and State cancer registries, and the International Association of Cancer Registries (IACR). The AACR meets regularly to discuss matters such as common coding systems, comparability of data between areas in Australia and involvement in Australia-wide cancer research projects.

Registry scope

The Western Australian Cancer Registry reports on cancers and other neoplasms diagnosed in persons while resident in Western Australia. A separate register is maintained for recording asbestos exposure and other history for all cases of mesothelioma. In practice, the Registry records available information about cancers diagnosed elsewhere, in Western Australians, as this is often vital to the interpretation of new reports or mortality information.

As in other Australian cancer registries, information concerning tumours diagnosed in Western Australia in persons ordinarily resident elsewhere in Australia, is sent to the relevant State or Territory cancer registry, and is not included in Western Australian incidence statistics.

Cancer deaths in current or former Western Australian residents are recorded when possible, regardless of place of death or address at diagnosis, to facilitate survival analysis. However, in routine tables of mortality, geographic location is based on place of residence at time of death rather than on the place of death. Accordingly, the Registry's mortality statistics routinely include only deaths, in Western Australia, of persons resident in Western Australia at the time. In contrast to incidence, mortality reports include deaths due to all non-melanoma skin cancers.

Legislative basis

The Registry acted with the delegated authority of the Executive Director of Public Health with respect to the Health (Notification of Cancer) Regulations 1981, until June 2011 when the new HEALTH (WESTERN AUSTRALIAN CANCER REGISTER) REGULATIONS 2011 took effect.

The Regulations require the notification of *in situ* neoplasms and all non-melanoma skin cancers other than basal cell and squamous cell carcinomas, as well as all invasive malignancies and a variety of other neoplasms (see **Appendix 2E**).

Sources of data

Most notifications are received from pathology laboratories, which supply pathology reports on paper or computer data files. The electronic notification system relies on the tumour codes or "notify Registry" flags generated by pathologists to select the reports which reach the Registry, and it is believed that this has enhanced the completeness of reporting from the larger hospital laboratories. Radiation oncologists also notify patients treated for cancer.

In-house linkage routines are used to link pathology and mortality data files to the Registry to permit creation of new records, or the updating of date, place and cause of death information. Additional cancer registrations are obtained from the remaining (unmatched) mortality records after electronically scanning the written cause of death and other fields on a data file. Data are now obtained from the W.A. Registrar-General's Office via the Data Linkage Branch of the Population Health Division. Records are created on the Cancer Registry for persons with these previously-unrecorded tumours, and efforts are then made to obtain independent verification of tumour details. Those for which no supporting information can be obtained after research are treated in subsequent reports as "death certificate only" (DCO) tumours.

Additional information including country of birth and Aboriginality or indigenous status, can often be obtained, from extracts of the W.A. Hospital Morbidity Data System (HMDS) files, or via on-line access to a Patient Master Index maintained in Perth Metropolitan Area government hospitals.

Data handling and maintenance

Since 2008 when a new SQL Server database was commissioned, Registry staff have converted all paper records into image files that are stored within the database; the process for historical information is now completed. This permits a limited number of users with limited access from remote sites to find all information without making enquiries of other staff, and free Registry staff from the task of locating paper records for coding or review.

New registrations and updates are made on the new custom-designed database, which also manages and stores the case lists and correspondence associated with the "further enquiry" process. In general, cancer cases are recorded with one demographic record for each person with a separate, linked, record for each tumour, each of which may have from one to many associated "notifications". Records which are incomplete or which are found to be inaccurate in the light of new information are progressively updated, and the data continually enhanced until the time of any final update such as that following confirmation of death information. Registry records that are duplicates of existing cases are now handled by cross-referencing to the "valid" case, rather than deletion, minimizing the repetition of "detective" work if more information later comes to hand.

Statistics are produced from database extracts using the Registry's own incidence and mortality rates calculation system and a variety of other statistical and graphics software packages. Software for routine statistical reports is constantly being developed and upgraded to reflect changes in coding systems, geographical area boundaries and the types of information requests received. The vast majority of tables in this report are created directly from this in-house software.

Where resources permit, customized tabulations using similar area and age group subdivisions are available to anyone who makes a request.

Coding practices

General

The coding of tumour data is based on the International Classification of Diseases for Oncology (ICD-O) which originated as an extension of Chapter II (Neoplasms) of the Ninth Revision of the International Classification of Diseases (ICD-9); which is superseded by ICD-10.

ICD-O permits separate coding of topography ("site"), morphology ("tissue") and behaviour, and thus allows a more comprehensive characterization of some tumours than the single-code ICD-9 and ICD-10 classification system. Topography and morphology codes in this report are from ICD-0 third edition (2000) (ICDO-3), a following the successful conversion of software, and translation of historical data in 2003.

In general, for incidence reporting, leukaemias, lymphomas and other lymphohaematopoietic malignancies are grouped on the basis of morphology codes, as for cutaneous melanoma, Kaposi sarcoma and mesothelioma, while others are tabulated on the basis of topography, or location. This Registry does use Behaviour code "6" to indicate tumours of unknown primary site.

For the sake of consistency in reporting of incidence and mortality data, causes of death are coded to morphology (lymphohaematopoietic malignancies, Kaposi sarcoma and mesothelioma) and topography (others). Melanoma deaths are coded to the ICD-10 code, C43x, to distinguish them from deaths due to non-melanoma skin cancers (C44x). In accordance with IACR guidelines adopted by AACR, melanomas of unknown primary site are treated as primary skin melanoma for tabulation purposes.

Diagnoses in non-Western Australian residents are excluded from incidence reporting routines but are recorded for reference. A system of 'aliasing' duplicate or otherwise invalid records allows ongoing reconciliation of old and current data, necessary for follow-up studies.

Cancer Registry mortality reporting has been based on death certificate coding performed within the Registry since 1990. Reconciliation with coding by the Australian Bureau of Statistics was once a useful monthly process but ABS has failed to support this since 2005. This exchange was extremely important, as annual ABS-coded mortality files are normally not released until well into the year following death, which is, in some cases, a delay of almost 2 years.

Multiple tumours

Two or more discrete tumours of different (3-character) sites in any individual are counted separately for the purposes of incidence statistics. However, in accordance with international practice, similar tumours arising in sites coded with the same first three characters are counted as one.

This, in effect, means that a person who has two similar tumours diagnosed, even many years apart, is reported only once in incidence statistics. This applies even when tumours arise in paired organs, e.g. lung or breast and are regarded as truly separate, unless the tumour types are different enough to permit both to be counted. Groups of types considered to be different, for the purposes of allowing the counting of more than one tumour of the same "site", are based on those in Jensen *et al* (1991).^b

WACR now uses the ICDO-3-based table as promulgated by the International Association of Cancer Registries (refer to http://www.iacr.com.fr/). Using these rules, for example, a squamous cell carcinoma of the lung and an adenocarcinoma of the lung arising at any time will both be counted in incidence statistics. Lymphohaematopoietic malignancies are treated

^a World Health Organization (2000) *ICD-O: International classification of diseases for oncology* (Third Edition). WHO, Geneva.

b Jensen OM, Parkin DM, MacLennan R *et al* (1991) *Cancer Registration: Principles and methods*. IARC Scientific Publications No. 95, Lyon, France.

differently, being tabulated by morphology, and their discovery in a particular site does not preclude the counting of different types of neoplasms in the same site. The urinary tract is treated as a special case of an "extended site", whereby multiple transitional cell carcinomas of sites C65x to C68x, *including* bladder (C67x), are counted only once in a person.

While these practices govern the reporting of cancers for incidence statistics in accordance with international practice, it is an inescapable conclusion that multiple tumours have separate effects on health, and the best illustration of this is in relation to survival. Cases occur in which a person has a breast carcinoma, and is treated and considered cured, only to die from a second primary breast carcinoma arising many years later. Measuring survival time from the first tumour diagnosis (the "incident" tumour) and ignoring the presence of the second, can lead to a simplistic analysis which falsely underestimates cure rates. To allow better analysis, the Registry now separately records all tumours, and statistics counting tumours, rather than cases, can be provided if required.

This Report uses the "multiple-primary" rules based on the ICDO-3 classification and tumour groupings will differ slightly from those used some previous publications (see Appendix 2F).

"Death certificate only" cancers

Death certificate only (DCO) cancers are those for which no information other than a death certificate is available. From mortality data, records of previously-unknown tumours are created on the Cancer Registry, and efforts are made to obtain independent verification of details. Those for which no supporting information can be obtained after research are treated in subsequent reports as "death certificate only" (DCO) tumours. Up to 60 tumours are followed up in this way each month, and supporting information is eventually obtained for the vast majority. Very few tumour records remain in this category. Tumours of unknown primary site have been consistently more common among DCO cases than among cancers in general.

To achieve such a low proportion of DCO cases, reporting of statistics must be delayed, until most follow-up is complete. Rapid access to death notifications assists the Registry to commence enquiries while information is still accessible. Due to workload issues, DCO cases are now been treated as "resolved" if a compatible hospital discharge record is found, and a special Basis of Diagnosis code of "H" is used.

Lymphomas

ICD-O codes are used for coding lymphomas, however several "in-house" morphology codes are used when the best ICD-O code is too general; these are shown in the footnote to the table in Appendix 2F(b). These codes are converted, when contributing data to others, to the relevant less-specific ICD-O code.

Basis of Diagnosis

Most notifications result from diagnoses made on the basis of tissue examination (histology, cytology, haematology), and these are generally regarded as the most reliable. Their percentage of the total cases is shown in the "TissDx" column of some tables in this report.

^a Breslow A (1970) Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172, 902-908

b Clark WH et al (1975) The developmental biology of primary cutaneous malignant melanoma. Seminars in Oncology 2, 83.

Additional data for specific tumour types

A number of additional data items are collected for some tumours. For primary invasive breast cancer, the Registry records maximum tumour diameter, number of axillary lymph nodes biopsied and the number affected by cancer, whether a tumour is multi-centric, and whether there is associated ductal carcinoma in situ (DCIS) outside the margins of the invasive tumour. For primary skin melanoma, the maximum thickness of the tumour and Clark's level are recorded (Breslow 1970^a Clark *et al* 1975^b), and are used in many of this Registry's reports.

Quality assurance

Data quality is assessed in various ways, both continuous and occasional. On a continuous basis, all coding on pathology reports, and the details entered on the database, are checked by a second member of the Registry staff, and queries are referred to a Registry medical officer. In addition, the Registry database system incorporates various "unusual case" warnings, based on dates, sex, and age. A case-flagging system, based on site and tissue combinations and the rules encapsulated in a modified version of IARC's "Check" routine, 5 warns of unusual records. A verification code is assigned to records which do not fit the "rules" but which are believed to be correctly coded.

Available external indicators of Registry completeness are all potentially biased in favour of cancers which are more often serious, causing hospitalization or death. Reports from radiation oncologists serve as a useful avenue for checking receipt of reports based on previous pathology specimens, and enables recording of a small number of cancers which were not diagnosed histologically. The Hospital Morbidity System, which records details of all hospitalizations in Western Australia, is another potential source of information regarding Registry completeness.

If trends in incidence, mortality and migration are constant, then the ratio of the number of new cancer diagnoses registered to the number of cancer deaths (mortality to incidence ratio) serves as a crude indicator of completeness.

Uses of Cancer Registry data

Non-identifying data are available for release to interested parties, subject to time constraints, as data files or as finished tables and figures. Only data which do not identify any patient, care provider or institution can be treated in this manner. Release of named information is strictly controlled (see "Confidentiality guidelines") and data can only be released to persons other than the original providers (or other clinicians involved in ongoing care of the individual) with personal consent, or a formal approval from the Department of Health (WA)'s Human Research Ethics Committee.

Data are used in a wide variety of research projects, including the recruitment of subjects for descriptive and case-control studies. Specific requests have included data on incidence in specific areas, cancer deaths by location and institution type, melanoma levels and depths, mesothelioma deaths and occupation, teenage cancers, myeloma survival and occular melanoma. Registry data have been used in a number of studies of cancer incidence, and in a number of national projects, most notably those commissioned by the National Breast Cancer Centre.

In addition to technical and statistical enquiries, the Registry receives general and personal enquiries regarding cancer services and medical problems; these are referred when appropriate to other agencies and treating physicians.

The Registry provides support for four hospital-based cancer registries (HBCRs). In the hospital setting, with clinical and pathological staging and treatment data, the availability of mortality data facilitates the assessment of outcomes using survival analysis.

Appendix 1B. Current issues

Registry staffing and workload

In 2003, a long process seeking reclassification of "Clerical officers" to a higher level, redesignated "Data quality officers", came to a successful conclusion. The resources now available to service the needs of a population of 2 million people now include -

Principal Medical Officer/Manager	1.0 fte
Medical Officer/coding adviser	0.2 fte
Data Quality Officers	3.5 fte
Mesothelioma research officer	0.25 fte
Analyst/programmer	1.0 fte

Additional resources used include financial/ Human Resources services, Epidemiology Branch advice on some statistical issues, and production/graphic design services from the Marketing Branch. However all reports such as this are produced primarily within the Registry itself.

Workload is not adequately represented by reported "cancer" totals. In 2005, there were 9151 invasive cancer cases as mentioned earlier in this report. However, in the same year there were 16275 pathology records added to the registry databases, and 20532 records were edited in some way by staff.

Increases in these workload estimates exceed population growth rates, and underscore the need to properly resource disease registries and ensure a continued capacity to deal with the demands of health service planners, researchers, students and the public.

Assessment of current notification system and Regulations

Until 2011, Western Australia was the only Australian State with no legal requirement for the direct notification of cancer diagnoses by hospitals; there is consequently some incompleteness in WA statistics for some cancer types. As a result of two successful "Graduate Officer" placement requests made under a new Department of Health program in 2004, a review and update of a previous assessment of the opportunities for more complete notification based on hospital data for non pathologically-diagnosed cancers, has recently been completed and was summarized in *Cancer incidence and mortality in Western Australia*, 2005.^a

These findings were published in support of a process of seeking changes to the Health (Notification of Cancer) Regulations 1981 so as to require hospital notification, among other things. Current data systems cannot be used satisfactorily for this purpose as there are 3 key data items - basis of diagnosis, date of diagnosis and place of residence at diagnosis - that are not included. The Registry has participated in consultations concerning a replacement of the (public) hospital Patient Administration System (PAS), and a cancer notification module from the currently-favoured replacement system has been demonstrated. New Regulations are now in place but effective changes in some aspects of notification must await changes in hospital information systems.

^aThrelfall TJ, Thompson JR (2007). Cancer incidence and mortality in Western Australia, 2005. Department of Health, Western Australia, Perth. Statistical Series Number 81.

Appendix 2. Technical and miscellaneous information

Appendix 2A. Glossary

General

Risk

TD%

ABS Australian Bureau of Statistics

Age-adjusted rate - rate resulting from age-standardization using only a subset of the entire age range for cases and population, e.g. 0 - 15 years.

ASR Age-standardized rate per 100,000 persons ("World standard"

population) (Segi 1960)^a

ASPR Age-specific rate per 100,000 persons in a specified age range

BCC Basal cell carcinoma

CHIC Confidentiality of Health Information Committee

DCO Death certificate only

LHN Lymphohaematopoietic Neoplasms

NMSC Non-melanoma skin cancer SCC Squamous cell carcinoma

SD Standard deviation

ICD-O International Classification of Diseases for Oncology LR Lifetime risk (to a particular age, usually 75 years)

NOS Not otherwise specified

PYLL Person-years of life lost (before a particular age, usually 75 years)

Additional terms used in column headings of incidence and mortality tables:

95%c.i. Statistical 95% confidence interval Crude Crude rate per 100,000 persons

Cum inc Cumulative incidence (%)(before a particular age, usually 75 years)

Lifetime risk (usually to age 75; 1 in n). In some tables, "-" indicates no data, "*" indicates a risk of less than 1 in 1,000.

Percentage of diagnoses made on basis of tissue examination (histology,

haematology or cytology).

^a Segi M (1960) *Cancer mortality for selected sites in 24 countries (1950-1957)*. Sendai, Japan, Tohoku University Press.

Appendix 2B. Statistical methods and formulae

Age groups

The basis for most statistics is a summation of cases by five-year age groups. Age groups are expressed in whole years, ie "10-14" means 10.0 to 14.99.... years.

Rates

Rates in this report are calculated separately for males and females and are expressed as cases per 100,000 person-years. (If one year's data are being analyzed, this is equivalent to n cases per 100,000 population for that year.)

Age-specific rates are based on five-year age intervals and are calculated by dividing the numbers of cases by the population of the same sex and age group, over the relevant period.

Crude rates are calculated simply as the total cases divided by the total population over a wide age range; they are not suitable as a basis for comparison of rates in different areas if the age-structures of the populations differ.

Age-standardized rates (ASR in Tables) are calculated by the direct method ^a and represent a summation of weighted age-specific rates (weighting being determined by the relative proportion of the population in each age group compared with the proportion in the World Standard Population ^b). Weightings by other population standards can be used if requested.

The standard deviation, or Estimated Standard Error (ESE) is used as a measure of variability for rates in tables; an approximate 95% confidence interval for a rate is (rate \pm 1.96 ESE).

Formulae:

$$ASR = 10^5 \times \Sigma_i \, r_i \times w_i; \qquad ESE = 10^5 / W \times \left[\sum_i \left\{ r_i \times (1 - r_i) \times w_i^2 / n_i \right\} \right]^{1/2},$$

where w_i is the World Standard Population ^b for the *i*th age group, $W = \Sigma_i w_i$ and Σ_i denotes summation over all (relevant) age groups.

Subsets of the full age range: where a subset of age groups is considered, the term ageadjusted rate is used instead of ASR, to indicate that standardization has taken only the age groups of interest into account for both cases and population.

Comparison of rates between different areas may be done using indirect standardization. In this process, for example, the State population and age-specific rates are used to calculate an expected number of cases in different areas, based on their populations; the observed and expected numbers are compared using the Standardized Incidence (or Mortality) Ratio and a 95% confidence interval.

Relative survival has been calculated using Relsurv 2.5 (Hedelin^c) which produces 5-year survival for even most recent cases by mathematical modelling. Detailed methods may be found in Threlfall TJ, Brameld K (2000) *Cancer survival in Western Australian residents*, 1982-1997 (see WACR Publications) - which used an earlier version of the software.

^a Rothman KJ (1986) *Modern epidemiology*. Little, Brown & Company, Boston.

^b Segi M (1960) Cancer mortality for selected sites in 24 countries (1950-1957). Sendai, Japan, Tohoku University Press.

^c Hedelin G (2001) Relsurv A program for relative survival. Laboratory for Epidemiology and Public Health, Faculty of Medicine, 6700 Strasbourg Cedex, France.

Cumulative Incidence and Lifetime Risk

The cumulative incidence of a condition (at a given age) is a measure of the proportion of all persons who have, by that age, been affected by the condition; the Registry calculates this for cancer incidence, and death due to cancer. Cumulative rates are calculated by summing the age-specific rates for specified five year age groups, and are expressed as percentages unless otherwise noted.

In general, a **risk** is derived from the cumulative rate and is interpreted as a "1 in n" chance of developing the disease, while cumulative rates are commonly presented as percentages affected. In Registry reports, risk is usually presented as lifetime risk derived from the cumulative risk for age groups 0-4 to 70-74. However, in tables restricted to age subgroups, risk is derived from the cumulative rate calculated for the age groups listed - e.g. 15-39 years, 40-64 years and 65 years and older.

The method for Risk calculations assumes that the risks at the time of estimation remain the same throughout life, and does not account for the effects of death from other causes or interventions which may reduce the chances of a cancer diagnosis.

Formulae:

The formulae for CI and Risk are:

$$CI = \Sigma_i r_i \times 5$$
; $Risk = 1/(1 - e^{-CI})$.

Person years of life lost

Person-years of life lost (PYLL) is an estimate of the number of years of life lost due to specific causes of death, and is calculated up to age 75 years, as an index of premature death. The calculations rely on the use of all-causes mortality data for the whole of Western Australia using the methods of Hakulinen and Teppo as presented in Holman *et al.* ^{a.}

In this report the PYLL is calculated for age 0 to 74 years as a measure of premature death.

Formulae:

For each cause of death, the PYLL lost for the *i*th five-year age group is given by: $S_i = 5 \times \{ \sum_{j=0,...,i-1} \{ d_j \times p_i^{1/2} \times P_{j+1,i} \times [a_i \times (1 - p_i) + p_i] + d_i \times (1 - a_i) \times (1 + p_i^{1/2})/2 \}$

where a_i is the proportion of the ith five-year interval that a person dying during that interval lives, on average. The values used are 0.09, 0.46, 0.54, 0.57, 0.49, 0.50, 0.52, 0.54, 0.54, 0.54, 0.53, 0.52, 0.52, 0.52, 0.51, 0.51, 0.48, 0.45 for age groups 0-4, 5-9, ..., 85+, d_i is the number of deaths from the cause of death of interest in the ith age group, p_i is the probability of surviving the ith age interval after eliminating the cause of death of interest, and

$$P_{i+1,i} = \prod_{k=i+1,\dots,i-1} p_k$$
 for $j+1 < i$, or 1 for $j+1 = i$.

The quantity p_i is calculated as -

$$p_i = \{ (1 - 5 \times a_i \times r_i) / (1 + 5 \times (1 - a_i) \times r_i) \}^{(D_i - d_i)/D_i}$$

where r_i is the death rate and D_i is the total number of deaths for the *i*th age group.

^a Holman CDJ, Hatton WM, Armstrong BK, English DR (1987) *Cancer mortality trends in Australia, volume II, 1910 - 1984.* Health Department of Western Australia, Perth, Occasional Paper number 18.

Appendix 2C. Populations and geographic areas

The following W.A. population data were used for calculation of 2009 rates in this report

Age	Males	(%)	Females	(%)	Total	(%)
0- 4	76509	6.7	72760	6.6	149269	6.6
5- 9	72629	6.4	68371	6.2	141000	6.3
10-14	76854	6.8	71453	6.5	148307	6.6
15-19	80834	7.1	75572	6.8	156406	7.0
20-24	88239	7.8	80455	7.3	168694	7.5
25-29	87430	7.7	78957	7.1	166387	7.4
30-34	79141	7.0	75971	6.9	155112	6.9
35-39	85454	7.5	82505	7.5	167959	7.5
40-44	82618	7.3	80052	7.2	162670	7.2
45-49	82513	7.2	80985	7.3	163498	7.3
50-54	75089	6.6	74386	6.7	149475	6.7
55-59	67618	5.9	66340	6.0	133958	6.0
60-64	58906	5.2	56161	5.1	115067	5.1
65-69	41997	3.7	41315	3.7	83312	3.7
70-74	31672	2.8	32960	3.0	64632	2.9
75-79	23326	2.0	26416	2.4	49742	2.2
80-84	16103	1.4	21116	1.9	37219	1.7
85 +	11189	1.0	21161	1.9	32350	1.4
TOTAL	1138121	(100)	1106936	(100)	2245057	(100)

(Data from Australian Bureau of Statistics as collated by Performance Activity & Quality Division, Department of Health, and used for calculation of rates in this Report.)


The Department of Health's area of responsibility is administered through 2 Area Health Services (AHS) (metropolitan) and the Country Health Service (WACHS), comprising 7 Regions. Overall, the area is divided into 34 Health Districts (HD), each lying entirely within an Area Health Service (AHS) or Health Region (HR). Areas may not match "current" arrangements at any given point in time however data files and population files are synchronized to ensure accurate calculation of incidence and mortality rates in this report.

The table and maps below should assist comparison of boundaries and area names with those used in previous reports.

Health District composition of Area Health Services and Regions as used for this Report

CHS Kimberley HR	CHS Goldfields HR	North Metro AHS
Kimberley HD	Northern Goldfields HD	NMAHS Central HD
CHS Pilbara HR	South East Coastal HD	NMAHS Stirling HD
East Pilbara HD	CHS Great Southern HR	NMAHS Oceanic HD
West Pilbara HD	Central Great Southern HD	NMAHS Valley and Hills HD
CHS Midwest HR	Lower Great Southern HD	NMAHS Joondalup HD
Gascoyne HD	CHS South West HR	NMAHS Wanneroo HD
Geraldton HD	Blackwood HD	
Midwest HD	Bunbury HD	South Metro AHS
Murchison HD	Busselton HD	SMAHS Armadale HD
CHS Wheatbelt HR	Leeuwin HD	SMAHS Bentley HD
Eastern Wheatbelt HD	Leschenault HD	SMAHS Fremantle HD
Southern Wheatbelt HD	Warren HD	SMAHS Peel HD
Western Wheatbelt HD	Wellington HD	SMAHS Rockingham-Kwinana HD

^{*} CHS - Country Health Service; AHS - Area Health Service



Appendix 2D. Confidentiality guidelines

- 1. Responsibility for the confidentiality of data held by the Cancer Registry will ultimately lie with the Director General of Health (hereafter referred to as the Director General).
- 2. All Cancer Registry staff will be instructed regarding the need for confidentiality. In addition, Cancer Registry staff will be required to sign a confidentiality declaration. The Principal Medical Officer of the Cancer Registry will be responsible to the Director General for ensuring that procedures for ensuring confidentiality are maintained.
- 3. Release of data may occur at a number of levels:
 - (a) Summarized statistical information containing no means of identifying any individual patient, doctor, laboratory or hospital will be available for the purposes of general information and education.
 - (b) More detailed statistical information, which may include data files for analysis, but containing no means of identifying any individual patient, doctor, laboratory or hospital, may be released by the Principal Medical Officer.
 - (c) Identified information will normally be made available to relevant Australian State or Territory Cancer Registries and to the the Australian Institute of Health and Welfare, for the purposes of improving data quality and consistency. Data are released to the AIHW subject to a provision that any use of such identified data for other purposes is to be referred to this Registry for approval.
 - (d) Special information pertaining to identified patients of a particular hospital or doctor may be released by the Principal Medical Officer to the Medical Superintendent of the hospital, or to the doctor, in response to a written request; such requests may be referred to the Department of Health (Western Australia)'s Human Research Ethics Committee if there is concern regarding the identification of individual service providers.
 - (e) Applications for further information required for specific areas of research will be referred to the Human Research Ethics Committee which, subject to formal application, may approve the release of identified information to researchers. Such approval will normally include directions regarding steps which may be taken by the researcher in approaching other persons or bodies for further information with respect to persons so identified.
 - (f) Approval for the release of identified information for the purposes of research (i.e. in the case of (e) above) will be subject to the Practice Code for the Use of Personal Health Information. This Code includes requirements for written protocols, signed confidentiality declarations, and consent.

The aims of the Committee are summarized in the Terms of Reference thus:

To review projects requiring the use or disclosure of personal health information without consent to ensure:

The public interest in the project outweighs the public interest in the protection of privacy; The project cannot be conducted using non-identifiable information;

It is impracticable to seek consent from the people whose information is to be used or disclosed;

The information requested is the minimum necessary to accomplish the purpose; and The project ensures the security of the information.

The Committee's details and relevant documentation may be found at http://www.health.wa.gov.au/healthdata/HREC/index.cfm

Appendix 2E. Cancer notification regulations

NOTE these Regulations, in force until June 2010, have been superseded by new Regulations – refer to the new Regulations and a summary of changes at http://www.health.wa.gov.au/wacr/home/regulations.cfm

HEALTH (NOTIFICATION OF CANCER) REGULATIONS 1981*

(as modified by the Health (Notification of Cancer) Amendment Regulations 1996)** MADE by His Excellency the Governor in Executive Council.

1. These regulations may be cited as the Health (Notification of Cancer) Regulations 1981.

These regulations shall come into operation on 1 August 1981

In these regulations, unless the contrary intention appears, the term "cancer" means any
malignant growth of human tissue which if unchecked is likely to spread to adjacent tissue
and beyond its site of origin and includes -

(a) all in situ neoplasms;

- (b) all malignant neoplasms of the skin other than primary basal cell carcinoma and primary squamous cell carcinoma;
- (c) all neoplasms of the brain, spinal cord and cranial nerves, and any other intracranial neoplasms, whether benign or malignant.

 Cancer is prescribed as a condition of health to which Part IXA of the Health Act 1911 applies.

5. (1) A medical practitioner who undertakes pathological or biochemical examinations of specimens of human origin, including blood, shall, within 30 days of becoming aware that any specimen indicates that the person from whom it is taken suffers from cancer, forward to the Executive Director of Public Health a copy of any report that he may make upon the examination.

(2) A report made under subregulation (1) of this regulation in respect of any person shall include - $\,$

(a) the full name and address of the person;

(aa) the sex and date of birth of the person;

- (b) the name of the medical practitioner by whom the person is referred for examination; and
- (c) if the person is a patient in a hospital, the name and address of the hospital.
- 6. A person who is in charge of any place in which cancer is treated by ionising radiation or accelerated atomic particles shall, within 30 days of the first occasion on which any person is so treated, furnish the Executive Director of Public Health with the following information in relation to that person, namely -

(a) full name and address of the person;

- (b) sex and date of birth of the person; and
- (c) the type of cancer for which that person is being treated.
- (d) the name of the medical practitioner by whom the person is referred for examination; and
- (e) if the person is a patient in a hospital, the name and address of the hospital.
- A fee of \$4 for each person in respect of whom notification is made under regulation 5 or 6
 is payable to the person who makes the notification to the Executive Director of Public
 Health.

8. (1) Where the Executive Director of Public Health is notified of the name of a person who suffers from cancer or who is treated for cancer the Executive Director of Public Health may request any medical practitioner or person in charge of a hospital to provide him with any information of the kind set out in the Schedule to these regulations that is known to the medical practitioner in relation to that person.

- (2) A person to whom a request is made pursuant to subregulation (1) of this regulation shall comply with that request within 30 days of the receipt of the request.
- (1) A person who contravenes a provision of the regulations specified in the Table to this subregulation commits an offence.

Table

Regulations 5, 6 and 8(2).

- (2) A person who commits an offence under subregulation (1) is liable to a penalty which is not more than \$1,000 and not less than -
 - (a) in the case of a first offence, \$100;
 - (b) in the case of a second offence, \$200; and
 - (c) in the case of a third or subsequent offence, \$500.

Citation.

Commencement.

Interpretation.

Cancer prescribed as a condition of health.

Notification by pathologist.

Notification by radiation oncologist.

Fee for notification.

Executive Director of Public Health may require further particulars.

^{(*} Published in the Gazette of 24 July 1981 at pp. 3056-6. For amendments to 15 January 1996 see 1994 Index to Legislation of Western Australia, Table 4, pp. 130-131.)

^{**} Presented in good faith as an accurate representation of the content of Regulations and Schedule as amended February 1996.

HEALTH (NOTIFICATION OF CANCER) REGULATIONS 1981* (as modified by the Health (Notification of Cancer) Amendment Regulations 1996)**

(continued)

Schedule.
NOTIFICATION OF CANCER.

NAME OF PATIENT:

ADDRESS:

SEX:

DATE OF BIRTH:

OCCUPATION:

MARITAL STATUS:

PLACE AND COUNTRY OF BIRTH:

RACE:

DATE OF DIAGNOSIS OF CANCER:

PLACE OF RESIDENCE OF PATIENT AT DIAGNOSIS OF CANCER:

DATE OF ADMISSION OR OUTPATIENT CONSULTATION:

PRIMARY SITE OF CANCER (where known):

MORPHOLOGICAL SUBTYPE OF CANCER (where known):

METHOD OF DIAGNOSIS OF CANCER:

By His Excellency's Command.

Clerk of the Council.

Appendix 2F. Cancer codes

(a) ICD-O Site codes

Codes(1)	Site/Topography	Codes	Site/Topography
C00 - C06	Lip, gum & mouth (excludes C01-C02)	C49	Connective, subcutaneous & other soft tissues
C01 - C02	Tongue	C50	Breast
C07	Parotid gland	C51	Vulva
C08	Salivary glands	C52	Vagina
C09 - C14	Pharynx (excludes C11)	C53	Cervix uteri
C11	Nasopharynx	C54	Corpus uteri (Uterus)
C15	Oesophagus	C55	Uterus, nos (not used)
C16	Stomach	C56	Ovary
C17	Small intestine	C57	Uterine adnexa & other fem. genital
C18	Colon	C58	Placenta
C19 - C20	Rectosigmoid junction & rectum	C60	Penis
C21	Anus	C61	Prostate gland
C22	Liver & intrahepatic bile ducts	C62	Testis
C23 - C24	Gallbladder & bile ducts	C63	Male genital, other
C25	Pancreas	C64	Kidney (excludes renal pelvis C65)
C30 - C31	Nasal cavity & sinuses, middle & inner ear	C65 - C68	Bladder & urinary tract
C32	Larynx	C69	Eye & lacrimal gland
C33 - C34	Lung, bronchus & trachea	C70	Meninges (cerebral & spinal)
C37	Thymus	C71	Brain
C38	Pleura, heart & mediastinum	C72	Spinal cord & cranial nerves
C40 - C41	Bones, joints & articular cartilages	C73	Thyroid gland
C44	Skin	C74	Adrenal gland
C47	Nervous system, peripheral & autonomic	C75	Endocrine glands, other
C48	Retroperitoneum and peritoneum	C80	Unknown primary site

Notes: (1) Only 1st 3 characters shown. Groupings based on IARC rules governing the reporting of incident cancers for ICDO-3. Using these same rules, non-lymphohaematopoietic neoplasms of primary sites reported as C26 (Intestinal tract NOS), C39 (respiratory tract ill-defined / NOS), C42 (haematopoietic system), C76 (large body regions NOS) and C77 (lymph nodes) are tabulated as cancers of unknown primary site.

(b) Morphology code groups for lymphohaematopoietic malignancies

The tabulation scheme for lymphohaematopoietic neoplasms (LHNs) used in previous WACR reports was based on a combination of groupings used in ICD-O, ICD9 and ICD10, which reflected, to varying degrees, previous well-accepted classification schemes such as the REAL and the Working Formulation. Increasingly, classification of such tumours as used by pathologists and clinicians has changed, and older headings have become somewhat irrelevant to modern medical practice.

The tabulation groupings used in this report are based on those used in the ICDO-3 classification, which has been influenced by the WHO Classification of Haematopoietic and Lymphoid Neoplasms (2001). In the current report, group headings still retain terms such as lymphoma and leukaemia, for the sake of familiarity. While these names remain in the WHO scheme for individual conditions, group headings have in many cases been replaced by less-specific terms such as "B-Cell neoplasms" and "T-cell neoplasms" which may be unfamiliar to some users of Cancer Registry data. Depending on developments in this area (and on decisions made by other Registries, and by others who are concerned that cancer classification should be compatible with non-cancer disease classifications using ICD-10), future reports may eventually follow the WHO classification scheme.

Since 2003, some conditions previously not regarded as malignant (e.g. polycythaemia and myelodysplastic diseases) are now included as "cancers".

Revised multi-level tabulation scheme for reporting of Malignant lymphohaematopoietic neoplasms (WACR 2003, updated 2011)

1 All l	ymphomas		WACR code Y**	ICDO-3 M codes
1a		as, NOS/unclassifiable	YUC	9590
1b	Hodgkin ly		YHO	9650-9667
1c	All NHL	ymphoma	YN*	
10	1c1	NHL, mature B Cell	YNB	9670-9671, 9673, 9675, 9678- 9680, 9684, 9687, 9689-9691,
	1c2	NHL, mature T / N-K cell	YNT	9695, 9698-9699,9766 9700-9702, 9705, 9708-9709, 9714, 9716, 9717-9719
	1c3	NHL, precursor cell lymphoblastic	YNP	9727-9729
	1c4	NHL, other / unclassifiable	YNO	9591, 9596-9599*
	1c1x	NHL, Burkitt (subset of 1c1)	YNBB	9687
2 Mye	eloma/Plasr	na Cell tumours	P*	9731-9734
3 All I	eukaemias		L**	
3a	Leukaemi	as, NOS/unclassifiable	LUC	9800-9801, 9805
3b	Leukaemi	as, lymphoid, all	LL*	
	3b1	Leukaemias, lymphoid, acute	LLA	9836-9837
	3b2	Leukaemias, lymphoid, chronic	LLC	9823
	3b3	Leukaemias, lymphoid, other/NOS	LLO	9820,9826, 9827, 9831-9834,
3c	Leukaemi	as, myeloid, all	LM*	
	3c1	Leukaemias, myeloid, acute	LMA	9840, 9861, 9866-9867, 9870- 9874, 9891,9895-9897, 9910,9920,9930-9931
	3c2	Leukaemias, myeloid, chronic	LMC	9863,9875-9876
	3c3	Leukaemias, myeloid, other & NOS	LMO	9860
3d	Other leuk	-	LOT	9940,9945-9946,9948
4 Oth	er lymphoh	aematopoietic malignancies		
4a		plastic diseases, all	HM*	
	4a1	Refractory anaemias/cytopaenias	HMR	9980-9985
	4a2	Myelodysplastic syndromes	HMS	9986-9989
4b	Chronic m	yeloproliferative diseases, all	HC*	
	4b1	Chronic MPD, NOS	HCX	9960
	4b2	Polycythaemia rubra vera	HCP	9950
	4b3	Myelofibrosis/sclerosis	HCS	9961
	4b4	Other chronic MPDs	HCO	9962-9964
4c	Other imm	nunoproliferative malignancies	HI*	
	4c1	Mast cell tumours	HIM	9740-9742
	4c2	Malig. histiocytic/dendritic cell	HIH	9750, 9754-9758
	4c3	neoplasms Other & U/S immunoproliferative neoplasms	HII	9760-9764

^{*9597, *9598} and *9599 are W.A.C.R. codes for "NOS" NHL which are able to be grouped as low, intermediate or high grade respectively but which could only be otherwise placed in the ICDO classification as code 9591.

Appendix 2G. WACR publications

Note: It is strongly recommended that retrospective studies utilize time-series that have been produced using updated versions of historical data, available from the Registry; and that figures from old reports not be used for such purposes. However, various topics of interest may be found in previous publications listed here.

FitzGerald P, Thomson N and Thompson J (1994) *Cancer incidence and mortality in Western Australia 1991*. Health Department of Western Australia, Perth, Statistical Series number 39.

Thompson J, FitzGerald P (1995) *Childhood cancer incidence, mortality and survival in Western Australia 1982-1991*. Health Statistics Branch, Health Department of Western Australia, Perth.

Threlfall TJ, Whitfort MJ, Thompson JR (1996) *Cancer incidence and mortality in Western Australia*, 1992-1994. Health Department of Western Australia, Perth, Statistical Series number 45.

Threlfall T, Morgan A (1996) *Malignant mesothelioma in Western Australia*, 1960 to 1994. Health Department of Western Australia, Perth, Statistical Series number 46.

Threlfall TJ (1997) *Cancer incidence and mortality projections for Western Australia*, 1996-2001. Health Department of Western Australia, Perth, Statistical Series number 50.

Threlfall TJ, Thompson JR (1997) *Cancer incidence and mortality in Western Australia*, 1995. Health Department of Western Australia, Perth, Statistical Series number 51.

Threlfall TJ, Thompson JR (1998) *Cancer incidence and mortality in Western Australia*, 1996. Health Department of Western Australia, Perth, Statistical Series number 55.

Threlfall TJ, Thompson JR (1999) *Cancer incidence and mortality in Western Australia*, 1997. Health Department of Western Australia, Perth, Statistical Series number 57.

Threlfall TJ, Brameld K (2000) *Cancer survival in Western Australian residents, 1982-1997*. Health Department of Western Australia, Perth, Statistical Series number 60.

Threlfall TJ, Thompson JR (2000) *Cancer incidence and mortality in Western Australia*, 1998. Health Department of Western Australia, Perth, Statistical Series number 61.

Threlfall TJ, Thompson JR (2002) *Cancer incidence and mortality in Western Australia*, 1999 and 2000. Health Department of Western Australia, Perth, Statistical Series number 65.

Threlfall TJ, Thompson JR (2003) *Cancer incidence and mortality in Western Australia*, 2001. Health Department of Western Australia, Perth, Statistical Series number 68.

Threlfall TJ, Thompson JR (2004) *Cancer incidence and mortality in Western Australia*, 2002. Department of Health, Western Australia, Perth. Statistical series number 71.

Threlfall TJ, Thompson JR, Olsen N (2005). *Cancer in Western Australia: Incidence and mortality 2003 and Mesothelioma 1960-2003.* Department of Health, Western Australia, Perth. Statistical series number 74.

Threlfall TJ, Thompson JR (2006). Cancer incidence and mortality in Western Australia, 2004. Department of Health, Western Australia, Perth. Statistical series number 76.

Threlfall TJ, Thompson JR (2007). Cancer incidence and mortality in Western Australia, 2005. Department of Health, Western Australia, Perth. Statistical Series Number 81.

Threlfall TJ, Thompson JR (2007). Cancer incidence and mortality in Western Australia, 2006. Department of Health, Western Australia, Perth. Statistical Series Number 82.

Threlfall TJ, Thompson JR (2009). Cancer incidence and mortality in Western Australia, 2007. Department of Health, Western Australia, Perth. Statistical series number 86.

Threlfall TJ, Thompson JR (2010). Cancer incidence and mortality in Western Australia, 2008. Department of Health, Western Australia, Perth. Statistical series number 87.

Appendix 2H. Guide to tables in Appendix 3

Note: The order of cancer types in the tables in Appendix 2F are the basis for the wide-format incidence and mortality tables in Appendix 3.

Terms and formatting

Terms used in table headings are explained under "Statistical methods" (Section 1.4) and abbreviations repeated in Appendix 2A.

Age groups are expressed in whole years, i.e. "10-14" means 10.0 to 14.99.... years.

For most cancers in the wide-format tables which follow, there are 2 rows for each sex. The upper one contains total cases, ASR, 95% confidence interval, risk and other summary statistics.

Under the headings for individual age groups, the upper rows also contain counts (cases or deaths) in whole numbers.

The numbers (1 decimal place) shown in the lower rows for each sex are age-specific rates per 100,000 for the relevant age group.

The larger, wide-format tables e.g. Appendices 3A, B and C, contain some sections which are summaries of others within the tables (e.g. "All Lymphomas"), hence the summation of case numbers or rates over all rows of the tables will not match the totals at the end of each table, which were calculated separately.

Order of cancer types within tables

In general, tables follow the order of cancer types as listed in **Appendix 2F**, with site-specific cancers listed first, then lymphohaematopoietic malignancies - lymphomas, myeloma, mast cell tumours, miscellaneous immunoproliferative tumours, then leukaemias - followed by the Unknown Primary Site and Total Cancers groups.

Note: The mortality appendix table includes deaths due to all non-melanoma skin cancers (NMSC), some of which are not listed in the Incidence tables. Some NMSC, such as Merkel cell or sweat gland carcinomas, are included in incidence statistics in this report, but these do NOT include basal cell carcinoma and squamous cell carcinoma (ICDO-3 morphology codes 8050 - 8110).

Notes -

Appendix 3A now contains an incidence data summary for the most common cancer types on page A3-10.

In Appendix 3B, the Total deaths due to cancer ("all cancer deaths", "all cancers") apears on page A3-19. The "Total deaths of Cancer Registry cases" on page A3_20 includes noncancer and all other deaths in persons with a valid WA tumour record.

	ix 3A. Ca											05.00	70.71	75 70	00.01	05 !	T-4-1	4 O D	050/ - :	TD0/		D:-I	4000
	5- 9 10-14 uth (C000-C069)			25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD% (Jumino	Risk	ASR2
M	an (C000-C009)	(1101 001	3 3.4	3 3.4	4 5.1	6 7.0	10 12.1	8 9.7	8 10.7	14 20.7	9 15.3	8 19.0	8 25.3	11 47.2	7 43.5	3 26.8	102	6.5	5.2-7.7	100.0	0.7	152	9.3 (7.5-11.1)
F			1 1.2			3 3.6	3 3.7	7 8.6	4 5.4	2 3.0	4 7.1	6 14.5	3 9.1	4 15.1	4 18.9	2 9.5	43	2.6	1.8-3.5	100.0	0.3	355	3.7 (2.6-4.9)
Tongue (C010-	C029)																						
М					1 1.3	1 1.2	1 1.2	3 3.6	5 6.7	4 5.9	8 13.6	8 19.0	2 6.3	5 21.4	2 12.4	1 8.9	41	2.6	1.8-3.4	95.0	0.3	341	3.6 (2.5-4.8)
F		1 1.3			1 1.3		2 2.5	4 4.9	2 2.7	2 3.0	3 5.3	2 4.8	1 3.0	3 11.4	2 9.5	1 4.7	24	1.5	0.9-2.1	100.0	0.1	690	2.1 (1.2-2.9)
Parotid gland (0	C070-C079)																						
M							1 1.2	1 1.2	1 1.3	3 4.4	3 5.1		1 3.2		1 6.2	1 8.9	12	0.7	0.3-1.2	92.0	0.1	1217	1.0 (0.4-1.6)
F		1 1.3						2 2.5		1 1.5	1 1.8	2 4.8			2 9.5	2 9.5	11	0.6	0.2-1.1	100.0	0.1	1678	0.9 (0.4-1.4)
	glands (not paro	tid) (C080	-C089																				
М				1 1.1				1 1.2	2 2.7		1 1.7	2 4.8				1 8.9	8	0.6	0.2-0.9	100.0	0.1	1743	0.7 (0.2-1.2)
F						1 1.2				2 3.0							3	0.2	0 - 0.4	100.0	0.0	4732	0.2 (0 - 0.5)
	-C149) (not C11)																					
М						2 2.3		6 7.3	13 17.3	8 11.8	16 27.2	8 19.0	5 15.8	6 25.7	3 18.6	1 8.9	68	4.3	3.3-5.3	97.0	0.5	199	5.9 (4.5-7.4)
F							1 1.2	1 1.2	2 2.7	1 1.5	2 3.6	3 7.3		1 3.8		1 4.7	12	8.0	0.3-1.2	92.0	0.1	1143	1.0 (0.4-1.6)
Nasopharynx (0 M	C110-C119)			1			2	1	2	3	1						10	0.7	0.3-1.1	100.0	0.1	1474	0.8 (0.3-1.4)
F				1.1			2.4	1.2	2.7	4.4 1	1.7						1	0.1	0 - 0.2	100.0	0.0	*	0.1 (0 - 0.2)
										1.5													
Oesophagus (C M	C150-C159)						5 6.1	4 4.8	8 10.7	10 14.8	9 15.3	12 28.6	14 44.2	10 42.9	10 62.1	6 53.6	88	5.1	4.0-6.2	95.0	0.6	161	8.3 (6.6-10.1)
F									2 2.7	3 4.5	5 8.9	3 7.3	2 6.1	7 26.5	8 37.9	8 37.8	38	1.7	1.1-2.2	97.0	0.1	680	3.1 (2.1-4.1)
Stomach (C160)-C169)														00	07.10							
М					1 1.3	1 1.2	3 3.6	5 6.1	8 10.7	15 22.2	18 30.6	12 28.6	16 50.5	10 42.9	21 130.4	11 98.3	121	6.8	5.6-8.1	95.0	0.8	130	11.4 (9.4-13.5)
F					2 2.6	2 2.4		5 6.2	2 2.7	1 1.5	3 5.3	5 12.1	8 24.3	8 30.3	3 14.2	7 33.1	46	2.5	1.7-3.2	93.0	0.3	351	4.0 (2.9-5.2)
Small intestine M	(C170-C179)	1			1	1	2	2	2	1	4	3	2			4	23	1.5	0.9-2.2	96.0	0.2	608	2.1 (1.2-3.0)
		1.2			1.3	1.2	2.4	2.4	2.7	1.5	6.8	7.1	6.3			35.7							. ,
F								1 1.2	2 2.7	1 1.5		1 2.4	2 6.1		1 4.7		8	0.5	0.1-0.8	100.0	0.1	1437	0.7 (0.2-1.2)

Append	dix 3A	Cance	r inc	ider	ice, \	West	ern	Aust	ralia	, 200)9												
Age 0-	4 5-9	10-14 15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD%	CumInc	Risk	ASR2
Colorectal ca	ancer (C18-	C20, C218)																					
М			1 1.1	8 9.2	2 2.5	8 9.4	19 23.0	29 35.1	53 70.6	65 96.1	98 166.4	111 264.3	116 366.3	96 411.6	88 546.5	45 402.2	739	43.2	40.0-46.4	98.0	5.2	20	69.8 (64.7-74.9)
F			2 2.5		6 7.9	7 8.5	15 18.7	24 29.6	33 44.4	54 81.4	55 97.9	61 147.6	77 233.6	71 268.8	72 341.0	65 307.2	545	28.8	26.2-31.4	96.0	3.4	30	46.6 (42.7-50.5)
Colon (C180-	-C189)																				***************************************		
М			1 1.1	5 5.7		1 1.2	11 13.3	12 14.5	25 33.3	43 63.6	58 98.5	68 161.9	78 246.3	69 295.8	68 422.3	32 286.0	471	26.7	24.2-29.2	97.0	3.2	32	45.1 (41.0-49.2)
F			1 1.2	1 1.3	3 3.9	4 4.8	9 11.2	14 17.3	19 25.5	27 40.7	37 65.9	40 96.8	62 188.1	56 212.0	55 260.5	51 241.0	379	19.3	17.2-21.4	95.0	2.3	44	32.5 (29.2-35.8)
Rectosigmoid	d junction &	rectum (C190	-C209)																		***************************************		
М				3 3.4	2 2.5	7 8.2	8 9.7	17 20.6	28 37.3	22 32.5	39 66.2	43 102.4	38 120.0	26 111.5	20 124.2	13 116.2	266	16.3	14.3-18.3	99.0	2.0	50	24.5 (21.5-27.4)
F			1 1.2	2 2.5		3 3.6	6 7.5	10 12.3	14 18.8	27 40.7	18 32.1	21 50.8	15 45.5	15 56.8	16 75.8	14 66.2	165	9.5	8.0-11.0	99.0	1.1	92	14.0 (11.9-16.2)
Anus (C210-	C219)	***************************************																					
М					1 1.3					1 1.5	2 3.4	2 4.8		2 8.6		1 8.9	9	0.5	0.2-0.9	89.0	0.1	1835	0.8 (0.3-1.4)
F								3 3.7	6 8.1	1 1.5	2 3.6	3 7.3		2 7.6	1 4.7	2 9.5	20	1.2	0.6-1.7	100.0	0.1	830	1.7 (0.9-2.4)
Liver & intrah	nepatic bile	ducts (C220-C	229)																				
	.6	`	,				2 2.4	4 4.8	10 13.3	12 17.7	10 17.0	7 16.7	12 37.9	5 21.4	7 43.5	5 44.7	76	4.7	3.6-5.8	55.0	0.6	178	7.0 (5.4-8.6)
F 1	1 .4	1 1.4		1 1.3	1 1.3	1 1.2		3 3.7	3 4.0	1 1.5	2 3.6	2 4.8	5 15.2	2 7.6	6 28.4	4 18.9	33	1.9	1.2-2.7	67.0	0.2	508	2.8 (1.9-3.8)
Gallbladder 8				1.0	1.0	1.2			1.0	1.0	0.0	1.0	10.2		20.1	10.0							
М		(,				1 1.2		2 2.4	1 1.3	3 4.4	11 18.7	4 9.5	5 15.8	5 21.4	3 18.6	3 26.8	38	2.2	1.5-3.0	89.0	0.3	375	3.5 (2.4-4.6)
F							1 1.2	1 1.2	3 4.0	2 3.0	4 7.1	3 7.3	5 15.2	3 11.4	6 28.4	5 23.6	33	1.7	1.0-2.3	82.0	0.2	512	2.8 (1.8-3.7)
Pancreas (Ca	250-C259)						1.2	1.2	4.0	3.0		7.5	13.2	11.7	20.4	23.0							
М					1 1.3	1 1.2	2 2.4	3 3.6	13 17.3	10 14.8	19 32.3	16 38.1	15 47.4	20 85.7	14 86.9	14 125.1	128	7.3	6.0-8.6	75.0	0.8	127	12.3 (10.1-14.5)
F						2 2.4	2 2.5		7 9.4	13 19.6	15 26.7	18 43.6	13 39.4	22 83.3	15	24 113.4	131	6.5	5.3-7.7	64.0	0.7	140	11.0 (9.1-12.9)
Nasal cavity/	sinuses mi	ddle & inner ea	ar (C30))-C319)		2.4	2.0		3.4	13.0	20.1	43.0	33.4	00.0	71.0	110.4							
M	oaooo,		a. (000.	,			3 3.6			1 1.5	2 3.4		2 6.3	1 4.3	2 12.4		11	0.6	0.3-1.0	82.0	0.1	1350	1.0 (0.4-1.6)
F						1 1.2			1 1.3					1 3.8	1 4.7	1 4.7	5	0.2	0.0-0.4	100.0	0.0	7824	0.4 (0.0-0.8)
Larynx (C320	0-C329)					1.2			1.3					3.0	4.7	4.1							
M	. 3020,				1 1.3	1 1.2	1 1.2	3 3.6	3 4.0	4 5.9	6 10.2	8 19.0	8 25.3	3 12.9	3 18.6		41	2.6	1.8-3.4	98.0	0.4	280	3.7 (2.6-4.8)
F								1 1.2		2 3.0	1 1.8	3 7.3	1 3.0			1 4.7	9	0.6	0.2-0.9	100.0	0.1	1226	0.7 (0.3-1.2)
								1.2		ა.0	1.8	1.3	ა.0			4.7							

App	endix	3A. Cance	er in	cide	nce, \	West	tern	Aust	ralia	, 200)9												
Age		5-9 10-14 15-19		24 25-2	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD%	CumInc	Risk	ASR2
	oronchus & t	trachea (C330-C34																					
M			1	1		4	4	10	22	48	78	95	102	97	71	51	583	32.9	30.1-35.6	88.0	4.0	25	56.3 (51.7-60.9)
_						4.7	4.8	12.1	29.3	71.0		226.2		415.8	440.9	455.8							
F				1	-	3	5	4	28	35	46	52	62	65	52	39	393	20.5	18.3-22.7	88.0	2.5	40	33.9 (30.5-37.3)
Thymu	s (C370-C3	70)	1	.2 1.	3	3.6	6.2	4.9	37.6	52.8	81.9	125.9	188.1	246.1	246.3	184.3							
M	3 (03/0-03	11 3)				1						1		1			3	0.2	0 - 0.4	100.0	0.0	5632	0.3 (0 - 0.6)
						1.2						2.4		4.3									0.0 (0 0.0)
F					1				1	1							3	0.2	0 - 0.5	67.0	0.0	4857	0.3 (0 - 0.6)
•				1.3					1.3	1.5							•	V	0 0.0	00	0.0	.00.	0.0 (0 0.0)
Pleura	heart & me	ediastinum (C380-C	389)	•																			
М	1							1			. 1						3	0.3	0 - 0.7	100.0	0.0	4744	0.2 (0 - 0.5)
	1.3							1.2			1.7												
F													1				1	0.1	0 - 0.2	100.0	0.0	6593	0.1 (0 - 0.3)
Donos	iointo 9 orti	ioular aartilagaa (C	400 C	10)									3.0										
M Bones	joints & arti	icular cartilages (C	400-C4	2		1	1	1		1	1		1	2			11	0.8	0.3-1.3	91.0	0.1	1490	1.0 (0.4-1.6)
IVI		1.2	2 2	.3		1.2	1.2	1.2		1.5	1.7		3.2	8.6			• • • • • • • • • • • • • • • • • • • •	0.0	0.5 1.5	31.0	0.1	1430	1.0 (0.4 1.0)
F				2			2		1				1	1		1	8	0.5	0.1-0.9	100.0	0.0	2137	0.7 (0.2-1.2)
Г			2	.5			2.5		1.3				3.0	3.8		4.7	•	0.5	0.1-0.9	100.0	0.0	2131	0.7 (0.2-1.2)
Skin (n	nelanoma or	nly) (C440-C449; M																					
M .				5	7 18		24	36	40	77	84	85	92	53	49	38	643	39.6	36.5-42.7	99.0	4.8	21	59.2 (54.5-63.8)
		1.2	2 5	.7 8.	22.7	39.8	29.0	43.6	53.3	113.9	142.6	202.4	290.5	227.2	304.3	339.6							
F				7 1	24	26	32	33	37	49	45	24	28	28	22	35	400	24.8	22.3-27.4	100.0	2.6	40	34.5 (31.1-37.9)
				.7 12.	7 31.6	31.5	40.0	40.7	49.7	73.9	80.1	58.1	85.0	106.0	104.2	165.4							
	ot melanom	na/SCC/BCC) (C44	0-C449	9)	_			_		_	_		_	_	_	_							
M		1			2 2.5			3 3.6		2 3.0	6 10.2	4 9.5	6 18.9	7 30.0	8 49.7	7 62.6	47	2.6	1.8-3.4	100.0	0.3	399	4.7 (3.3-6.0)
		1.3				1.2																	
F				1				1		3	2	5	3	1	7	8	33	1.6	1.0-2.2	100.0	0.2	583	2.7 (1.7-3.6)
Mocotk	olioma (MO	005; ICD10 C45)	1	.2 1.	3 1.3			1.2		4.5	3.6	12.1	9.1	3.8	33.2	37.8							
M	ienoma (M9	100, 100 10 040)				1		3	3	1	9	18	18	13	11	4	81	4.7	3.6-5.7	95.0	0.6	160	7.9 (6.1-9.6)
•••						1.2		3.6	4.0	1.5	15.3	42.9	56.8	55.7	68.3		•	•••	0.0 0	00.0	0.0	.00	1.0 (0.1 0.0)
F										1	1	1	1	4	3	3	14	0.6	0.2-0.9	93.0	0.0	2288	1.2 (0.6-1.8)
•										1.5	1.8	2.4	3.0	15.1	14.2			0.0	0.2 0.3	33.0	0.0	2200	1.2 (0.0 1.0)
Kaposi	sarcoma (N	M914; ICD10 C46)																					
M	,	, i										1		1			2	0.1	0 - 0.3	100.0	0.0	8400	0.2 (0 - 0.5)
												2.4		4.3									
F																	0						
	ıs system, p	eripheral/autonomi	c (C47	0-C479)													_						
М		1												2			3	0.2	0 - 0.5	100.0	0.0	*	0.3 (0 - 0.7)
		1.4												8.6									
F									1							1	2	0.1	0 - 0.2	100.0	0.0	*	0.2 (0 - 0.4)
									1.3							4.7							

Appendix 3A. C					•					•													
Age 0-4 5-9 10-14 Retroperitoneum and peritone				25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD%(CumInc	Risk	ASF
M	um (v	J40U-\	J409)		1 1.3						2 3.4	2 4.8					5	0.4	0.0-0.7	100.0	0.0	2123	0.4 (0.0-0.8
F									1 1.3	1 1.5	2 3.6	3 7.3		1 3.8	3 14.2	1 4.7	12	0.6	0.2-1.0	92.0	0.1	1463	1.0 (0.4-1.
Connective, subcutaneous &	other	soft tis	ssues	(C490-0	C499)																		
M			1 1.1	2.3			3 3.6		1 1.3	4 5.9	2 3.4	4 9.5	4 12.6	2 8.6	4 24.8		27	1.7	1.0-2.3	100.0	0.2	502	2.5 (1.5-3.
F		1 1.3	1 1.2			1 1.2	2 2.5	1 1.2	1 1.3	2 3.0	3 5.3	2 4.8	1 3.0	1 3.8	2 9.5	2 9.5	21	1.4	0.7-2.0	90.0	0.1	756	1.8 (1.0-2.
Breast (C500-C509)						***************************************						***************************************											
М						1 1.2						1 2.4	1 3.2	1 4.3	3 18.6		7	0.3	0.1-0.6	100.0	0.0	2982	0.7 (0.2-1.
F			2 2.5	6 7.6	20 26.3	57 69.1	101 126.2	173 213.6	158 212.4	165 248.7	167 297.4	128 309.8	106 321.6	80 302.8	83 393.1	67 316.6	1313	81.7	77.1-86.3	99.0	9.2	11	112.9 (107-11
Vulva (C510-C519)														***************************************									
F						2 2.4		3.7	1.3	3.0	3 5.3	1 2.4	4 12.1	4 15.1	1 4.7	2 9.5	23	1.3	0.7-1.9	100.0	0.2	659	2.0 (1.2-2.
Vagina (C520-C529)												0					_		0400	400.0	0.4	4040	0.0 (0.0.1
F (0500 0500)		1 1.3						1.2			1 1.8	2 4.8	2 6.1				7	0.5	0.1-0.9	100.0	0.1	1312	0.6 (0.2-1.
Cervix uteri (C530-C539) F			1 1.2	11 13.9	11 14.5	9 10.9	9 11.2	12 14.8	12 16.1	5 7.5	7 12.5	3 7.3	5 15.2	4 15.1	3 14.2		92	6.7	5.3-8.0	99.0	0.6	160	8.3 (6.6-10.
Corpus uteri (C540-C549) F		1			3	2	1	7	12	30	40	23	21	11	12	13	176	10.5	8.9-12.1	100.0	1.3	75	14.7 (12.5-16.
Jterus, nos (C550-C559)		1.3			3.9	2.4	1.2	8.6	16.1	45.2	71.2	55.7	63.7	41.6	56.8	61.4							
F (0000 0000)								1 1.2		2 3.0							3	0.2	0 - 0.4	100.0	0.0	4707	0.2 (0 - 0.
Ovary (C560-C569) F		2	1	1	1	5	6	8	7	14	22	14	13	10	6	7	117	7.3	5.9-8.7	94.0	0.9	116	10.0 (8.2-11.
		2.6	1.2	1.3	1.3	6.1	7.5	9.9	9.4	21.1	39.2	33.9	39.4	37.9	28.4	33.1							
Jterine adnexa & oth. fem ge F	n. (Cŧ	570-C5	579)		1 1.3					1 1.5		1 2.4	2 6.1	4 15.1		3 14.2	12	0.6	0.2-0.9	100.0	0.1	1769	1.1 (0.5-1.
Placenta (C580-C589)					1.0					1.0		<u> </u>	0.1	10.1		17.4							
F			1 1.2														1	0.1	0 - 0.3	100.0	0.0	*	0.1 (0 - 0.
Penis (C600-C609)																							
M								1 1.2		1 1.5				1 4.3			3	0.2	0 - 0.4	100.0	0.0	7433	0.3 (0 - 0
Prostate gland (C610-C619) M						1 1.2	12 14.5	55 66.7	127 169.1	271	386	379	305 963.0	243	165	86 768 6	2030	121.4	116-127	98.0	15.9	7	185.0 (177-19
Festis (C620-C629)	I	2	10	9	9	1.2	14.5	11	3	1	2	902.4	303.0	1.041.0	1024.1	7 00.0	72	5.7	4.3-7.0	100.0	0.4	226	6.2 (4.8-7.

App	endix	(3A.	Cai	nce	rinc	den	ce, V	Vest	ern	Aust	ralia	, 200	9												<u> </u>
Age			10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD% (CumInc	Risk	ASR2
Other m M	ale genit	al (C63	0-C639)																0						
, ,	C640-C6	549)																							
М	2 2.6				1 1.1			5 5.9	4 4.8	20 24.2	16 21.3	27 39.9	30 50.9	21 50.0	21 66.3	14 60.0	12 74.5	10 89.4	183	11.4	9.7-13.2	92.0	1.3	75	16.5 (14.0-18.9)
F	1.4	2 2.9					1 1.3	4 4.8	5 6.2	7 8.6	5 6.7	10 15.1	14 24.9	13 31.5	8 24.3	14 53.0	5 23.7	4 18.9	93	5.8	4.6-7.1	90.0	0.6	157	8.1 (6.5-9.8)
Bladder M	& urinary	y tract (C650-C6	i89)		1 1.1		1 1.2	4 4.8		13 17.3	9 13.3	21 35.7	32 76.2	23 72.6	27 115.8	33 204.9	27 241.3	191	10.4	8.9-11.9	96.0	1.1	90	18.8 (16.1-21.6)
F								1 1.2	1 1.2	4 4.9	2 2.7	4 6.0	4 7.1	7 16.9	11 33.4	12 45.4	14 66.3	17 80.3	77	3.5	2.6-4.3	97.0	0.4	272	6.5 (5.0-7.9
Eye & la M	crimal gl 2 2.6	and (C6	90-C69	9)			1 1.3		1 1.2	2 2.4	2 2.7	1 1.5	5 8.5	3 7.1	2 6.3		2 12.4	1 8.9	22	1.6	0.9-2.3	91.0	0.2	596	1.9 (1.1-2.8)
F	1 1.4										1 1.3			2 4.8	1 3.0	1 3.8			6	0.5	0.0-0.9	83.0	0.1	1888	0.6 (0.1-1.0)
Meninge		ral & sp	inal) (C7	'00-C7	09)																				
М												1 1.5		1 2.4					2	0.1	0 - 0.3	100.0	0.0	5182	0.2 (0 - 0.4)
F																			0						
Brain (C M	710-C71 2 2.6	9) 1 1.4	2 2.6	1 1.2	5 5.7	2 2.3	1 1.3	2 2.3	5 6.1	7 8.5	2 2.7	9 13.3	15 25.5	9 21.4	5 15.8	10 42.9	7 43.5		85	5.8	4.5-7.1	89.0	0.6	178	7.5 (5.9-9.1)
F	5 6.9		1 1.4		2 2.5	2 2.5	3 3.9	2 2.4	3 3.7	3 3.7	4 5.4	5 7.5	7 12.5	5 12.1	9 27.3	11 41.6	8 37.9	2 9.5	72	4.8	3.6-6.1	81.0	0.5	218	6.4 (4.9-7.9)
	ord & cra	anial nei	ves (C7	20-C72															_						
М										1 1.2					1 3.2			1 8.9	3	0.2	0 - 0.4	100.0	0.0	4578	0.3 (0 - 0.7)
F			1.4																1	0.1	0 - 0.4	0.0	0.0	*	0.1 (0 - 0.3
Thyroid M	gland (C	730-C7	39)	1 1.2	1 1.1	3 3.4	3 3.8	7 8.2	2 2.4	6 7.3	8 10.7	6 8.9	13 22.1	3 7.1	3 9.5	3 12.9	3 18.6	2 17.9	64	4.3	3.2-5.3	98.0	0.4	234	5.6 (4.2-7.0)
F				2 2.6	7 8.7	12 15.2	12 15.8	12 14.5	20	19 23.5	17 22.9	20 30.1	14 24.9	7 16.9	11 33.4	3	2 9.5	1 4.7	159	11.6	9.7-13.4	99.0	1.2	86	14.1 (11.9-16.3)
Adrenal	gland (C	740-C7	49)																						
М	1 1.3				1 1.1									1 2.4	3 9.5				6	0.5	0.1-0.9	100.0	0.1	1400	0.6 (0.1-1.0
F		1 1.5						1 1.2					1 1.8						3	0.3	0 - 0.6	100.0	0.0	4490	0.3 (0 - 0.6
Endocrir M	ne glands	s (not a	drenal) (C750-0	C759)				1		1				4				4	0.3	0.06	75.0	0.0	2857	0.4 (0.0.0.7
			1.3						1.2		1.3				1 3.2				-		0 - 0.6		0.0	2007	0.4 (0.0-0.7
F						1 1.3											1 4.7		2	0.1	0 - 0.3	50.0	0.0	*	0.2 (0 - 0.4)

13	J -		10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD% (CumInc	Risk	AS
1 1 1 2 2 3 3 1 1 2 3 8 8 8 8 8 8 8 1 15 8 8 8 1 16 10 17 0 2 1 2 8 0 0 0 1 17 0 10 0 0 1 10 0 0 0 1 10 0 0 1 10 0 0 0 1 10 0 0 0 1 10 0 0 0 1 10 0 0 0 1 10 0 0 0 1 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			assifiahla																						
Section Sect		1	assinable	•															10	0.7	0.2-1.2	90.0	0.1	1370	0.9 (0.3-
1																			4	0.1	0.0-0.2	50.0	0.0	*	0.3 (0.0-
13		lymphoma					••••••••••					***************************************						·····			***************************************				
Net	И				-														33	2.7	1.8-3.7	97.0	0.2	501	2.8 (1.8-
1 1 1 2 5 5 5 10 11 20 20 20 21 22 20 20 16 11.5 1242 143.0 1 1 1 2 5 5 5 10 11 20 20 20 21 22 20 20 16 11.5 1242 143.0 1 1 1 1 2 7.5 7.5 8.6 8.1 1.0 14 20 19.0 17 21 16 18 18 148 8.0 6.6 9.4 99.0 0.9 110 12.6 11. mature B cell 1 1 1 1 2 4 5 8 8 8 14 15 8 22 30.6 40.5 61.6 79.5 75.8 85.1 1 1 1 1 2 4 5 8 8 8 14 15 8 22 30.6 40.5 61.6 79.5 75.8 85.1 1 1 1 1 2 2 5 5 4 5 5 9 7.7 97. 97. 97. 97. 97. 97. 97. 97. 9																			20	1.7	0.9-2.5	100.0	0.1	690	1.8 (1.0-
1																			212	12.8	11.0-14.5	98.0	1.4	71	20.1 (17.4-2
II. mature B cell								2	6	7	6	14	20	19	17	21	16	18	148	8.0	6.6-9.4	99.0	0.9	110	12.6 (10.5-1
1	,	1						5	8	8	14	15	18	17	20	19	17	8	156	9.4	7.9-11.0	99.0	1.0	96	14.7 (12.3-1
HL mature T/NK cell 1 1 1 1 5 2 2 2 2 4 1 1 1 22 1.3 0.8-1.9 100.0 0.1 721 2 1.3 1.2 1.2 1.3 0.3 3.4 4.8 6.3 17.1 6.2 8.9 1 1 1 1 1 1 2 2 2 3 3 13 0.8 0.3-1.3 100.0 0.1 721 2 HL, precursor cell lymphoblastic 1.2 1 1.2 1 1.2 1 1.2 1 1 2 1 3 3 1 6 7 3 2 7 3 2 7 1 1.2 1 1.2 2 4 1.3 4.4 1.7 14.3 22.1 12.9 12.4 62.6 1 1 2 2 1 3 4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5		1.3	1.3	1.2			5.1	2	5	4	5	13	14	13	12	16	16	8	109	5.9	4.7-7.1	99.0	0.7	150	9.3 (7.6-1
1.3	IL, ma	ture T/NK cell																01.0							
1.3 1.2 1.2 1.3 3.6 4.8 6.1 14.2 ***Li, precursor cell lymphoblastic 1 1.2 ***Li, precursor cell lymphoblastic 1 1.2 ***Li, other/unclassifiable 1 0.1 *	1																	-	22	1.3	0.8-1.9	100.0	0.1	721	2.1 (1.2-
1 0.1 0 - 0.3 100.0 0.0 * 10.0 1.2																			13	0.8	0.3-1.3	100.0	0.1	1023	1.1 (0.5-
HL, other/unclassifiable 1		cursor cell lym	phoblasti	1															1	0.1	0 - 0.3	100.0	0.0	*	0.1 (0 -
1 2 1 3 1 6 7 3 2 7 33 1.9 1.2-2.6 94.0 0.2 422 3 1.2 2.4 1.3 4.4 1.7 14.3 22.1 12.9 12.4 62.6 2 1.2 2.4 1.3 4.4 1.7 14.3 22.1 12.9 12.4 62.6 2 1.3 0.8-1.9 96.0 0.1 670 2 2.5 1.5 7.1 9.7 9.1 18.9 33.1 2 5 16.2 14.1-18.3 98.0 1.7 59 23.8 2.6 2.6 4.9 7.9 6.9 12.6 5.9 18.2 15.8 29.3 31.1 45.8 61.9 94.7 124.3 124.2 143.0 2 19 19 19 172 9.8 8.2-11.4 98.0 1.1 95 14.7 (FELOMA reloma/plasma cell tumours 1 3 7 4 11 6 14 9 10 5 7 7 4.0 3.0-4.9 94.0 0.5 206 6 12 12.3 12.4 14.7 14.3 12.3 12.3 12.3 12.3 12.3 12.3 12.3 12																			0						
Prophomas (all)	,	er/unclassifiab	le						-		-				-				33	1.9	1.2-2.6	94.0	0.2	422	3.3 (2.2-
1 2 2 4 7 6 10 5 15 13 22 21 27 26 30 29 20 16 255 16.2 14.1-18.3 98.0 1.7 59 23.8 2.6 2.6 4.9 7.9 6.9 12.6 5.9 18.2 15.8 29.3 31.1 45.8 61.9 94.7 124.3 124.2 143.0 4 3 4 2 4 6 8 6 15 22 19 19 22 19 19 172 9.8 8.2-11.4 98.0 1.1 95 14.7 5.3 3.7 5.1 2.6 4.8 7.5 9.9 8.1 22.6 39.2 46.0 57.6 83.3 90.0 89.8 7/ELOMA reloma/plasma cell tumours 1 1 3 7 4 11 6 14 9 10 5 70 4.0 3.0-4.9 94.0 0.5 206 6 12.2 3.6 9.3 5.9 18.7 14.3 44.2 38.6 62.1 44.7												-							26	1.3	0.8-1.9	96.0	0.1	670	2.2 (1.3-
4 3 4 2 4 6 8 6 15 22 19 19 22 19 19 19 172 9.8 8.2-11.4 98.0 1.1 95 14.7 5.3 3.7 5.1 2.6 4.8 7.5 9.9 8.1 22.6 39.2 46.0 57.6 83.3 90.0 89.8 VELOMA reloma/plasma cell tumours 1 1 3 7 4 11 6 14 9 10 5 70 4.0 3.0-4.9 94.0 0.5 206 6 11.2 3.6 9.3 5.9 18.7 14.3 44.2 38.6 62.1 44.7		2			-														255	16.2	14.1-18.3	98.0	1.7	59	23.8 (20.9-2
YELOMA reloma/plasma cell tumours 1 3 7 4 11 6 14 9 10 5 70 4.0 3.0-4.9 94.0 0.5 206 6 1.2 3.6 9.3 5.9 18.7 14.3 44.2 38.6 62.1 44.7			0	4	3	4	2	4	6	8	6	15	22	19	19	22	19	19	172	9.8	8.2-11.4	98.0	1.1	95	14.7 (12.5-1
1 3 7 4 11 6 14 9 10 5 70 4.0 3.0-4.9 94.0 0.5 206 6 1.2 3.6 9.3 5.9 18.7 14.3 44.2 38.6 62.1 44.7			ımouro																						
		i/piasilia cell lu	iiii0ui5						-										70	4.0	3.0-4.9	94.0	0.5	206	6.7 (5.1
1								1	-	2	4	5	8	8	5	7	12	10	62	3.0	2.2-3.9	94.0	0.3	306	5.1 (3.8

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD% (CumInc	Risk	ASI
	EMIAS	01 1																							
еикаеі М	mias, NO	5/uncias	ssifiable												1		2	2	5	0.2	0.0-0.4	80.0	0.0	6335	0.6 (0.1-1
															3.2		12.4	17.9	•	V. <u>-</u>	0.0 0	00.0	0.0	0000	0.0 (0.1
F															1.0				1	0.1	0 - 0.2	100.0	0.0	6593	0.1 (0 - 0
															3.0				•	•	0 0.2	.00.0	0.0	0000	0 (0 0
	mias, lym																								
M	6	4 = =	2			3 3.4	1 1.3		3 3.6	5 6.1	7 9.3	7	10 17.0	9 21.4	22 69.5	8 34.3	1 6.2	3	91	6.8	5.3-8.3	99.0	8.0	127	8.4 (6.7-10
	7.8	5.5	2.6			3.4				6.1		10.4						26.8							
=	5 6.9	1 1.5	1 1.4	1 1.3			1 1.3	1 1.2	3 3.7		7 9.4	3 4.5	5 8.9	6 14.5	5 15.2	5 18.9	5 23.7	12 56.7	61	3.9	2.8-5.1	93.0	0.3	287	5.2 (3.9-6
eukaei	mias, lym			1.3			1.3	1.2	3.1		9.4	4.5	0.9	14.5	15.2	10.9	23.1	30.7							
VI	6	4	2			2	1		1	1		1			2				20	2.3	1.3-3.4	100.0	0.1	673	1.8 (1.0-2
	7.8	5.5	2.6			2.3	1.3		1.2	1.2		1.5			6.3										
F	5	1	1	1			1		1		1			1					12	1.5	0.6-2.4	100.0	0.1	1151	1.1 (0.5-1
	6.9	1.5	1.4	1.3			1.3		1.2		1.3			2.4											
eukaei M	mias, lym	phoid, c	hronic							4	_	0	9	9	40	8	1	3	65	4.0	2050	98.0	0.0	170	04/40
VI									1 1.2	4 4.8	5 6.7	6 8.9	15.3	21.4	19 60.0	34.3	6.2	26.8	65	4.0	3.0-5.0	98.0	0.6	170	6.1 (4.6-
=										1.0	6	3				5		11	43	2.0	1 1 2 7	91.0	0.2	464	2 5 (2 5
									1 1.2		8.1	4.5	4 7.1	3 7.3	5 15.2	18.9	5 23.7	52.0	43	2.0	1.4-2.7	91.0	0.2	461	3.5 (2.5-
eukaeı	mias, lym	phoid, o	ther/NC)S				***************************************														***************************************	~~~~~		
M						1			1		2		1		1				6	0.4	0.1-0.8	100.0	0.0	2026	0.5 (0.1-1
						1.1			1.2		2.7		1.7		3.2										
F								1	1				1	2				1	6	0.4	0.1-0.7	100.0	0.0	2202	0.5 (0.1-
						~=~~~		1.2	1.2		~~~~		1.8	4.8				4.7			······································		~~~~		
eukaei M	mias, my 1	eloid, all		3	2	1	2	2	1	6	4	4	7	4	9	10	7	9	73	4.6	3.5-5.7	99.0	0.4	238	7.1 (5.4-
VI	1.3	1.4		3.7	2.3	1.1	2.5	2.3	1.2	7.3	5.3	5.9	11.9	9.5	28.4	42.9	43.5	80.4	7.5	4.0	0.0 0.1	33.0	0.4	200	7.1 (5.4
=	1			2	2		5	1	1	5	1	5	3	3	3	7	4	5	48	3.0	2.0-3.9	98.0	0.3	383	4.2 (3.0-
	1.4			2.6	2.5		6.6	1.2	1.2	6.2	1.3	7.5	5.3	7.3	9.1	26.5	18.9	23.6	-10	0.0	2.0 0.0	00.0	0.0	000	1.2 (0.0)
eukaeı	mias, my	eloid, ac	ute																***************************************			***************************************			
M	1	. 1		2	2		2	2	. 1	5	. 1	3	2	2	7	8	6	7	52	3.2	2.3-4.2	98.0	0.3	360	5.2 (3.7-
	1.3	1.4		2.5	2.3		2.5	2.3	1.2	6.1	1.3	4.4	3.4	4.8	22.1	34.3	37.3	62.6							
=	. 1			. 1	. 1		2	. 1	1	4		3	2	2	1	5	2	2	28	1.8	1.1-2.5	100.0	0.1	669	2.5 (1.5-
	1.4 mias, my	oloid ob	ronio	1.3	1.2		2.6	1.2	1.2	4.9		4.5	3.6	4.8	3.0	18.9	9.5	9.5							
	ilias, iliy	eloiu, cri	TOTIC	1		1				1	3	1			1		1		9	0.6	0.2-1.1	100.0	0.1	1637	0.8 (0.3-
				1.2		1.1				1.2	4.0	1.5			3.2		6.2				V				0.0 (0.0
				1	1		3			1		2	1		2	2		1	14	0.9	0.4-1.5	100.0	0.1	1075	1.3 (0.6-
M					-		3.9			1.2		3.0	1.8		6.1	7.6		4.7		0.0	0.4 1.0	700.0	0.1	1010	1.0 (0.0
Л				1.3	1.2																				
/I : eukaei	mias, my	eloid, otl	ner/NOS		1.2																				
/I · ·ukaei	mias, my	eloid, otl	ner/NOS		1.2		<u> </u>						5	2	1	2		2	12	0.7	0.3-1.1	100.0	0.1	1219	1.1 (0.5-
M =	mias, my	eloid, otl	ner/NOS		1.2								5 8.5	2 4.8	1 3.2	2 8.6	2	2 17.9 2	12	0.7	0.3-1.1	100.0	0.1	1219 5313	1.1 (0.5- ⁻ 0.5 (0.1-

F EIYELODYS efractory a M F Iyelodyspla M F	s (all) 7 9.1 6 8.2 SPLAS anaemi	5 6.9 1 1.5 STIC D			2 2.3 2 2.5	4 4.6	3 3.8 6	2 2.3	4	11	IN AN ANNA AN								0						
eukaemias YELODYS efractory a yelodyspla yelodyspla	7 9.1 6 8.2 SPLAS anaemi	6.9 1 1.5 STIC D	2.6 1 1.4 ISEASE	3.7 3 4.0	2.3		3.8		-	11															
V THE STATE OF TH	7 9.1 6 8.2 SPLAS anaemi	6.9 1 1.5 STIC D	2.6 1 1.4 ISEASE	3.7 3 4.0	2.3		3.8		-	11									0						
EXYELODYS efractory a yelodyspla yelodyspla yelodyspla	9.1 6 8.2 SPLAS anaemi	6.9 1 1.5 STIC D	2.6 1 1.4 ISEASE	3.7 3 4.0	2.3		3.8		-	11				***************************************		***************************************									
YELODYS efractory a M - yelodyspla M yelodyspla	8.2 SPLAS anaemi	STIC D	1.4 ISEASE	4.0 S			6		4.8	13.3	11 14.6	11 16.3	17 28.9	13 31.0	32 101.0	18 77.2	10 62.1	14 125.1	169	11.6	9.7-13.4	98.0	1.2	82	16.1 (13.6-18
efractory a yelodyspla yelodyspla	anaemi						7.9	2 2.4	4 5.0	5 6.2	8 10.8	8 12.1	8 14.2	9 21.8	9 27.3	12 45.4	9 42.6	17 80.3	110	7.0	5.5-8.5	95.0	0.6	160	9.4 (7.7-11
yelodyspla n yelodyspla		iid3/cyt	орастна	3																					
yelodyspla M F yelodyspla	astic sy											1 1.5	3 5.1	2 4.8	2 6.3	3 12.9	2 12.4	4 35.7	17	0.9	0.5-1.3	94.0	0.1	1134	1.7 (0.9-2
yelodyspla	astic sy									1 1.2		1 1.5		1 2.4	1 3	1 3.8	3 14.2	3 14.2	11	0.4	0.2-0.7	91.0	0.0	2441	0.9 (0.4-1
yelodyspla		yndron	nes							1 1.2		1 1.5			4 12.6	4 17.1	6 37.3	6 53.6	22	1.0	0.6-1.4	82.0	0.1	1306	2.4 (1.4-3
											2 2.7	1 1.5	1 1.8	2 4.8	2 6.1	1 3.8	4 18.9	4 18.9	17	0.8	0.4-1.2	94.0	0.1	1185	1.4 (0.7-2
М	astic di	isease	s, all							1 1.2	***************************************	2 3.0	3 5.1	2 4.8	6 18.9	7 30.0	8 49.7	10 89.4	39	1.9	1.3-2.5	87.0	0.2	607	4.1 (2.8-5
=										1 1.2	2 2.7	2 3.0	1	3 7.3	3 9.1	2 7.6	7 33.2	7 33.1	28	1.2	0.7-1.7	93.0	0.1	798	2.3 (1.4-
HRONIC N						S																			
hronic mye M	eloprol	liferativ	e disor	ler, NO	S											2.0 8.6			2	0.1	0 - 0.2	100.0	0.0	*	0.2 (0 - 0
F																			0						
olycythaen M	mia rub	ora ver	а									1 1.5	3	2 4.8	1 3.2		1	2 17.9	10	0.6	0.2-1.0	100.0	0.1	1381	0.9 (0.3-1
=												1.5 3 4.5	5.1 1 1.8	4.8	3.2		6.2	17.9	4	0.3	0.0-0.5	50.0	0.0	3174	0.3 (0.0-0
yelofibrosi	is/sclei	rosis								····•		4.5	1.0												
Ä										1 1.2		1 1.5	1 1.7		1 3.2		2 12.4		6	0.3	0.1-0.6	83.0	0.0	2651	0.5 (0.1-
:												1 1.5	1 1.8		1 3.0	1 3.8			4	0.2	0 - 0.5	100.0	0.0	3164	0.4 (0.0-
her chroni	nic mye	eloprol	ferative	d/o								1.5	1.0		5.0	0.0									
1							1 1.3				1 1.3						1 6.2		3	0.2	0 - 0.4	100.0	0.0	7707	0.3 (0 -
=																									

Age			10-14		20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD% C	CumInc	Risk	ASR
	c myelopi	oliferati	ve d/o, a	II												_		_							
M							1 1.3			1 1.2	1 1.3	2 3.0	4 6.8	2 4.8	2 6.3	2 8.6	4 24.8	2 17.9	21	1.2	0.7-1.7	95.0	0.1	812	2.0 (1.1-2.
							1.3										24.0	17.9							
F										1	2	4	3	3	2	2			17	1.1	0.6-1.6	82.0	0.1	699	1.5 (0.8-2.
THE	R CHRON	IIC IMN	IINODD	OI IEEE	ATIVE	DISEA	eee			1.2	2.7	6.0	5.3	7.3	6.1	7.6									
	ell tumou		UNOFR	OLIFER	AIIVE	DISEA	JEJ																		
M	o taoa.																		0						
F																			0						
istioc	ytic/dend	itic cell	maligna	ncies				***************************************								***************************************							***************************************		
М										1									1	0.1	0 - 0.2	100.0	0.0	*	0.1 (0 - 0.
										1.2															
F																			0						
	2 LI/C :		1:6																						
itner a M	& U/S imn	nunopro	iliterative	neopia	sms								1		1	3			5	0.3	0.0-0.5	80.0	0.0	4120	0.5 (0.1-1.
IVI													1.7		3.2	12.9			,	0.5	0.0-0.3	00.0	0.0	4120	0.5 (0.1-1.
F													1		3			1	5	0.3	0.0-0.5	100.0	0.1	1838	0.4 (0.0-0.
Г													1.8		9.1			4.7	3	0.3	0.0-0.5	100.0	0.1	1030	0.4 (0.0-0.
ther o	chronic im	munop	roliferativ	e d/o. a	ull	~*~~~	·····						1.0		O.1										
М				,						1			1		1	3			6	0.3	0.1-0.6	83.0	0.0	3297	0.6 (0.1-1
										1.2			1.7		3.2	12.9									
F													1		3			1	5	0.3	0.0-0.5	100.0	0.1	1838	0.4 (0.0-0.
													1.8		9.1			4.7							,
Inknov M	wn primai	y site ((C26, C39	, C76, 0	C80; Be	haviour	,				_	40	04	4.4	40	40	04	20	138	7.7	0404	70.0	0.0	400	40.0 (44.0.45
IVI	2 2.6	1.4					1 1.3			4 4.8	5 6.7	10 14.8	21 35.7	14 33.3	16 50.5	13 55.7	21 130.4	30 268.1	138	7.7	6.4-9.1	70.0	8.0	133	13.6 (11.3-15.
_	2.0	1.7					1.5	_	_																
F						1 1.3		2 2.4	2 2.5	4 4.9	- 4	4	3	10	15 45.5	17	23	30	115	5.0	3.9-6.0	63.0	0.5	205	9.6 (7.8-11.
						1.3		2.4	2.5	4.9	5.4	6.0	5.3	24.2	45.5	64.4	108.9	141.8							
II car	ncers																								
M	21	8	9	14	40	47	62	100	143	263	413	663	955	925	895	731	602	400	6291	378.2	369-388	95.0	45.2	3	585.0 (571-59
	27.4	11.0	11.7	17.3	45.3	53.8	78.3	117.0	173.1	318.7	550.0	980.5	1621.2	2203	2826	3134	3738	3575							,
F	14	4	5	16	34	55	95	151	223	350	382	475	522	457	463	441	414	413	4514	264.5	256-273	94.0	29.3	4	387.2 (376-39
	19.2	5.9	7.0	21.2	42.3				278.6					1106	1405	1669	1961	1952				20	_5.0	•	22 (0.00

App	endi	x 3/	A. Ca	anc	er in	cic	den	ce, V	Vest	ern	Aust	ralia	, 200	09												
Age	0- 4	5- 9	10-14	15-1	9 20-2	24 2	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD%	CumInc	Risk	ASR
Sum	mary o	of m	ost co	omm	on c	anc	er ty	/pes	200x																	
Prostat M	e gland (C610-	C619)						1 1.2	12 14.5	55 66.7	127	271	386 655.3	379	305	243	165 1024.7	86 768.6	2030	121.4	116-127	98.0	15.9	7	185.0 (177-193
Breast M	(C500-C5	509)							1 1.2	14.5	00.7	109.1	400.8	033.3	1 2.4	1 3.2	1 4.3	3	700.0	7	0.3	0.1-0.6	100.0	0.0	2982	0.7 (0.2-1.2
F					2	2 .5	6 7.6	20 26.3	57 69.1	101 126.2	173 213.6	158 212.4	165 248.7	167 297.4	128 309.8	106	80 302.8	83	67 316.6	1313	81.7	77.1-86.3	99.0	9.2	11	112.9 (107-119
Colore M	ctal cance	er (C1	8-C20, C	218)	1	1	8 9.2	2 2.5	8 9.4	19 23.0	29 35.1	53 70.6	65 96.1	98 166.4	111 264.3	116 366.3	96 411.6	88 546.5	45 402.2	739	43.2	40.0-46.4	98.0	5.2	20	69.8 (64.7-74.9
F						 2 .5	3 3.8	6 7.9	7 8.5	15 18.7	24 29.6	33 44.4	54 81.4	55 97.9	61 147.6	77 233.6	71	72	65	545	28.8	26.2-31.4	96.0	3.4	30	46.6 (42.7-50.5
Skin (m M	elanoma	only)	(C440-C	:449; N	1	5	74) 7 8.0	18 22.7	34 39.8	24 29.0	36 43.6	40 53.3	77 113.9	84 142.6	85 202.4	92 290.5	53 227.2	49 304.3	38 339.6	643	39.6	36.5-42.7	99.0	4.8	21	59.2 (54.5-63.8
F						7	10 12.7	24 31.6	26 31.5	32 40.0	33 40.7	37 49.7	49 73.9	45 80.1	24 58.1	28 85.0	28	22	35	400	24.8	22.3-27.4	100.0	2.6	40	34.5 (31.1-37.9)
Lung, b M	ronchus	& trac	hea (C3	30-C34	,	1			4 4.7	4 4.8	10 12.1	22 29.3	48 71.0	78 132.4	95 226.2	102 322.1	97 415.8	71 440.9	51 455.8	583	32.9	30.1-35.6	88.0	4.0	25	56.3 (51.7-60.9
F						1	1 1.3		3 3.6	5 6.2	4 4.9	28 37.6	35 52.8	46 81.9	52 125.9	62	65 246.1	52	39	393	20.5	18.3-22.7	88.0	2.5	40	33.9 (30.5-37.3
Lymph M	omas (all) 2 2.6)	2 2.6	4.		7 .9	6 6.9	10 12.6	5 5.9	15 18.2	13 15.8	22 29.3	21 31.1	27 45.8	26 61.9	30 94.7	29 124.3	20 124.2	16 143.0	255	16.2	14.1-18.3	98.0	1.7	59	23.8 (20.9-26.8
F				5.	4 3 3	3 .7	4 5.1	2 2.6	4 4.8	6 7.5	8 9.9	6 8.1	15 22.6	22 39.2	19 46.0	19 57.6	22 83.3	19 90.0	19 89.8	172	9.8	8.2-11.4	98.0	1.1	95	14.7 (12.5-16.9
	vn primar	ry site	(C26, C	39, C7	6, C80;	Beh	aviour	,																		
М	2 2.6	1 1.4	ļ					1 1.3			4 4.8	5 6.7	10 14.8	21 35.7	14 33.3	16 50.5	13 55.7	21 130.4	30 268.1	138	7.7	6.4-9.1	70.0	0.8	133	13.6 (11.3-15.9)
F							1 1.3		2 2.4	2 2.5	4 4.9	4 5.4	4 6.0	3 5.3	10 24.2	15 45.5	17 64.4	23 108.9	30 141.8	115	5.0	3.9-6.0	63.0	0.5	205	9.6 (7.8-11.3
All car M	cers 21 27.4	8 11.0		1- 17.:		10 .3	47 53.8	62 78.3	100 117.0	143 173.1	263 318.7	413 550.0	663 980.5	955 1621.2	925 2203	895 2826	731 3134	602 3738	400 3575	6291	378.2	369-388	95.0	45.2	3	585.0 (571-599
F	14 19.2	5.9	5	17 1 21	6 3	34	55	95	151 183.0	223	350	382 513.5	475	522 929.5	457 1106	463 1405	441 1669	414	413 1952	4514	264.5	256-273	94.0	29.3	4	387.2 (376-399

Age 0-4 5-9 10-14 15-19 20-24 25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL C	umlnc	Risk	ASR2
ip, gum & mouth (C000-C069) (not C01 C02) M				1	1	1	4	2	5		3	2	19	1.1	0.6-1.6	134.0	0.2	638	1.8 (1.0-2.6
				1.2	1.3	1.5	6.8	4.8	15.8		18.6	17.9							,
F								1 2.4	1 3.0	1 3.8	2 9.5	3 14.2	8	0.3	0.1-0.5	9.5	0.0	3667	0.6 (0.2-1.1
ongue (C010-C029)									3.0			14.2	***************************************			***************************************		***************************************	
M				1 1.2	1 1.3	2 3.0	1 1.7	6 14.3		3 12.9	2 12.4	1 8.9	17	1.0	0.5-1.5	131.5	0.1	931	1.6 (0.8-2.3
F				1.2	1.0	5.0	1	14.5	2	1 1	1	0.5	5	0.3	0.0-0.5	16.7	0.0	2549	0.5 (0.1-0.9
							1.8		6.1	3.8	4.7			U.U	0.0 0.5		0.0		0.5 (0.1 0.0
arotid gland (C070-C079) M										1			1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3
vi										4.3			•	0.0	0 - 0.1	0.0	0.0		0.1 (0 - 0
F					1		1			1		2	5	0.2	0.0-0.4	33.1	0.0	6401	0.4 (0.0-0.7
lajor salivary glands (not parotid) (C080-C089)					1.3		1.8			3.8		9.5							
M													0					-	
=													0					-	
harynx (C090-C149) (not C11)																			
М			1 1.2	1 1.2	1 1.3	4 5.9	4 6.8	5 11.9	4 12.6	1 4.3	1 6.2		22	1.4	0.8-2.0	230.9	0.2	488	1.9 (1.1-2.
=			1.2	1.2	1.0	0.0	1	1 1.3	12.0	4.5	0.2		2	0.1	0 - 0.3	19.0	0.0	4761	0.2 (0 - 0.
							1.8	2.4					_	••••	0 0.0				0.2 (0 0.
asopharynx (C110-C119) M													0					-	
F													0					-	
esophagus (C150-C159)																	-		
M			3 3.6	3 3.6	5 6.7	6 8.9	8 13.6	7 16.7	10 31.6	7 30.0	19 118.0	5 44.7	73	3.9	3.0-4.8	531.0	0.4	237	7.1 (5.4-8.
F			5.0	5.0	1	2	3	4	2	4	3	10	29	1.3	0.8-1.8	123.5	0.1	786	2.3 (1.5-3.2
					1.3	3.0	5.3	9.7	6.1	15.1	14.2	47.3			0.0 1.0	. 20.0	···		2.0 (0
tomach (C160-C169) M				4	10	8	16	3	7	7	16	10	81	4.4	3.4-5.4	659.1	0.4	232	7.7 (6.0-9.
vi				4.8	13.3	11.8	27.2	7.1	22.1	30.0	99.4	89.4	01	7.7	0.4 0.4	000.1	0.4	202	7.7 (0.0 3.
=	1 1.3	1 1.2	1 1.2	2 2.5	2 2.7	1 1.5	3 5.3		5 15.2	5 18.9	2 9.5	13 61.4	36	1.6	1.0-2.2	266.2	0.2	647	3.0 (2.0-3.
mall intestine (C170-C179)	1.3	1.2	1.2	2.5	2.1	1.0	J.J		13.2	10.5	3.3	01.4							
1							3 5.1	1 2.4	2 6.3		2 12.4	2 17.9	10	0.6	0.2-0.9	46.3	0.1	1451	1.0 (0.4-1
						1	J. I	2.4	6.3 2	1	12.4	11.3	6	0.3	0.0-0.5	21.4	0.0	2641	0.5 (0.1-1.
						1.5			6.1	3.8	9.5		U	0.3	0.0-0.3	۷1. 4	0.0	∠∪ + I	0.3 (0.1-1.

Age 0-4	5-9 10-14 15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL Cum	Inc	Risk	ASR2
Colorectal cance	r (C18-C20, C218)																					
М	1 1.2	2 2.3		2 2.5	2 2.3	3 3.6	4 4.8	11 14.6	10 14.8	32 54.3	24 57.1	37 116.8	32 137.2	39 242.2	29 259.2	228	12.5	10.8-14.2	1509.8	1.4	73	22.5 (19.5-25.4)
F			2 2.5	1 1.3	1 1.2	5 6.2	8 9.9	11 14.8	11 16.6	17 30.3	22 53.2	29 88.0	29 109.8	28 132.6	45 212.7	209	10.1	8.6-11.6	1379.1	1.1	90	17.5 (15.1-19.9)
olon (C180-C18	89)																					
M	1 1.2	2 2.3		1 1.3		1 1.2	2 2.4	5 6.7	8 11.8	17 28.9	14 33.3	23 72.6	22 94.3	27 167.7	23 205.6	146	7.8	6.5-9.1	854.8	8.0	124	14.6 (12.2-17.0)
F			1 1.3	1 1.3	1 1.2	5 6.2	5 6.2	9 12.1	6 9.0	12 21.4	14 33.9	20 60.7	25 94.6	21 99.5	34 160.7	154	7.3	6.0-8.6	989.8	8.0	131	13.0 (10.9-15.1)
ectosigmoid jur	nction & rectum (C190-	C209)								***************************************			***************************************				***************************************	***************************************			***************************************	
M				1 1.3	2 2.3	2 2.4	2 2.4	6 8.0	2 3.0	15 25.5	10 23.8	14 44.2	10 42.9	12 74.5	6 53.6	82	4.7	3.7-5.8	652.6	0.6	178	7.8 (6.1-9.6)
F			1 1.3				3 3.7	2 2.7	5 7.5	5 8.9	8 19.4	9 27.3	4 15.1	7 33.2	11 52.0	55	2.8	2.0-3.6	387.7	0.4	283	4.6 (3.3-5.8)
nus (C210-C21 M	9)									1	1			1		3	0.2	0 - 0.4	18.5	0.0	4904	0.3 (0 - 0.6)
										1.7	2.4			6.2								
F												1 3.0	1 3.8		2 9.5	4	0.1	0 - 0.3	2.4	0.0	6593	0.3 (0 - 0.7)
	tic bile ducts (C220-C2	229)																				
M 1 1.3						2 2.4		6 8.0	5 7.4	9 15.3	7 16.7	9 28.4	9 38.6	6 37.3	5 44.7	59	3.5	2.5-4.4	509.8	0.4	252	5.6 (4.2-7.1)
F							1 1.2	2 2.7		1 1.8	3 7.3	4 12.1	4 15.1	6 28.4	3 14.2	24	1.1	0.6-1.6	111.5	0.1	797	2.1 (1.2-2.9)
	e ducts (C230-C249)																					
М								1 1.3	4 5.9	5 8.5	6 14.3	7 22.1	5 21.4	6 37.3	3 26.8	37	2.0	1.4-2.7	201.2	0.3	384	3.6 (2.4-4.7)
F					1 1.2	1 1.2	1 1.2	1 1.3	1 1.5	2 3.6	5 12.1	3 9.1	7 26.5	5 23.7	7 33.1	34	1.6	1.0-2.2	197.1	0.2	639	2.9 (1.9-3.9)
ancreas (C250-	-C259)						_	_	_													
М							2 2.4	7 9.3	8 11.8	13 22.1	10 23.8	15 47.4	16 68.6	11 68.3	10 89.4	92	5.1	4.0-6.2	579.9	0.6	172	9.0 (7.1-10.8)
F						4 5.0		8 10.8	6 9.0	4 7.1	15 36.3	13 39.4	20 75.7	16 75.8	26 122.9	112	5.1	4.1-6.1	579.8	0.5	186	9.4 (7.7-11.2)
lasal cavity/sinu M	ises, middle & inner ea	r (C300	-C319)			1		1				1	2			5	0.3	0.0-0.5	53.1	0.0	3510	0.5 (0.1-1.0)
F						1.2		1.3				3.2	8.6		0	•		0.04	0.0	0.0	*	0.4 (00.0)
															9.5	2	0.0	0 - 0.1	0.0	0.0		0.1 (0 - 0.3)
arynx (C320-C3 M	329)				1	1	1	4	2	4	4	2	3	2	1	22	1.3	0.8-1.9	221.7	0.2	656	2.0 (1.2-2.9)
IVI					1.2	1.2	1.2	1.3	3.0	6.8	9.5	6.3	12.9	12.4	8.9	22	1.3	0.6-1.9	221.1	U.Z	000	2.0 (1.2-2.9)
F											2 4.8	2 6.1				4	0.3	0.0-0.5	19.1	0.1	1834	0.4 (0.0-0.7)

Appendix 3B	. Cancer m	ortali	ty, V	/este	rn A	ustr	alia,	200	9												
	10-14 15-19 20-2	24 25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL C	CumInc	Risk	ASR2
Lung, bronchus & trache M	,	1 .1	1 1.3	1 1.2	6 7.3	9 10.9	14 18.6	34 50.3	48 81.5	69 164.3	94 296.8	86 368.7	71 440.9	49 437.9	483	26.5	24.0-28.9	2646.1	3.2	32	47.8 (43.5-52.1)
F	·	 1 1.3		1 1.2	5 6.2	9	18 24.2	24 36.2	33 58.8	39 94.4	49 148.7	56 212.0	41 194.2	44 207.9	320	16.2	14.3-18.1	2049.3	1.9	53	27.4 (24.4-30.5)
Thymus (C370-C379) M												1 4.3			1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3)
F											1 3.0			1 4.7	2	0.1	0 - 0.2	2.4	0.0	6593	0.2 (0 - 0.4)
Pleura, heart & mediasti M 1 1.4	inum (C380-C389)					2 2.4					2 6.3				5	0.4	0.0-0.8	119.7	0.1	1978	0.5 (0.1-0.9)
F															0					-	
Bones, joints & articular M	cartilages (C400-C4	419)				1 1.2						2 8.6			3	0.2	0 - 0.3	25.3	0.0	*	0.3 (0 - 0.7)
F	1 1.4						1 1.3		1 1.8			1 3.8			4	0.3	0 - 0.6	93.5	0.0	4421	0.4 (0.0-0.7)
Skin (melanoma only) (C M 1 1.4	C430-C439)	1 1.1	1 1.3	1 1.2	2 2.4	2 2.4	2 2.7	11 16.3	7 11.9	10 23.8	13 41.0	13 55.7	15 93.2	10 89.4	89	4.9	3.9-6.0	694.4	0.5	190	8.7 (6.9-10.6)
F			1 1.3		4 5.0	1 1.2	6 8.1	5 7.5	5 8.9	5 12.1	4 12.1	7 26.5	2 9.5	8 37.8	48	2.6	1.8-3.4	505.8	0.3	356	4.1 (2.9-5.3)
Skin (non-melanoma; in M	cludes SCC-BCC) (C440-C44	9) 1 1.3		1 1.2		1 1.3	1 1.5	5 8.5	6 14.3	6 18.9	9 38.6	5 31.1	9 80.4	44	2.4	1.6-3.1	220.2	0.2	426	4.5 (3.2-5.8)
F								2 3.0	1 1.8		1 3.0	2 7.6	2 9.5	11 52.0	19	0.6	0.3-1.0	47.5	0.0	2555	1.4 (0.8-2.0)
Mesothelioma (M905; IC	CD10 C45)					4	_	6	11	16	13	12	8	7	79	4.6	3.5-5.6	508.9	0.6	176	7.5 (5.8-9.2)
IVI						4.8	2 2.7	8.9	18.7	38.1	41.0	51.4	49.7	62.6	79	4.0	3.5-5.6	500.9	0.6	170	7.5 (5.6-9.2)
F							1 1.3	1 1.5	1 1.8	2 4.8		2 7.6	3 14.2	1 4.7	11	0.5	0.2-0.8	64.0	0.0	2112	0.9 (0.4-1.5)
Kaposi sarcoma (M914; M	ICD10 C46)									***************************************					0					-	
F															0					-	
Nervous system, periphe	eral/autonomic (C47	70-C479)												***************************************							
М												1 4.3			1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3)
F															0					-	

Age 0-4 5-9 10-14 15-19 2	20-24 25	5-29 3	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL (Cumino	Risk	ASR2
Retroperitoneum and peritoneum (C480-	·C489)	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	00 00		10 10	000.	00 00	00 0 .	00 00			00 0 .	00 1			00 / 0 0		, u	11.011	
M													1		1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3
													6.2								
F								1 1.5	2 3.6	1 2.4	2 6.1	1 3.8	1 4.7		8	0.5	0.1-0.8	52.3	0.1	1476	0.7 (0.2-1.2
Connective, subcutaneous & other soft ti	issues (C	490-C4	199)					1.5	3.0	2.4	0.1	3.0	4.7								
M	1		/					1		4		1	1	2	10	0.6	0.2-1.0	93.5	0.1	1648	1.0 (0.4-1.6
	1.1							1.5		9.5		4.3	6.2	17.9							
F	1						1		3	1			1		7	0.5	0.1-0.8	114.7	0.1	1933	0.6 (0.1-1.0
Breast (C500-C509)	1.2					•···	1.3		5.3	2.4		***************************************	4.7	***************************************	***************************************		***************************************	***************************************	***************************************	***************************************	
M												1			1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3
												4.3			•	0.0	0 0	0.0	0.0		0 (0 0.0)
F		2	1	5	10	16	28	27	29	27	22	20	27	34	248	13.7	11.8-15.5	2681.2	1.5	66	20.8 (18.2-23.4
		2.5	1.3	6.1	12.5	19.8	37.6	40.7	51.6	65.4	66.7	75.7	127.9	160.7	•						
Vulva (C510-C519) F				1						4		4	1	2	8		0400	45.0	0.0	2004	07/0044
r				1.2						1 2.4	1 3.0	1 3.8	4.7	3 14.2	8	0.3	0.1-0.6	45.3	0.0	3001	0.7 (0.2-1.1)
Vagina (C520-C529)	***************************************														***************************************		***************************************				
F													1	1	2	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3)
Cervix uteri (C530-C539)													4.7	4.7							
F			1	2	2	2	3	6	3	4	1	2	2	2	30	1.8	1.1-2.5	456.1	0.2	502	2.5 (1.6-3.5)
•			1.3	2.4	2.5	2.5	4.0	9.0	5.3	9.7	3.0	7.6	9.5	9.5							(
Corpus uteri (C540-C549)							_	_	_	_			_	_							
F					1 1.2	1 1.2	2 2.7	3.0	2 3.6	8 19.4	4 12.1	4 15.1	3 14.2	5 23.6	32	1.7	1.1-2.3	223.2	0.2	463	2.7 (1.8-3.7)
Uterus, nos (C550-C559)					1.2		<u> </u>	0.0	0.0	10.4	12.1	10.1	17.2	20.0							
F							1		1						2	0.1	0 - 0.3	33.1	0.0	6401	0.2 (0 - 0.4)
0(0500,0500)	-					•	1.3		1.8												
Ovary (C560-C569)		1		1	3	1	8	5	9	9	5	8	6	7	63	3.5	2.6-4.4	636.9	0.4	255	5.4 (4.0-6.7)
•		1.3		1.2	3.7	1.2	10.8	7.5	16.0	21.8	15.2	30.3	28.4	33.1	00	0.0	2.0 1.1	000.0	0.1	200	0.1 (4.0 0.7)
Uterine adnexa & oth. fem gen. (C570-C	579)				***************************************	•															
F								2 3.0		1 2.4				2 9.5	5	0.2	0.0-0.5	40.3	0.0	3680	0.4 (0.0-0.7)
Placenta (C580-C589)								3.0		2.4				9.5							
F															0					-	
Penis (C600-C609) M															0						
IVI															U					-	
Prostate gland (C610-C619)						•															
M						1	3	4	13	22	28	47	59	78	255	12.1	10.5-13.6	522.5	0.9	115	27.5 (24.1-30.9
Testis (C620-C629)						1.2	4.0	5.9	22.1	52.4	88.4	201.5	366.4	697.1							
M							1				1				2	0.1	0 - 0.3	23.0	0.0	4456	0.2 (0 - 0.5
							1.3				3.2										- (

A 0.4 F.O. 40.44 4F.40 00.04	05.00 00.04	25.20	10 11	45 40	FO F 4	FF F0	CO C4	CF CO	70.74	75 70	00.04	05.	T-4-'	A CD	050/ - :	DVII O		Diele	A CDO
Age 0-4 5-9 10-14 15-19 20-24 Other male genital (C630-C639)	25-29 30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL C	uminc	Risk	ASR2
M													0					-	
Kidney (C640-C649)																			
М		1 1.2		2 2.4	4 5.3	8 11.8	2 3.4	5 11.9	5 15.8	9 38.6	8 49.7	10 89.4	54	2.8	2.1-3.6	366.8	0.3	386	5.4 (3.9-6.9)
F		1.2		1	2	2	1	5	4	5	3	6	30	1.5	0.9-2.1	194.7	0.2	586	2.6 (1.6-3.5)
		1.2		1.2	2.7	3.0	1.8	12.1	12.1	18.9	14.2	28.4		1.0	0.0 2.1	104.7	0.2		2.0 (1.0 0.0)
Bladder & urinary tract (C650-C689)			0			•	40	40		40	45	0.4		4.5	0555	400.0	0.4	000	0.7 (0.0.40.0)
М			2 2.4	1 1.2	4 5.3	2 3.0	10 17.0	12 28.6	9 28.4	10 42.9	15 93.2	21 187.7	86	4.5	3.5-5.5	420.8	0.4	233	8.7 (6.9-10.6)
F				2		1		5	5	6	9	10	38	1.6	1.0-2.1	116.4	0.2	641	3.2 (2.1-4.2)
				2.5		1.5		12.1	15.2	22.7	42.6	47.3			2		·	· · · ·	0.2 (2.1 1.2)
Eye & lacrimal gland (C690-C699) M					2	2					2	1	7	0.4	0.1-0.6	73.5	0.0	3558	0.7 (0.2-1.2)
IVI					2.7	3.0					12.4	8.9	,	0.4	0.1-0.0	73.5	0.0	3336	0.7 (0.2-1.2)
F			1		1	1	1	1		1			6	0.4	0.1-0.7	87.7	0.0	2410	0.5 (0.1-0.9)
			1.2		1.3	1.5	1.8	2.4		3.8									
Meninges (cerebral & spinal) (C700-C709) M													0						
IVI													U					-	
F													0					-	
Brain (C710-C719)		***************************************		***************************************						***************************************	******		***************************************	***************************************	******			***************************************	
M 1 1	1	2	2	4	5	2	8	11	7	6	6		56	3.6	2.6-4.5	709.8	0.4	236	5.1 (3.8-6.5)
1.3 1.2	1.1	2.3	2.4	4.8	6.7	3.0	13.6	26.2	22.1	25.7	37.3								
F 1 1.5	1 1.3	1 1.2	2 2.5	1 1.2	3 4.0	8 12.1	11 19.6	4 9.7	12 36.4	6 22.7	9 42.6	3 14.2	62	3.5	2.6-4.5	620.0	0.4	224	5.4 (4.0-6.7)
Spinal cord & cranial nerves (C720-C729)	1.0	1.2	2.0	1.2	4.0	12.1	19.0	9.1	30.4	22.1	42.0	14.2							
M												1	1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.4)
_												8.9							
F													0					-	
Thyroid gland (C730-C739)																			
M					2 2.7			1	1 3.2	1 4.3	1 6.2	1	7	0.4	0.1-0.7	50.7	0.0	2439	0.7 (0.2-1.2)
_					2.7			2.4	3.2		6.2	8.9	_		0005	00.4	0.0	F 470	0.4 (0.0.0.0)
F				1 1.2				1 2.4		2 7.6		1 4.7	5	0.2	0.0-0.5	33.1	0.0	5472	0.4 (0.0-0.8)
Adrenal gland (C740-C749)																			
M								1 2.4					1	0.1	0 - 0.2	7.0	0.0	8400	0.1 (0 - 0.2)
F													4	0.1	0 02	7.1	0.0	0064	0.1 (00.3)
F								1 2.4					1	0.1	0 - 0.2	7.1	0.0	8264	0.1 (0 - 0.3)
Endocrine glands (not adrenal) (C750-C759)																			
М													0					-	
F							4				4		•	0.1	0 00	11.0	0.0	*	0.2 (00.4)
Г							1 1.8				1 4.7		2	0.1	0 - 0.2	11.9	0.0		0.2 (0 - 0.4)

Table Tabl	Age 0-4 5-9 10-14 15-19 2	20-24 25-29 30-	34 35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL C	umlnc	Risk	ASR2
F																				
F														1	0.1	0 - 0.2	20.7	0.0	*	0.1 (0 - 0.3
No.						1.3														
Hodgishimphoma in the properties of the properti	F											9.5	-	3	0.1	0 - 0.2	0.0	0.0	*	0.2 (0 - 0.5
12									·		-									
The tensor of	М													2	0.1	0 - 0.3	37.2	0.0	4622	0.2 (0 - 0.5
13	F	1	1.2						1		1			4	0.3	0-06	55.3	0.0	2976	0.4 (0.0-0.7
M														7	0.5	0 - 0.0	33.3	0.0	2370	0.4 (0.0-0.7
1.2	All NHL		4			_	_	-	_	4.4		4.4	40	A=		0740	405.4	0.4	0.40	00/5000
F	M													67	3.6	2.7-4.6	425.1	0.4	248	6.6 (5.0-8.2
NHL, mature B cell M	F			1										56	2.3	1.6-3.0	254.1	0.2	509	4.6 (3.4-5.9
M		••••	1.2	1.2													-			
F 1.2			1		1	5	3	6	6	6	2	9	8	47	2.6	1 8-3 4	337 1	0.3	352	46 (32-59
1.2 2.5 3.0 1.8 4.8 12.1 26.5 47.4 47.3														••			00111	0.0	002	(0.2 0.0
NHL, mature T/NK cell M 1,2 1,5 1,7 2,4 3,2 1,7 1,6 2,7 3,0 3,7 1,7 1,7 1,7 1,7 1,7 1,7 1,7 1,7 1,7 1	F							-						39	1.5	1.0-2.1	156.7	0.1	786	3.2 (2.2-4.3
M	NILL mature T/NIK cell		1.2		2.5		3.0	1.8	4.8	12.1	26.5	47.4	47.3							
F S S S S S S S S S S S S S S S S S S S					1		1	1	1	1	4	1	2	12	0.6	0.3-1.0	62.2	0.0	2015	1.2 (0.5-1.9
Section 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					1.2		1.5	1.7	2.4	3.2	17.1	6.2	17.9							
NHL, precursor cell lymphoblastic M	F													7	0.4	0.1-0.7	40.4	0.1	1753	0.6 (0.2-1.1
M	NHL. precursor cell lymphoblastic							5.3		6.1	3.8	4.7								
NHL, other/unclassifiable M 1 1 4 1 2 8 0.4 0.1-0.7 25.6 0.1 1418 0.8 (0.3-1.4 1.5 12.6 6.2 17.9 F 13 5 10 0.4 0.1-0.6 56.9 0.0 8052 0.8 (0.3-1.4 1.7 1.7 1.7 1.7 1.7 1.7 1.7														0					-	
NHL, other/unclassifiable M 1 1 4 1 2 8 0.4 0.1-0.7 25.6 0.1 1418 0.8 (0.3-1.4 1.5 12.6 6.2 17.9 F 13 5 10 0.4 0.1-0.6 56.9 0.0 8052 0.8 (0.3-1.4 1.7 1.7 1.7 1.7 1.7 1.7 1.7																				
M	F													0					-	
F 1.5 12.6 6.2 17.9 F 1 1 1 1 2 12 11.4 23.6 Lymphomas (all) M 2 2 6 5 7 7 7 12 6 11 12 70 3.8 2.9-4.8 483.0 0.4 231 6.9 (5.3-8.4) 2 3 2 4 8.0 7.4 11.9 16.7 37.9 25.7 68.3 107.2 F 1 1 1 1 3 2 2 4 3 7 12 13 16 63 2.7 1.9-3.4 309.4 0.2 435 5.2 (3.9-6.4) MYELOMA Myeloma/plasma cell tumours M 9 2 2 2 5 10 8 5 5 7 6 45 7.5 M 9 2 2 2 5 10 8 5 5 7 6 45 7.5 M 9 2 3 5 10 8 5 5 7 6 45 7.5 M 9 2 5 7 8 7 8 7 8 7 8 8 7 8 8 7 8 8 8 7 8	NHL, other/unclassifiable																			
F 1 1 1 1 1 2 1.2 1.1.4 23.6 10 0.4 0.1-0.6 56.9 0.0 8052 0.8 (0.3-1.5 1.2 1.2 1.2 11.4 23.6 1.4 23.6	М													8	0.4	0.1-0.7	25.6	0.1	1418	0.8 (0.3-1.4
Lymphomas (all)	E			4	1		1.5			12.0	2	0.2		10	0.4	0106	56.0	0.0	9052	00/0212
M 2 2 2 6 5 7 7 12 6 11 12 70 3.8 2.9-4.8 483.0 0.4 231 6.9 (5.3-8.0 1.0.2) F 1 1 1 1 3 2 2 4 3 7 12 13 16 63 2.7 1.9-3.4 309.4 0.2 435 5.2 (3.9-6.0 1.0.2) MYELOMA Myeloma/plasma cell tumours M 2 2 2 5 10 8 5 7 6 45 2.5 1.8-3.3 220.0 0.3 317 4.4 (3.1-5.1 1.0.2) F 2 2 4 6 3 7 5 6 36 1.8 1.1-2.4 213.6 0.2 534 3.0 (2.0-4.0 1.0.2)	r			-	-									10	0.4	0.1-0.0	30.9	0.0	0032	0.6 (0.3-1.3
E	Lymphomas (all)							_	_	40			40			0040	400.0	0.4	004	00/5000
F 1 1 1 3 2 4 3 7 12 13 16 63 2.7 1.9-3.4 309.4 0.2 435 5.2 (3.9-6.6) MYELOMA Myeloma/plasma cell tumours M	M													70	3.8	2.9-4.8	483.0	0.4	231	6.9 (5.3-8.6
1.3 1.2 1.2 3.7 3.0 7.1 7.3 21.2 45.4 61.6 75.6 MYELOMA Myeloma/plasma cell tumours M 2 2 5 10 8 5 7 6 45 2.5 1.8-3.3 220.0 0.3 317 4.4 (3.1-5.1 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	F	1		1										63	2.7	1.9-3.4	309.4	0.2	435	5.2 (3.9-6.6
Myeloma/plasma cell tumours M 2 2 5 10 8 5 7 6 45 2.5 1.8-3.3 220.0 0.3 317 4.4 (3.1-5.7) 2.7 3.0 8.5 23.8 25.3 21.4 43.5 53.6 F 1 2 2 4 6 3 7 5 6 36 1.8 1.1-2.4 213.6 0.2 534 3.0 (2.0-4.1)				1.2																
M 2 2 5 10 8 5 7 6 45 2.5 1.8-3.3 220.0 0.3 317 4.4 (3.1-5.5 2.7 3.0 8.5 23.8 25.3 21.4 43.5 53.6 F 1 2 2 4 6 3 7 5 6 36 1.8 1.1-2.4 213.6 0.2 534 3.0 (2.0-4.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3																				
F 1 2 2 4 6 3 7 5 6 36 1.8 1.1-2.4 213.6 0.2 534 3.0 (2.0-4.0 cm)														45	2.5	1.8-3.3	220.0	0.3	317	4.4 (3.1-5.7
						2.7		8.5												
	F			1 1.2	2 2.5		2 3.0	4 7.1	6 14.5	3 9.1	7 26.5	5 23.7	6 28.4	36	1.8	1.1-2.4	213.6	0.2	534	3.0 (2.0-4.0

Age 0-4 5-9 10-14 15	5-19 20)-24 2	5-29	30-34 3	5-39 40-4	14 4	5-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL C	CumInc	Risk	ASR2
LEUKAEMIAS																						
Leukaemias, NOS/unclassifiable M												1 3.2		1 6.2		2	0.1	0 - 0.2	2.4	0.0	6335	0.2 (0 - 0.5)
F												1			1 4.7	2	0.1	0 - 0.2	2.4	0.0	6593	0.2 (0 - 0.4)
Leukaemias, lymphoid, all	***************************************										••••••••••		•••••									
М	1 1.2							2 2.7	3 4.4	1 1.7	1 2.4	4 12.6	1 4.3	3 18.6	1 8.9	17	1.0	0.5-1.5	171.6	0.1	799	1.6 (0.8-2.4)
F								1 1.3		1 1.8			1 3.8	1 4.7	9 42.5	13	0.4	0.2-0.7	33.1	0.0	6401	0.9 (0.4-1.4)
Leukaemias, lymphoid, acute																						
М	1 1.2							1 1.3								2	0.2	0 - 0.4	74.6	0.0	7786	0.2 (0 - 0.4)
F								1 1.3		1 1.8						2	0.1	0 - 0.3	33.1	0.0	6401	0.2 (0 - 0.4)
Leukaemias, lymphoid, chronic																						
М								1 1.3	3 4.4	1 1.7	1 2.4	4 12.6	1 4.3	3 18.6	1 8.9	15	0.8	0.4-1.2	97.0	0.1	890	1.4 (0.7-2.2)
F														1 4.7	8 37.8	9	0.2	0.1-0.4	0.0	0.0	*	0.6 (0.2-1.0)
Leukaemias, lymphoid, other/NOS M																0					_	
F													1 3.8		1 4.7	2	0.1	0 - 0.1	0.0	0.0	*	0.2 (0 - 0.4)
Leukaemias, myeloid, all M	1 1.2					1	3 3.6	1 1.3	1 1.5	3 5.1	10 23.8	4 12.6	9 38.6	5 31.1	8 71.5	46	2.6	1.8-3.4	310.4	0.3	397	4.6 (3.3-6.0)
F 2 2.8	1.2	1 1.2	1 1.3	1 1.3	•		2 2.5	1.0	3 4.5	7.1	3 7.3	4 12.1	6 22.7	4 18.9	2 9.5	33	2.0	1.2-2.7	438.2	0.2	499	2.9 (1.9-3.9)
Leukaemias, myeloid, acute																						
M	1 1.2						3 3.6	1 1.3			7 16.7	3 9.5	7 30.0	4 24.8	6 53.6	32	1.8	1.1-2.4	206.4	0.2	619	3.3 (2.1-4.4)
F 2 2.8		1 1.2	1 1.3	1 1.3			2 2.5		3 4.5	4 7.1	3 7.3	2 6.1	5 18.9	1 4.7		25	1.7	1.0-2.4	433.4	0.2	588	2.2 (1.3-3.1)
Leukaemias, myeloid, chronic	***************************************						·····				***************************************					•						
M						1 .2			1 1.5					1 6.2		3	0.2	0 - 0.4	46.1	0.0	7437	0.3 (0 - 0.6)
F												1 3.0		2 9.5		3	0.1	0 - 0.2	2.4	0.0	6593	0.3 (0 - 0.6)
Leukaemias, myeloid, other/NOS																						
М										3 5.1	3 7.1	1 3.2	2 8.6		2 17.9	11	0.7	0.3-1.1	57.8	0.1	1300	1.0 (0.4-1.7)

Age	Appendix	3B. Can	cer	mor	talit	y, We	stern	Aust	ralia	200	9												
F		5-9 10-14 15	5-19	20-24 2	25-29	30-34 3	5-39 40-4	4 45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL C	umlnc	Risk	ASR2
Control properties (all purples of control proper																	0					-	
M	F																0					-	
F 2 1 1 1 1 2 2 1 3 3 5 3 5 3 5 5 7 5 12 48 25 173 3 43 02 24 3 40 2851 WELLOWING MATCH DISEASES Refractory anaemisal cytopaenisa Myelodysplastic giseases, all Myelodysplastic diseases, all Myelodysplastic diseas																	65	3.7	2.7-4.6	484.6	0.4	255	6.4 (4.8-8.0)
Metadory anaemias/ropaemias Marian	F	2						2	1	3	5	3	5	7	5	12	48	2.5	1.7-3.3	473.8	0.2	433	4.0 (2.8-5.1)
Methods 1 1 2 3 3 1 2 9 6 2 7 7 6 9 5 1 7 9 7 6 9 5 1 7 9 7 9 7 9 7 9 9 7 9 9 7 9 9 9 9 9 9		TIC DISEASES	;								0.0						***************************************						
Myelodysplastic syndromes Myelodysplastic syndromes Myelodysplastic syndromes Myelodysplastic syndromes F		as/cytopaeriias															6	0.3	0.0-0.5	9.4	0.0	3612	0.6 (0.1-1.1)
March 1	F																5	0.1	0.0-0.3	0.0	0.0	*	0.4 (0.0-0.8)
Myelodysplastic diseases, all Myelodysplastic diseases, al		ndromes															16	0.6	0.3-0.9	4.8	0.0	3168	1.7 (0.9-2.6)
Myelodysplastic diseases, all Minimum	F																15	0.4	0.2-0.7	7.1	0.0	8264	1.2 (0.6-1.8)
CHRONIC MYELOPROLIFERATIVE DISEASES Chronic myeloproliferative disorder, NOS 1		seases, all										1		6	10	2	22	0.9	0.5-1.3	14.1	0.1	1688	2.4 (1.4-3.4)
Chronic myeloproliferative disorder, NOS	F																20	0.6	0.3-0.9	7.1	0.0	8264	1.6 (0.9-2.3)
M 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td></td> <td></td> <td></td> <td></td> <td>3</td> <td></td> <td>***************************************</td>					3																		***************************************
Polycythaemia rubra vera M		erative disorde	r, NO	5										-			2	0.1	0 - 0.2	0.0	0.0	*	0.2 (0 - 0.6)
M 0 - F 1 3 0 14.2 3 14.2 4 0.1 0 - 0.3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	F																0					-	
Myelofibrosis/sclerosis M		a vera															0					-	
Myelofibrosis/sclerosis M 3 3 0.1 0 - 0.3 0.0 0.0 * 0.3 (0 - 0.7) F 1 2 3 0.1 0 - 0.2 16.6 0.0 * 0.2 (0 - 0.4) Other chronic myeloproliferative d/o M 2 1 1 1 4 0.2 0 - 0.5 13.9 0.0 4200 0.4 (0.0-0.8) 4.8 4.3 8.9	F																4	0.1	0 - 0.3	2.4	0.0	6593	0.3 (0 - 0.6)
F 2 3 0.1 0 - 0.2 16.6 0.0 * 0.2 (0 - 0.4) 1.5 9.5 Other chronic myeloproliferative d/o M 2 1 1 1 1 4 0.2 0 - 0.5 13.9 0.0 4200 0.4 (0.0 - 0.8) 4.8 4.3 8.9		osis	***************************************														3	0.1	0 - 0.3	0.0	0.0	*	0.3 (0 - 0.7)
Other chronic myeloproliferative d/o M 2 1 1 1 4 0.2 0 - 0.5 13.9 0.0 4200 0.4 (0.0-0.8) 4.8 4.3 8.9	F																3	0.1	0 - 0.2	16.6	0.0	*	0.2 (0 - 0.4)
4.8 4.3 8.9		oproliferative d	/o							1.0													
F 0 -	М																4	0.2	0 - 0.5	13.9	0.0	4200	0.4 (0.0-0.8)
-	F																0					-	

Append	ix 3	B. C	ance	er n	nor	tality	y, W	este	rn A	ustr	alia,	200	9												
						•			40-44					65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL (CumInc	Risk	ASR2
Chronic myelo M	prolife	ative d/	o, all											2 4.8		5 21.4		2 17.9	9	0.4	0.1-0.7	13.9	0.0	4200	1.0 (0.3-1.6)
F												1 1.5			1 3.0			5 23.6	7	0.2	0.0-0.4	19.0	0.0	4404	0.5 (0.1-0.9)
OTHER CHRO		MUNO	PROLIF	ERAT	(IVE	DISEAS	ES			•															
М																			0					-	
F																			0					-	
Histiocytic/den M	dritic c	ell malig	nancies											1.0 2.4					1	0.1	0 - 0.2	7.0	0.0	8400	0.1 (0 - 0.2)
F																			0					-	
Other & U/S in M	nmuno	orolifera	tive neo	olasm	S			•••••					1 1.7	1 2.4			1 6.2		3	0.2	0 - 0.4	18.5	0.0	4904	0.3 (0 - 0.6)
F																		3 14.2	3	0.1	0 - 0.2	0.0	0.0	*	0.2 (0 - 0.4)
Other chronic i	immun	oprolifer	ative d/o	, all														· · · · · · · · · · · · · · · · · · ·							
М		•											1 1.7	2 4.8			1 6.2		4	0.2	0 - 0.5	25.4	0.0	3097	0.3 (0.0-0.7)
F																		3 14.2	3	0.1	0 - 0.2	0.0	0.0	*	0.2 (0 - 0.4)
		(000			(0)																				
Unknown prim M	ary site	e (C80 o	r Benav	our 6/	9)		1 1.3			1 1.2	3 4.0	7 10.4	8 13.6	8 19.0	11 34.7	5 21.4	20 124.2	24 214.5	88	4.5	3.5-5.5	414.1	0.4	238	9.0 (7.1-10.9)
F						1 1.3		2 2.4		3	4 5.4	3 4.5	6	5 12.1	12 36.4	11 41.6	17 80.5	30 141.8	94	4.0	3.1-4.9	466.3	0.4	262	7.6 (6.1-9.2)
Total deaths	e duo	to can	cor		***************************************									•••••											
M 1		2	1 -		4 4.5	2 2.3	6 7.6	10 11.7	25 30.3	49 59.4	99 131.8	139 205.6	229 389	274 652	321 1014	322 1380	358 2223	312 2789	2158	117.1	112-122	13351.0	12.6	8	214.2 (205-223)
F F		1	3		2	10	6	18	41	57	106	120	156	186	203	240	225	330	1704	84.3	80.0-88.7	12660.6	9.2	11	143.1 (136-150)
	1.	5 4.	۷		2.5	12.7	7.9	21.8	51.2	70.4	142.5	180.9	211.8	450	616	909	1066	1560							

	endix						•				-			65.60	70.74	75-79	80-84	85 +	Total	ASR	95% c.i.	DVII 1	CumInc	Risk	ASR2
Age	0- 4							35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASK	95% C.I.	PYLL	Jumine	RISK	ASRZ
Othe	r non-	"cand	cer" n	norta	lity d	ata, 2	009																		
Deaths	due to be	enign tur	mours in	CR ca	ses																				
М		-								1.0 1.2	1.0 1.3						1.0 6.2	1.0 8.9	4	0.2	0 - 0.4	46	0.0	7863	0.4 (0.0-0.8
F														2 4.8					2	0.1	0 - 0.3	14	0.0	4132	0.2 (0 - 0.4)
Deaths M	due to ly	mphoha	ematop	oietic tu	mours	of uncer	tain ma	lignant	potential	***************************************			***************************************		***************************************		***************************************		0	***************************************				-	
F															1				1	0.1	0 - 0.2	2	0.0	6593	0.1 (0 - 0.3
Deaths M	due to no	on-lympl	hohaem	atopoie	tic tumo	ours of u	ıncertaiı	n/unspe	cified na	ture					3.0				0						
IVI																			U					-	
F																2 7.6	1 4.7		3	0.1	0 - 0.2	0	0.0	*	0.3 (0 - 0.6
	ncer deat	hs in CF	R cases																						
М							1 1.3		2 2.4	6 7.3	11 14.6	14 20.7	39 66.2	42 100.0	84 265.2	163 698.8	229 1422.1	387 3458.8	978	44.6	41.7-47.4	1655	2.4	42	108.0 (101-115
F							3 3.9		2 2.5	8 9.9	5 6.7	6 9.0	14 24.9	24 58.1	40 121.4	81 306.6	147 696.2	459 2169.1	789	24.2	22.4-26.1	1034	1.2	85	58.9 (54.7-63.0
	of undete	ermined	cause ii	n CR ca	ses								_		_		_	_							
М									1 1.2	1 1.2		1 1.5	9 15.3		8 25.3	1 4.3	5 31.1	6 53.6	32	1.8	1.1-2.4	194	0.2	451	3.1 (2.0-4.2)
F										1 1.2		1 1.5	2 3.6	1 2.4	1 3.0	2 7.6	1 4.7	4 18.9	13	0.6	0.2-1.0	76	0.1	1702	1.0 (0.5-1.6
	hs (Can		non-ca	ncer) o	f Cance		try case											***************************************							
М	1 1.3	2 2.8	1 1.3	4 4.9	4 4.5	2 2.3	7 8.8	10 11.7	27 32.7	56 67.9	111 147.8	153 226.3	268 455.0	316 752.4	405 1278.7	485 2079.2	588 3651.5	701 6265.1	3141	162.0	156-168	15185	15.0	7	322.7 (311-334)
F		1 1.5	3 4.2		2 2.5	10 12.7	9 11.8	18 21.8	43 53.7	65 80.3	111 149.2	126 189.9	170 302.7	212 513.1	244 740.3	323 1222.7	373 1766.4	789 3728.6	2499	108.9	104-114	13773	10.4	10	202.5 (195-211)

	Male									males							All							
	_	Grou		10 14	Total	ASD	05% o i	TD0/	Aç 0	ge Gro 1-4		10 14	Total	ASD	95%c.i.	TD0/		ge Gro 1-4		10 14	Total	۸SD	95%c.i.	TD0
I. LEUKAEMIAS, MYELOPROI		1-4 ATIV	E AN	D MY	Total ELODY	SPLAS	95%c.i. STIC DISE			1-4	5-9	10-14	TOLAI	ASK	95%0.1.	10%	- 0	1-4	5-9	10-14	TOLAI	ASK	95%0.1.	10%
All		7 1.6	5 6.9	2 2.6	14	6.6	3.1-10.0		1 6.5	5 8.7	1 1.5	1 1.4	8	4.1	1.2-6.9	100	1 3.2	12 10.2	6 4.3	3 2.0	22	5.4	3.1-7.6	100
Lymphoid leukaemia		6 9.9	4 5.5	2 2.6	12	5.6	2.4-8.8	100		5 8.7	1 1.5	1 1.4	7	3.6	0.9-6.2	100		11 9.3	5 3.5	3 2.0	19	4.6	2.5-6.7	100
Acute myeloid leukaemia		1 1.7	1 1.4		2	1.0	0 - 2.3	100	1 6.5				1	0.5	0 - 1.5	100	1 3.2	1 0.8	1 0.7		3	0.7	0 - 1.6	100
Chronic MPDs					0								0								0			
MDS & other MPDs					0								0								0			
Unspecified/other leukaemia					0								0								0			
II. LYMPHOMAS			***************************************	***************************************	***************************************									•••••••								***************************************		
All		2 3.3		2 2.6	4	1.8	0.0-3.5	100					0					2 1.7		2 1.3	4	0.9	0.0-1.8	100
Hodgkin lymphoma				1 1.3	1	0.4	0 - 1.1	100					0							1 0.7	1	0.2	0 - 0.6	100
Non-Hodgkin lymphoma exc Burki					0								0								0			
Burkitt lymphoma		1 1.7		1 1.3	2	0.9	0 - 2.1	100					0					1 0.8		1 0.7	2	0.5	0 - 1.1	100
Misc. lymphoreticular neoplasms					0								0								0			
Unspecified lymphoma		1 1.7			1	0.5	0 - 1.5	100					0					1 0.8			1	0.3	0 - 0.8	100
III. CNS AND INTRACRANIAL	SPINA	٨L																						
All	1 6.3	3 5.0	4 5.5	3 3.9	11	4.9	2.0-7.9	91	1 6.5	5 8.7	2 2.9	2 2.8	10	5.0	1.9-8.0	90	2 6.4	8 6.8	6 4.3	5 3.4	21	4.9	2.8-7.1	91
Ependymoma/choroid plexus	1 6.3	1 1.7			2	1.0	0 - 2.4	100		1 1.7			1	0.5	0 - 1.6	100	1 3.2	2 1.7			3	8.0	0 - 1.6	100
Astrocytoma			3 4.1	1 1.3	4	1.7	0.0-3.4	100	1 6.5	2 3.5	1 1.5	2 2.8	6	2.9	0.6-5.2	83	1 3.2	2 1.7	4 2.8	3 2.0	10	2.3	0.9-3.7	90
Embryonal tumours		1 1.7	1 1.4		2	1.0	0 - 2.3	100		2 3.5			2	1.1	0 - 2.6	100		3 2.5	1 0.7		4	1.0	0.0-2.0	100
Other gliomas				2 2.6	2	8.0	0 - 1.8	50					0							2 1.3	2	0.4	0 - 0.9	50
Other intracranial/spinal		1 1.7			1	0.5	0 - 1.5	100			1 1.5		1	0.5	0 - 1.4	100		1 0.8	1 0.7		2	0.5	0 - 1.2	100
Unspecified					0								0								0			

Appendix 3C. Childh		les							Female							AII .	•						
		e Grou 1-4	up 5-9	10-14	Total	ΔSR	95%c.i.	TD%	Age G		9 10-14	Total	ΔSR	95%c i	TD%		ge Gro		10-14	Total	ΔSR	95%c.i.	TD9
IV. NEUROBLASTOMA & PE								1070		1 0	0 10 14	Total	71011	00700.11	1070			0.0	10 11	Total	71011	00700.11	,
All	1 6.3	1 1.7	1 1.4		3	1.4	0 - 3.1	100		1.	1 5	1	0.5	0 - 1.4	100	1 3.2	1 0.8	2 1.4		4	1.0	0.0-1.9	10
Neuroblastoma/ganglioneurobl.	1 6.3	1 1.7	1 1.4		3	1.4	0 - 3.1	100		1.	1 5	1	0.5	0 - 1.4	100	1 3.2	1 0.8	2 1.4		4	1.0	0.0-1.9	10
Other					0							0								0			
V. RETINOBLASTOMA	***************************************																						
All		2 3.3			2	1.0	0 - 2.4	100	1.	1 7		1	0.5	0 - 1.6	0		3 2.5			3	8.0	0 - 1.7	6
VI. RENAL TUMOURS All	2 12.5				2	1.0	0 - 2.3	100	1.		2	3	1.5	0 - 3.2	100	2 6.4	1 0.8	2 1.4		5	1.2	0.1-2.3	10
Nephroblastoma/oth non-epithel.	2 12.5				2	1.0	0 - 2.3	100		1	2	3	1.5	0 - 3.2	100	2 6.4	0.8 0.8	2 1.4		5	1.2	0.1-2.3	10
Renal carcinoma					0							0								0			
Unspecified					0							0								0			
VII. HEPATIC TUMOURS		·····	~*~~~															***************************************					
All	2 12.5				2	1.0	0 - 2.3	50	1.	1 7	1 1.4	2	0.9	0 - 2.3	100	2 6.4	1 0.8		1 0.7	4	1.0	0.0-1.9	7
Hepatoblastoma	1 6.3				1	0.5	0 - 1.4	100	1.	1 7	1 1.4	2	0.9	0 - 2.3	100	1 3.2	1 0.8		1 0.7	3	0.7	0 - 1.5	10
Hepatic carcinoma					0							0								0			
Unspecified	1 6.3				1	0.5	0 - 1.4	0				0				1 3.2				1	0.2	0 - 0.7	
VIII. BONE All					0							0								0			
Osteosarcoma					0							0								0			
Chondrosarcoma					0							0								0			
Ewing & related sarcoma					0							0								0			
Other specified					0							0								0			
Unspecified					0							0								0			

Appendix 3C. Childho		ncer, We	stern	Aus	tralia, 2	2009 (nal (Class	ificatio)					
	Males Age Gro	un					Females Age Gro					,	All Age Gro	מווה					
	0 1-4		Total	ASR	95%c.i.	TD%	0 1-4	5-9 10-14	Total	ASR	95%c.i.	TD%	0 1-4	5-9	10-14	Total	ASR	95%c.i.	TD%
IX. SOFT TISSUE SARCOMA																			
All	2 3.3	1 1.3	3	1.4	0 - 3.0	100		1 1.4	1	0.4	0 - 1.2	100	2 1.7		2 1.3	4	0.9	0.0-1.8	100
Rhabdomyosarcoma	1 1.7		1	0.5	0 - 1.5	100			0				1 0.8			1	0.3	0 - 0.8	100
Fibrosarcoma/Neurofibrosarc.	1 1.7		1	0.5	0 - 1.5	100			0				1 0.8			1	0.3	0 - 0.8	100
Kaposi sarcoma			0						0							0			
Other specified		1 1.3	1	0.4	0 - 1.1	100		1 1.4	1	0.4	0 - 1.2	100			2 1.3	2	0.4	0 - 0.9	100
Unspecified			0						0							0			
X. GONADAL AND GERM CEL	L		***************************************							***************************************					•••••••••••	••••			
All		2 2.6	2	8.0	0 - 1.8	100		1 1.4	1	0.4	0 - 1.2	100			3 2.0	3	0.6	0 - 1.3	100
Intracranial/spinal		1 1.3	1	0.4	0 - 1.1	100		1 1.4	1	0.4	0 - 1.2	100			2 1.3	2	0.4	0 - 0.9	100
Other/unspecified non-gonadal			0						0							0			
Gonadal germ cell		1 1.3	1	0.4	0 - 1.1	100			0						1 0.7	1	0.2	0 - 0.6	100
Gonadal carcinoma			0						0							0			
Other and unspecified			0						0	***************************************				******************************		0	*******************		
XI. OTHER EPITHELIAL / MEL	ANOMA																		
All			0						0							0			
Adrenocortical carcinoma			0						0							0			
Thyroid carcinoma			0						0							0			
Nasopharyngeal carcinoma			0						0							0			
Malignant melanoma			0						0							0			
Skin carcinomas			0						0							0			
Other/unspecified carcinoma			0						0							0			

Appendix 3C. Childl	nood	l car	ncer	, We	sterr	Aus	tralia, 2	009	(WI	HOI	ntern	atic	nal (Class	ificatio	n, ve	ersi	on 3)					
		ales ge Gro	up							males ge Gro							AII A	ge Gro	up					
	0	1-4	5-9	10-14	Total	ASR	95%c.i.	TD%	0	1-4	5-9 1	10-14	Total	ASR	95%c.i.	TD%	0	1-4	5-9	10-14	Total	ASR	95%c.i.	TD%
XII. OTHER																								
All			1		1	0.4	0 - 1.3	0					0						1		1	0.2	0 - 0.7	0
			1.4																0.7					
Other specified malignancy					0								0								0			
Other unspecified malignancy			1		1	0.4	0 - 1.3	0					0						1		1	0.2	0 - 0.7	0
			1.4																0.7					
Total																	-							
	6	17	11	10	44	20.3	14.2-26.3	93	2	13	6	6	27	13.3	8.2-18.3	93			17	16	71	16.9	12.9-20.8	93
	37.6	28.1	15.1	13.0					13.1	22.6	8.8	8.4					25.6	25.4	12.1	10.8				

											•
CHS Kimberley Reg	gion										
Males	•					Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	14	20.3	85.4	39.9-131	10	Breast	14	29.2	93.0	41.8-144	13
Melanoma (skin)	11	15.9	53.8	21.0-86.5	22	Melanoma (skin)	7	14.6	40.7	8.7-72.6	19
Colorectal	9	13.0	52.0	17.2-86.8	23	Colorectal	5	10.4	32.1	3.7-60.5	32
Colon	7	10.1	39.9	9.6-70.1	26	Colon	2	4.2	14.8	0 - 35.4	97
Rectum	2	2.9	12.1	0 - 29.5	280	Rectum	3	6.3	17.3	0 - 36.9	47
Liver	5	7.2	21.2	2.6-39.7	43	Pancreas	3	6.3	26.9	0 - 58.6	25
Oesophagus	4	5.8	19.4	0 - 38.9	41	Lung	3	6.3	20.0	0 - 43.0	65
, •	3	4.3	17.7	0 - 38.0	86	Cervix	2	4.2	13.6	0 - 43.0	
Pharynx											68
Lung	3	4.3	21.2	0 - 45.3	36	Uterus	2	4.2	16.6	0 - 39.6	49
Testis	3	4.3	11.8	0 - 25.2	95	Unknown primary	2	4.2	20.4	0 - 48.5	38
Leukaemia	3	4.3	15.5	0 - 33.4	81						
Leukaemia NOS	0										
Lymphoid leukaemia	3	4.3	15.5	0 - 33.4	81						
Myeloid leukaemia	0										
Leukaemia, other	0										
All cancers	69	100.0	379.0	288-470	3	All cancers	48	100.0	330.7	234-428	3
CHS Pilbara Region	า										
Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	14	23.7	57.7	21.5-94.0	16	Breast	18	36.7	97.3	40.6-154	8
Lung	8	13.6	56.7	14.6-98.8	14	Colorectal	7	14.3	42.3	6.3-78.4	19
Melanoma (skin)	8	13.6	39.8	7.1-72.6	21	Colon	4	8.2	24.3	0 - 53.4	32
Kidney	4	6.8	10.6	0.2-21.1	108	Rectum	3	6.1	18.0	0 - 39.5	47
•									40.8		
Stomach	3	5.1	8.0	0 - 17.1	128	Melanoma (skin)	6	12.2		0 - 83.9	16
Mesothelioma	3	5.1	20.5	0 - 46.2	25	Lymphoma	4	8.2	32.1	0 - 66.3	22
Brain	3	5.1	8.7	0 - 18.6	129	Lymphoma NOS	0				
Leukaemia	3	5.1	14.6	0 - 33.7	52	Hodgkin lymphoma	1	2.0	5.0	0 - 14.7	161
Leukaemia NOS	0					NHL	3	6.1	27.1	0 - 59.9	26
Lymphoid leukaemia	3	5.1	14.6	0 - 33.7	52	Brain	3	6.1	13.4	0 - 28.7	93
Myeloid leukaemia	0					Lung	2	4.1	18.4	0 - 46.3	36
Leukaemia, other	0					Uterus	2	4.1	19.6	0 - 50.9	304
Colorectal	2	3.4	7.8	0 - 19.2	116		_				
Colon	1	1.7	2.7	0 - 8.1	437						
Rectum	1	1.7	5.1	0 - 15.1	158						
All cancers	59	100.0	271.4	190-352	3	All cancers	49	100.0	292.5	193-392	3
CHS Midwest Region	on										
Males			4.00	250/	D: 1	Females		٥,		0=0/ :	D: 1
5	Cases	%	ASR	95%c.i.	Risk	.	Cases	%	ASR	95%c.i.	Risk
Prostate	57	28.1	107.3	79.0-136	8	Breast	26	22.2	57.9	35.2-80.6	19
Lung	25	12.3	46.0	27.6-64.4	19	Colorectal	22	18.8	43.1	24.3-61.9	20
Melanoma (skin)	21	10.3	42.4	23.8-60.9	22	Colon	15	12.8	28.5	13.4-43.7	29
Colorectal	17	8.4	30.8	16.0-45.6	22	Rectum	7	6.0	14.5	3.4-25.7	61
Colon	9	4.4	15.5	5.2-25.8	43	Melanoma (skin)	14	12.0	30.6	14.3-46.9	26
Rectum	8	3.9	15.3	4.6-25.9	42	Lung	11	9.4	24.1	9.7-38.5	25
Lymphoma	9	4.4	16.5	5.3-27.7	56	Uterus	8	6.8	20.0	5.5-34.5	41
Lymphoma NOS	0					Cervix	4	3.4	11.6	0 - 23.4	109
Hodgkin lymphoma	2	1.0	3.7	0 - 9.1	498	Thyroid gland	4	3.4	10.8	0.2-21.4	112
NHL	7	3.4	12.8	3.0-22.7	63	Leukaemia	4	3.4	7.7	0.2-21.4	131
								3.4	1.1	0 - 10.4	13
Pancreas	7	3.4	14.4	3.7-25.2	68	Leukaemia NOS	0			o o =	*
Bladder & urinary tract	6	3.0	9.6	1.6-17.5	286	Lymphoid leukaemia	2	1.7	2.8	0 - 6.7	
Unknown primary	6	3.0	10.0	1.8-18.3	100	Myeloid leukaemia	2	1.7	4.8	0 - 11.6	13
Lip, gum & mouth	5	2.5	9.6	0.8-18.4	112	Leukaemia, other	0				
Liver	5	2.5	10.0	1.1-18.9	83	Pancreas	3	2.6	5.8	0 - 12.7	140
Kidney	5	2.5	9.6	1.2-18.1	60	Bladder & urinary tract	3	2.6	7.5	0 - 16.0	102
						Unknown primary	3	2.6	4.5	0 - 9.9	183
All cancors	202	100.0	204 7	226 447	•		44-	100.0	255.0		
All cancers	203	100.0	391.7	336-447	3	All cancers	117	100.0	∠55.0	207-303	4

CHS Wheatbelt Reg	jion										
Males	•	0/	405	050/ - 1	D'-1	Females	0	0/	405	050/ - 1	Б
December	Cases	%	ASR	95%c.i.	Risk	Description	Cases	%	ASR	95%c.i.	Risl
Prostate	96	32.5	128.9	103-155	7	Breast	53	28.5	88.0	63.1-113	1:
Colorectal	38	12.9	50.0	33.6-66.5	16	Colorectal	29	15.6	45.5	26.9-64.1	2
Colon	15	5.1	18.6	8.7-28.4	50	Colon	20	10.8	31.9	15.7-48.2	3
Rectum	23	7.8	31.5	18.3-44.6	24	Rectum	9	4.8	13.6	4.5-22.7	6
Melanoma (skin)	30	10.2	37.6	23.8-51.4	22	Melanoma (skin)	19	10.2	26.0	13.5-38.5	3
Lung	24	8.1	32.0	18.9-45.1	25	Lung	16	8.6	19.5	9.0-30.0	4
Lymphoma	11	3.7	19.0	6.7-31.2	44	Ovary	8	4.3	11.2	3.1-19.4	6
Lymphoma NOS	1	0.3	1.5	0 - 4.5	527	Lymphoma	7	3.8	14.8	2.5-27.2	5
Hodgkin lymphoma	2	0.7	5.4	0 - 13.6	247	Lymphoma NOS	0				
NHL	8	2.7	12.0	3.5-20.6	60	Hodgkin lymphoma	2	1.1	6.5	0 - 16.5	19
Leukaemia	11	3.7	16.5	6.3-26.7	49	NHL	5	2.7	8.3	1.0-15.6	6
Leukaemia NOS	0					Thyroid gland	6	3.2	16.1	1.9-30.3	7
Lymphoid leukaemia	6	2.0	9.8	1.6-18.0	64	Cervix	5	2.7	10.4	1.2-19.6	10
Myeloid leukaemia	5	1.7	6.7		195		5	2.7	7.3	0.7-14.0	8
		1.7	0.7	0.6-12.8	195	Unknown primary					
Leukaemia, other	0			. =		Pancreas	4	2.2	4.5	0 - 9.2	21
Bladder & urinary tract	10	3.4	12.4	4.5-20.3	73	Skin (NMSC exc. SCC/BCC) Bladder & urinary tract	3	1.6 1.6	4.6 2.0	0 - 10.1 0 - 4.2	25
All cancers	295	100.0	412.8	364-462	3	All cancers	186	100.0		252-347	
CHS Goldfields Reg ^{Males}	ion					Females					
-	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Ris
Prostate	44	29.9	132.5	93.2-172	6	Breast	21	24.7	70.8	39.8-102	1
Lung	23	15.6	68.8	40.5-97.1	11	Colorectal	12	14.1	40.4	16.9-63.8	2
Colorectal	13	8.8	35.1	15.8-54.4	24	Colon	7	8.2	21.9	5.1-38.6	4
	9			8.0-39.0			5				
Colon		6.1	23.5		43	Rectum		5.9	18.5	2.1-34.9	3
Rectum	4	2.7	11.6	0.0-23.1	55	Melanoma (skin)	7	8.2	21.6	5.4-37.8	3
Melanoma (skin)	11	7.5	30.1	12.0-48.2	31	Uterus	7	8.2	25.6	6.4-44.8	2
Lip, gum & mouth	5	3.4	13.4	1.6-25.1	73	Lung	6	7.1	22.8	4.4-41.3	2
Kidney	5	3.4	14.2	1.6-26.9	42	Thyroid gland	5	5.9	17.4	2.0-32.8	6
Bladder & urinary tract	5	3.4	14.6	1.7-27.5	62	Stomach	3	3.5	9.9	0 - 21.3	6
Stomach	4	2.7	11.3	0.1-22.4	92	Pancreas	3	3.5	9.3	0 - 20.1	19
Pancreas	4	2.7	12.1	0.1-24.1	56	Cervix	3	3.5	9.8	0 - 20.9	11
Gallbladder / bile ducts	3	2.0	8.4	0 - 17.9	146	Unknown primary	3	3.5	7.0	0 - 15.1	26
Larynx	3	2.0	8.1	0 - 17.5	86	Brain	2	2.4	4.7	0 - 11.2	43
Mesothelioma	3	2.0	10.3	0 - 22.0	50	Brain	_			0 11.2	-10
Brain	3	2.0	10.3	0 - 21.9	74						
Lymphoma	3	2.0	7.6	0 - 16.3	174						
All cancers	147	100.0	429.2	360-499	2	All cancers	85	100.0	278.5	218-339	
CHS Great Southerr	n Regio	n									
Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Ris
Prostate	63	33.3	112.4	83.8-141	7	Breast	30	21.9	63.6	40.0-87.3	1
Melanoma (skin)	18	9.5	39.9	19.6-60.2	21	Melanoma (skin)	16	11.7	34.5	15.6-53.4	3
Colorectal	16	8.5	30.9	15.1-46.7	25	Colorectal	14	10.2	22.9	10.1-35.7	2
Colon	15	7.9	28.3	13.4-43.1	27	Colon	12	8.8	20.1	8.1-32.1	3
Rectum	1	0.5	2.7	0 - 7.9	453	Rectum	2	1.5	2.8	0 - 7.2	37
Lung	13	6.9	24.6	10.8-38.5	36	Lung	12	8.8	22.9	9.1-36.6	4
Lymphoma	11	5.8	23.3	8.4-38.3	40	Uterus	9	6.6	19.5	6.1-32.9	3
* *		5.0	23.3	0.4-30.3	40						
Lymphoma NOS	0					Myeloma	7	5.1	12.4	2.3-22.5	7
Hodgkin lymphoma	0		•			Lymphoma	6	4.4	10.3	0 - 21.0	17
NHL	11	5.8	23.3	8.4-38.3	40	Lymphoma NOS	0				
Kidney	8	4.2	14.8	4.1-25.5	60	Hodgkin lymphoma	1	0.7	4.7	0 - 13.8	38
Leukaemia	7	3.7	17.2	3.3-31.0	55	NHL	5	3.6	5.6	0 - 11.3	33
Leukaemia NOS	1	0.5	0.9	0 - 2.7	*	Pancreas	5	3.6	8.6	0.4-16.8	11
	4	2.1	11.3	0 - 23.3	82	Cervix	4	2.9	10.3	0 - 21.4	12
Lymphoid leukaemia	•	1.1	4.9	0 - 11.8	167	Unknown primary	4	2.9	2.8	0.1-5.5	*
Lymphoid leukaemia Myeloid leukaemia	2		-	-	-	Leukaemia	4	2.9	7.3	0 - 14.8	10
Myeloid leukaemia	0										
		3.2	9.7	1.6-17.9	126	Leuraeiiiia	•	2.0	7.0	0 - 14.0	

	Cases	%	ASR	95%c.i.	Risk	Females	Cases	%	ASR	95%c.i.	R
Prostate	150	31.8	121.4	102-141	7	Breast	92	26.7	77.8	61.3-94.3	ĸ
Colorectal	65	13.8	51.0	38.2-63.8	17	Colorectal	46	13.4	33.3	23.1-43.4	
Colon	40	8.5	32.2	22.0-42.4	24	Colon	35	10.2	24.8	16.1-33.5	
Rectum	24	5.1	18.3	10.6-26.0	57	Rectum	11	3.2	8.5	3.2-13.7	1
Melanoma (skin)	64	13.6	52.7	39.4-66.0	16	Melanoma (skin)	40	11.6	41.0	27.5-54.4	
Lung	38	8.1	26.5	17.8-35.3	32	Lung	30	8.7	21.4	13.3-29.5	
Lymphoma	19	4.0	17.6	9.4-25.9	43	Leukaemia	13	3.8	12.0	4.3-19.7	
Lymphoma NOS	1	0.2	0.9	0 - 2.7	646	Leukaemia NOS	0	3.0	12.0	4.5-15.7	
, ,	4	0.2	5.2	0 - 2.7	252	Lymphoid leukaemia	9	2.6	8.9	1.9-15.9	
Hodgkin lymphoma						Myeloid leukaemia	4	1.2			
NHL	14	3.0	11.5	5.4-17.7	56	•		1.2	3.0	0 - 6.3	
Bladder & urinary tract	16	3.4	10.9	5.4-16.4	77	Leukaemia, other	0	0.0		07450	
Stomach	13	2.8	9.8	4.3-15.4	85	Uterus	11	3.2	9.4	3.7-15.0	
Pancreas	10	2.1	5.9	2.1-9.6	514	Pancreas	10	2.9	6.2	2.1-10.3	
Kidney	8	1.7	6.0	1.8-10.3	145	Thyroid gland	9	2.6	8.3	2.8-13.8	
_ip, gum & mouth	7	1.5	7.2	1.6-12.7	109	Lip, gum & mouth	8	2.3	6.8	2.0-11.5	
Mesothelioma	7	1.5	5.3	1.3-9.3	121	Ovary	8	2.3	6.8	2.0-11.6	
3rain = T	7	1.5	6.6	1.3-11.8	135	Cervix	7	2.0	6.9	1.8-12.1	
_eukaemia	7	1.5	7.4	1.4-13.5	129	Brain	7	2.0	7.5	1.3-13.7	
Leukaemia NOS	0					Myeloma	7	2.0	4.9	1.0-8.8	
Lymphoid leukaemia	4	8.0	4.5	0 - 9.2	215	Kidney	5	1.5	4.2	0.5-8.0	
Myeloid leukaemia	3	0.6	2.9	0 - 6.7	322	Bladder & urinary tract	5	1.5	3.4	0.2-6.6	
Leukaemia, other	Ō					Unknown primary	5	1.5	3.3	0.2-6.4	
Myeloma	7	1.5	4.5	1.0-8.0	215	Lymphoma	5	1.5	4.4	0.3-8.4	
Testis	6	1.3	7.7	1.4-14.1	176	Lymphoma NOS	0			0.0 0	
Jnknown primary	6	1.3	5.7	0.3-11.0	183	Hodgkin lymphoma	1	0.3	1.2	0 - 3.7	
Pharynx	5	1.1	4.1	0.4-7.8	231	NHL	4	1.2	3.1	0 - 6.4	
_iver	4	0.8	3.2	0.4-7.8	201	Oesophagus	4	1.2	1.9	0 - 0.4	
Skin (NMSC exc. SCC/BCC)		0.8	2.8	0.1-0.3	347	Liver	4	1.2	4.3	0 - 3.9	
All cancers	472	100.0	380.9	345-416	3	All cancers	344	100.0	287.3	255-320	
VA Country - all lales	_					Females					
S	Cases	%	ASR	95%c.i.			_			0=0/ '	
Prostate					Risk	5 .	Cases	%	ASR	95%c.i.	
	438	30.5	116.2	105-127	7	Breast	254	26.3	75.2	65.7-84.6	
, ,	163	30.5 11.4	116.2 43.8	105-127 37.0-50.7	7 20	Colorectal	254 135	26.3 14.0	75.2 36.9	65.7-84.6 30.4-43.4	
Colorectal	163 160	30.5 11.4 11.2	116.2 43.8 41.4	105-127 37.0-50.7 34.8-47.9	7 20 20	Colorectal Colon	254 135 95	26.3 14.0 9.8	75.2 36.9 25.5	65.7-84.6 30.4-43.4 20.1-30.9	
, ,	163	30.5 11.4	116.2 43.8	105-127 37.0-50.7	7 20	Colorectal	254 135	26.3 14.0	75.2 36.9	65.7-84.6 30.4-43.4	
Colorectal	163 160	30.5 11.4 11.2	116.2 43.8 41.4	105-127 37.0-50.7 34.8-47.9	7 20 20	Colorectal Colon	254 135 95	26.3 14.0 9.8	75.2 36.9 25.5	65.7-84.6 30.4-43.4 20.1-30.9	
Colorectal Colon Rectum	163 160 96	30.5 11.4 11.2 6.7	116.2 43.8 41.4 24.7	105-127 37.0-50.7 34.8-47.9 19.7-29.8	7 20 20 32	Colorectal Colon Rectum	254 135 95 40	26.3 14.0 9.8 4.1	75.2 36.9 25.5 11.4	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1	
Colorectal Colon Rectum Lung	163 160 96 63	30.5 11.4 11.2 6.7 4.4	116.2 43.8 41.4 24.7 16.4	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6	7 20 20 32 50	Colorectal Colon Rectum Melanoma (skin)	254 135 95 40 109	26.3 14.0 9.8 4.1 11.3	75.2 36.9 25.5 11.4 33.9	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5	
Colorectal Colon Rectum Lung	163 160 96 63 134	30.5 11.4 11.2 6.7 4.4 9.3	116.2 43.8 41.4 24.7 16.4 34.5	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4	7 20 20 32 50 24	Colorectal Colon Rectum Melanoma (skin) Lung	254 135 95 40 109 80	26.3 14.0 9.8 4.1 11.3 8.3	75.2 36.9 25.5 11.4 33.9 21.5	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS	163 160 96 63 134 56	30.5 11.4 11.2 6.7 4.4 9.3 3.9	116.2 43.8 41.4 24.7 16.4 34.5 16.6	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1	7 20 20 32 50 24 52	Colorectal Colon Rectum Melanoma (skin) Lung Uterus	254 135 95 40 109 80 41	26.3 14.0 9.8 4.1 11.3 8.3 4.2	75.2 36.9 25.5 11.4 33.9 21.5 13.0	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma	163 160 96 63 134 56 2	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4	7 20 20 32 50 24 52 1136	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas	254 135 95 40 109 80 41 28	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	163 160 96 63 134 56 2	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0	7 20 20 32 50 24 52 1136 374	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia	254 135 95 40 109 80 41 28 27	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6	
Colorectal Colon Rectum .ung .ymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract	163 160 96 63 134 56 2 10	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7	7 20 20 32 50 24 52 1136 374 63	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia	254 135 95 40 109 80 41 28 27	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney	163 160 96 63 134 56 2 10 44 44 37	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0-1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2	7 20 20 32 50 24 52 1136 374 63 96 81	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	254 135 95 40 109 80 41 28 27 0	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia	163 160 96 63 134 56 2 10 44 44 37 36	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2	7 20 20 32 50 24 52 1136 374 63 96	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	254 135 95 40 109 80 41 28 27 0 17	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS	163 160 96 63 134 56 2 10 44 44 37 36	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4	7 20 20 32 50 24 52 1136 374 63 96 81 76	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix	254 135 95 40 109 80 41 28 27 0 17 10 0	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract (idney Leukaemia Leukaemia NOS Lymphoid leukaemia	163 160 96 63 134 56 2 10 44 44 37 36 1	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5	7 20 20 32 50 24 52 1136 374 63 96 81 76 *	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	163 160 96 63 134 56 2 10 44 44 37 36 1	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4	7 20 20 32 50 24 52 1136 374 63 96 81 76	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0	7 20 20 32 50 24 52 1136 374 63 96 81 76 *	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas	163 160 96 63 134 56 2 10 44 44 37 36 1 1 24 11 0	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8	116.2 43.8 41.4 24.7 16.4 34.5 16.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0	7 20 20 32 50 24 52 1136 374 63 96 81 76 *	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma NOS Hodgkin lymphoma	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6 0.5	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8	
Colorectal Colon Rectum .ung .ung .ymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney .eukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas .ip, gum & mouth	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 7.9 8.9	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0	7 20 20 32 50 24 52 1136 374 63 96 81 76 * 100 311	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NHL	254 135 95 40 109 80 41 28 27 0 17 10 0 26 25 5 5	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6 0.5 2.1	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0	
Colorectal Colon Rectum Lung Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stomach	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5	7 20 20 32 50 24 52 1136 374 63 96 81 76 * 100 311	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6 0.5 2.1 2.3	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract (idney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stornach Unknown primary	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.5 0.1 1.7 0.8 2.2 2.2 2.1 2.0	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3	7 20 20 32 50 24 52 1136 374 63 96 * 100 311 135 103 110 124	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 20 22	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6 0.5 2.1 2.3 2.0	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stormach Unknown primary Desophagus	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 0.1 1.7 0.8 2.2 2.2 2.1 2.0 1.5	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 7.9 8.9 7.7 7.5 5.4	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8	7 20 20 32 50 24 52 1136 374 63 96 81 176 * 100 311 135 103 110 124 133	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma Ovary	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 22 19	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stormach Unknown primary Desophagus	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.5 0.1 1.7 0.8 2.2 2.2 2.1 2.0	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3	7 20 20 32 50 24 52 1136 374 63 96 * 100 311 135 103 110 124	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma NHL Unknown primary Myeloma Ovary Brain	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 20 22	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6 0.5 2.1 2.3 2.0	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stomach Unknown primary Desophagus Liver	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 0.1 1.7 0.8 2.2 2.2 2.1 2.0 1.5	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 7.9 8.9 7.7 7.5 5.4	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8	7 20 20 32 50 24 52 1136 374 63 96 81 176 * 100 311 135 103 110 124 133	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma Ovary	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 22 19	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7	
Colorectal Colon Rectum Lung Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stomach Juhknown primary Desophagus Liver Myeloma	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21 20	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8 2.2 2.2 2.2 1.5 1.4	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 7.9 8.9 7.7 7.5 5.4 5.2	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8 2.9-7.5	7 20 20 32 50 24 52 1136 374 63 96 81 76 * 100 311 135 103 110 124 133 141	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma NHL Unknown primary Myeloma Ovary Brain	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 20 22 19 18	26.3 14.0 9.8 4.1 11.3 4.2 2.9 2.8 1.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7 2.4-7.9	
Colorectal Colon Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stormach Juknown primary Desophagus Liver Myeloma Pharynx	163 160 96 63 134 56 2 10 44 44 37 36 1 1 24 11 0 32 31 30 29 21 20 20	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8 2.2 2.2 2.1 2.0 1.5 1.4	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1 7.9 8.9 7.7 7.5 5.4 5.2 5.0	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8 2.9-7.5 2.7-7.2	7 20 20 32 50 24 52 1136 374 63 96 81 76 * 100 311 135 103 110 124 133 141 135	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NHL Unknown primary Myeloma Ovary Brain Lip, gum & mouth	254 135 95 40 109 80 41 28 27 0 17 10 0 26 25 0 5 20 22 19 18 16	26.3 14.0 9.8 4.1 11.3 4.2 2.9 2.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9 1.7	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2 5.2 4.3	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7 2.4-7.9 2.0-6.6	
Colorectal Colon Rectum Lung Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stomach Unknown primary Desophagus Liver Myeloma Pharynx Mesothelioma	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21 20 20	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.6 2.5 0.1 1.7 0.8 2.2 2.2 2.1 2.0 1.5 1.4 1.4	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1 7.9 8.9 7.7 7.5 5.4 5.2 5.0 5.1	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8 2.9-7.5 2.7-7.2 2.8-7.5	7 20 20 32 50 24 52 1136 374 63 96 81 76 * 100 311 135 103 110 124 135 151	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma Ovary Brain Lip, gum & mouth Bladder & urinary tract Oesophagus	254 135 95 40 109 80 41 28 27 0 17 10 0 26 25 0 5 20 22 19 18 16 14	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.7 2.6 0.5 2.1 2.3 2.0 1.9 1.7 1.4	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2 5.2 5.2 4.3 3.4	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7 2.4-7.9 2.0-6.6 1.5-5.3	
Colorectal Colon Rectum Lung Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Lip, gum & mouth Stomach Unknown primary Oesophagus Liver Myeloma Pharynx Mesothelioma Brain	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21 20 20 19	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.5 0.1 1.7 0.8 2.2 2.2 2.1 2.0 1.5 1.4 1.3 1.3	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1 7.9 8.9 7.7 7.5 5.4 5.2 5.1 5.3 6.6	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8 2.9-7.5 2.7-7.2 2.8-7.5 2.9-7.7 3.5-9.7	7 20 20 32 50 24 52 1136 374 63 96 81 76 * 100 311 135 103 110 124 133 141 135 151 118	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma Ovary Brain Lip, gum & mouth Bladder & urinary tract Oesophagus Kidney	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 20 22 19 18 16 14 14	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9 1.7 1.4 1.4 1.1	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2 5.2 5.2 4.3 3.4 2.5	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7 2.4-7.9 2.0-6.6 1.5-5.3 0.9-4.0 1.0-4.7	
Colorectal Colon Rectum Lung Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia teukaemia, other Pancreas Lip, gum & mouth Stomach Unknown primary Oesophagus Liver Myeloma Pharynx Mesothelioma Brain Testis	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21 20 20 19 19 19	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.5 0.1 1.7 0.8 2.2 2.1 2.0 1.5 1.4 1.4 1.3 1.3 1.3	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1 7.9 8.9 7.7 7.5 5.4 5.2 5.0 5.1 6.6 6.6 6.6	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8 2.9-7.5 2.7-7.2 2.8-7.5 2.9-7.7 2.8-8.4	7 20 20 32 50 24 52 1136 374 63 96 81 176 * 100 311 135 103 110 124 133 141 135 151 118 161 228	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma Ovary Brain Lip, gum & mouth Bladder & urinary tract Oesophagus Kidney Liver	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 20 22 19 18 16 14 11 10 9	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9 1.7 1.4 1.1 1.0 0.9	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2 5.2 4.3 3.4 2.5 2.2 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7 2.4-7.9 2.0-6.6 1.5-5.3 0.9-4.0 1.0-4.7 0.9-5.3	
Rectum Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	163 160 96 63 134 56 2 10 44 44 37 36 1 24 11 0 32 31 30 29 21 20 20 19	30.5 11.4 11.2 6.7 4.4 9.3 3.9 0.1 0.7 3.1 2.5 0.1 1.7 0.8 2.2 2.2 2.1 2.0 1.5 1.4 1.3 1.3	116.2 43.8 41.4 24.7 16.4 34.5 16.6 0.6 3.6 12.4 10.5 9.9 11.3 0.1 8.1 3.1 7.9 8.9 7.7 7.5 5.4 5.2 5.1 5.3 6.6	105-127 37.0-50.7 34.8-47.9 19.7-29.8 12.3-20.6 28.5-40.4 12.1-21.1 0 - 1.4 1.3-6.0 8.6-16.2 7.3-13.7 6.7-13.2 7.4-15.2 0 - 0.4 4.7-11.5 1.2-5.0 5.1-10.7 5.7-12.2 4.9-10.5 4.6-10.3 3.1-7.8 2.9-7.5 2.7-7.2 2.8-7.5 2.9-7.7 3.5-9.7	7 20 20 32 50 24 52 1136 374 63 96 * 100 311 135 103 110 124 133 141 135 151 118	Colorectal Colon Rectum Melanoma (skin) Lung Uterus Pancreas Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Cervix Thyroid gland Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Unknown primary Myeloma Ovary Brain Lip, gum & mouth Bladder & urinary tract Oesophagus Kidney	254 135 95 40 109 80 41 28 27 0 17 10 0 26 26 25 0 5 20 22 19 18 16 14 14 11	26.3 14.0 9.8 4.1 11.3 8.3 4.2 2.9 2.8 1.0 2.7 2.6 0.5 2.1 2.3 2.0 1.9 1.7 1.4 1.4 1.1	75.2 36.9 25.5 11.4 33.9 21.5 13.0 6.9 7.9 5.3 2.6 8.8 9.2 7.6 2.1 5.5 4.8 5.2 5.2 5.2 4.3 3.4 2.5 5.2	65.7-84.6 30.4-43.4 20.1-30.9 7.8-15.1 27.3-40.5 16.5-26.4 8.9-17.0 4.2-9.6 4.6-11.1 2.6-8.0 0.9-4.2 5.3-12.2 5.6-12.9 4.4-10.8 0.2-4.1 3.0-8.0 2.6-7.0 2.8-7.6 2.7-7.7 2.4-7.9 2.0-6.6 1.5-5.3 0.9-4.0 1.0-4.7	

North Metro AHS											
Males	Casas	0/	ACD	OE9/ o i	Diek	Females	Coooo	0/	ACD	05% a :	Diek
Prostate	Cases 823	% 33.5	ASR 124.1	95%c.i. 115-133	Risk 7	Breast	Cases 581	% 31.0	ASR 86.5	95%c.i. 79.2-93.7	Risk 11
Colorectal	297	12.1	43.8	38.7-48.9	19	Colorectal	205	10.9	25.2	21.5-28.9	35
Colon	182	7.4	25.6	21.8-29.4	33	Colon	141	7.5	16.5	13.6-19.4	51
Rectum	114	4.6	18.0	14.6-21.3	45	Rectum	63	3.4	8.6	6.4-10.9	108
Melanoma (skin)	252	10.2	38.5	33.6-43.3	21	Lung	151	8.1	18.9	15.7-22.1	44
Lung	212	8.6	30.5	26.2-34.7	27	Melanoma (skin)	138	7.4	20.4	16.8-24.0	47
Lymphoma	103	4.2	16.5	13.2-19.8	62	Thyroid gland	79	4.2	13.4	10.4-16.4	72
Lymphoma NOS	5	0.2	1.0	0.0-2.0	1326	Uterus	67	3.6	9.0	6.8-11.3	96
Hodgkin lymphoma	12	0.5	2.3	1.0-3.7	563	Lymphoma	62	3.3	8.2	6.0-10.5	118
NHL	86	3.5	13.1	10.3-16.0	73	Lymphoma NOS	3	0.2	0.2	0 - 0.4	*
Bladder & urinary tract	76	3.1	10.2	7.8-12.5	97	Hodgkin lymphoma	9	0.5	1.9	0.6-3.2	559
Leukaemia	74	3.0	12.8	9.6-16.0	78	NHL	50	2.7	6.1	4.3-8.0	150
Leukaemia NOS	3	0.1	0.3	0 - 0.8	2458	Ovary	60	3.2	9.2	6.7-11.6	93
Lymphoid leukaemia	38	1.5	7.1	4.7-9.6	128	Pancreas	55	2.9	6.6	4.7-8.6	127
Myeloid leukaemia	33	1.3	5.4	3.4-7.4	217	Unknown primary	48	2.6	4.9	3.4-6.5	241
Leukaemia, other	0					Leukaemia	46	2.5	7.2	4.8-9.6	166
Kidney	67	2.7	10.4	7.9-13.0	81	Leukaemia NOS	1	0.1	0.1	0 - 0.4	2708
Unknown primary	64	2.6	8.9	6.6-11.2	114	Lymphoid leukaemia	21	1.1	3.3	1.6-5.0	393
Stomach	49	2.0	6.7	4.8-8.7	131	Myeloid leukaemia	24	1.3	3.7	2.0-5.4	319
Pancreas	46	1.9	6.7	4.7-8.7	131	Leukaemia, other	0	0.0		E 4 40 0	4.40
Testis	35	1.4	6.7	4.4-8.9	191	Cervix	44	2.3	7.7	5.4-10.0	140
Brain	33	1.3	5.1	3.2-6.9	221	Kidney	40	2.1	6.1	4.1-8.2	146
Lip, gum & mouth	32	1.3	5.0	3.3-6.8	193	Bladder & urinary tract	39	2.1	4.1	2.7-5.5 2.1-4.7	261
Mesothelioma	29 27	1.2	3.9	2.4-5.4	223	Myeloma Brain	31 27	1.7	3.4		291
Oesophagus Liver	27	1.1 1.1	3.9 4.6	2.4-5.3 2.7-6.5	249 184	Stomach	22	1.4 1.2	5.0 2.8	2.8-7.1 1.6-4.1	232 256
Thyroid gland	27	1.1	4.6	2.6-5.9	228	Gallbladder / bile ducts	17	0.9	1.8	0.9-2.8	619
Pharynx	22	0.9	3.3	1.9-4.7	267	Skin (NMSC exc. SCC/BCC)	17	0.9	1.8	0.8-2.8	627
Myeloma	20	0.8	2.9	1.6-4.2	309	Liver	16	0.9	1.9	0.8-2.8	446
Gallbladder / bile ducts	19	0.8	2.7	1.5-4.0	310	Lip, gum & mouth	15	0.8	2.1	1.0-3.2	407
All cancers	2460	100.0	371.9	357-387	3	All cancers	1874	100.0	261.2	249-274	407
South Metro AHS Males	Casas	0/	ΛCD	05% o i	Dick	Females	Casas	0/	ΛCD	05% o i	Dick
Males	Cases	% 32.1	ASR	95%c.i.	Risk		Cases	% 28.5	ASR	95%c.i.	Risk
Males Prostate	768	32.1	121.1	112-130	7	Breast	477	28.5	79.7	72.3-87.2	12
Males Prostate Colorectal	768 282	32.1 11.8	121.1 43.5	112-130 38.2-48.8	7 20	Breast Colorectal	477 205	28.5 12.3	79.7 28.6	72.3-87.2 24.3-32.8	12 31
Males Prostate Colorectal Colon	768 282 193	32.1 11.8 8.1	121.1 43.5 29.0	112-130 38.2-48.8 24.7-33.3	7 20 30	Breast Colorectal Colon	477 205 143	28.5 12.3 8.6	79.7 28.6 19.2	72.3-87.2 24.3-32.8 15.8-22.6	12 31 47
Males Prostate Colorectal Colon Rectum	768 282	32.1 11.8	121.1 43.5	112-130 38.2-48.8	7 20	Breast Colorectal Colon Rectum	477 205	28.5 12.3	79.7 28.6	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9	12 31
Males Prostate Colorectal Colon	768 282 193 89	32.1 11.8 8.1 3.7	121.1 43.5 29.0 14.5	112-130 38.2-48.8 24.7-33.3 11.4-17.6	7 20 30 58	Breast Colorectal Colon	477 205 143 62	28.5 12.3 8.6 3.7	79.7 28.6 19.2 9.3	72.3-87.2 24.3-32.8 15.8-22.6	12 31 47 90
Males Prostate Colorectal Colon Rectum Lung	768 282 193 89 237	32.1 11.8 8.1 3.7 9.9	121.1 43.5 29.0 14.5 34.2	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8	7 20 30 58 25	Breast Colorectal Colon Rectum Lung	477 205 143 62 162	28.5 12.3 8.6 3.7 9.7	79.7 28.6 19.2 9.3 21.6	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1	12 31 47 90 38
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin)	768 282 193 89 237 228	32.1 11.8 8.1 3.7 9.9 9.5	121.1 43.5 29.0 14.5 34.2 38.4	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5	7 20 30 58 25 23	Breast Colorectal Colon Rectum Lung Melanoma (skin)	477 205 143 62 162 153	28.5 12.3 8.6 3.7 9.7 9.2	79.7 28.6 19.2 9.3 21.6 24.9	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0	12 31 47 90 38 40
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma	768 282 193 89 237 228 96	32.1 11.8 8.1 3.7 9.9 9.5 4.0	121.1 43.5 29.0 14.5 34.2 38.4 15.5	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7	7 20 30 58 25 23 62	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma	477 205 143 62 162 153 85	28.5 12.3 8.6 3.7 9.7 9.2 5.1	79.7 28.6 19.2 9.3 21.6 24.9 12.7	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7	12 31 47 90 38 40 71
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NHL	768 282 193 89 237 228 96 3 11	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3	7 20 30 58 25 23 62 1662 559 73	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	477 205 143 62 162 153 85 1 6	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1	12 31 47 90 38 40 71 * 1075 76
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney	768 282 193 89 237 228 96 3 11 82	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7	7 20 30 58 25 23 62 1662 559 73 67	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus	477 205 143 62 162 153 85 1 6 78	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7 4.1	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4	12 31 47 90 38 40 71 * 1075 76
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract	768 282 193 89 237 228 96 3 11 82 79	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0-1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3	7 20 30 58 25 23 62 1662 559 73 67 81	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland	477 205 143 62 162 153 85 1 6 78 68 52	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4	12 31 47 90 38 40 71 * 1075 76 69 96
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia	768 282 193 89 237 228 96 3 11 82 79 71	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1	7 20 30 58 25 23 62 1662 559 73 67 81 91	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas	477 205 143 62 162 153 85 1 6 78 68 52 48	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.9	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9	12 31 47 90 38 40 71 * 1075 76 69 96 153
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS	768 282 193 89 237 228 96 3 11 82 79 71 59	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3	7 20 30 58 25 23 62 1662 559 73 67 81 91	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary	477 205 143 62 162 153 85 1 6 78 68 52 48	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8	12 31 47 90 38 40 71 * 1075 76 69 96 153 204
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia	768 282 193 89 237 228 96 3 11 82 79 71 59 1	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7	7 20 30 58 25 23 62 1662 559 73 67 81 91 *	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney	477 205 143 62 162 153 85 1 6 78 68 52 48 45	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	768 282 193 89 237 228 96 3 11 82 79 71 59 1	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3	7 20 30 58 25 23 62 1662 559 73 67 81 91	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	768 282 193 89 237 228 96 3 11 82 79 71 59 1 29 0	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas	768 282 193 89 237 228 96 3 11 82 79 71 59 1 29 0 50	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia	477 205 143 62 162 153 85 1 6 78 68 52 48 45 39 37	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary	768 282 193 89 237 228 96 3 11 82 79 71 59 1 29 29 0 50	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach	768 282 193 89 237 228 96 3 11 82 79 71 29 29 0 50 45	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus	768 282 193 89 237 228 96 3 11 82 79 71 59 1 29 29 0 50 45 42	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8	121.1 43.5 29.0 14.5 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23	28.5 12.3 8.6 3.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.5 6.0 5.1 7.2 6.4 6.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth	768 282 193 89 237 228 96 3 11 82 79 71 59 0 50 45 42 40	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.8 1.7	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4	7 20 30 58 25 23 62 1662 559 73 67 81 152 226 119 168 144 130 161	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma	768 282 193 89 237 228 96 3 11 82 79 71 59 0 50 45 42 40 39 33	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.7 1.6 1.4	121.1 43.5 29.0 14.5 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6 5.1	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8	7 20 30 58 25 23 62 1662 559 73 67 81 152 226 119 168 144 130 161 148	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.7 2.6 2.3 2.2 1.4 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain	768 282 193 89 237 228 96 3 11 82 79 71 59 0 50 45 42 40 39 33 33	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8 1.7 1.6 1.4	121.1 43.5 29.0 14.5 34.2 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.3 6.5 5.1 6.3	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 4.0-8.7	7 20 30 58 25 23 62 1662 559 73 67 81 91 1 * 152 226 119 168 144 130 161 148 153	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6 2.6-6.2 1.6-4.1 2.3-5.9	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain Myeloma	768 282 193 89 237 228 96 3 11 82 79 1 29 0 0 45 42 40 39 33 33 30	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8 1.7 1.6 1.4 1.4	121.1 43.5 29.0 14.5 34.2 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6 5.1 6.3 4.5	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 4.0-8.7 2.9-6.2	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226 119 168 144 130 161 148 153 199	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix Stomach	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22 18	28.5 12.3 8.6 3.7 9.2 5.1 0.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1 2.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256 487
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain Myeloma Liver	768 282 193 89 237 228 96 3 11 82 79 1 29 0 50 45 42 40 39 33 33 30 29	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8 1.7 1.6 1.4 1.4 1.3	121.1 43.5 29.0 14.5 34.2 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6 5.1 6.3 4.5	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 4.0-8.7 2.9-6.2 2.8-6.1	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226 119 168 144 130 161 148 153 199 207	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix Stomach Lip, gum & mouth	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22 21 18	28.5 12.3 8.6 3.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1 2.2 2.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6 2.6-6.2 1.6-4.1 2.3-5.9 1.1-3.4 1.0-3.5	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256 487 421
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain Myeloma Liver Pharynx	768 282 193 89 237 228 96 3 11 82 79 71 29 29 0 50 45 42 40 39 33 33 33 30 29 27	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8 1.7 1.6 1.4 1.4 1.3 1.2	121.1 43.5 29.0 14.5 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6 5.1 6.3 4.4 4.9	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 7.2-9.6.2	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226 119 168 144 130 161 148 153 199 207 180	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix Stomach Lip, gum & mouth Oesophagus	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22 18 14 14	28.5 12.3 8.6 3.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8 1.7 1.4 1.3 1.1 0.8 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1 2.2 2.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6 2.6-6.2 1.6-4.1 2.3-5.9 1.1-3.4 1.0-3.5 0.8-2.9	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256 487 421 447
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain Myeloma Liver Pharynx Thyroid gland	768 282 193 89 237 228 96 3 11 82 79 71 59 0 50 45 42 40 39 33 33 30 29 27 26	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8 1.7 1.6 1.4 1.4 1.3 1.2 1.1	121.1 43.5 29.0 14.5 38.4 15.5 0.5 2.6 12.4 13.5 10.7 7.5 6.6 6.4 6.3 6.6 5.1 6.3 4.4 4.9	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 4.0-8.7 2.9-6.2 2.8-6.1 3.1-6.8 3.0-6.8	7 20 30 58 25 23 62 1662 559 73 67 81 191 * 152 226 119 168 144 130 161 148 153 199 207 180 198	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix Stomach Lip, gum & mouth Oesophagus Myeloma	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22 18 14 14	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8 1.7 1.4 1.3 1.1 0.8 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.7 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1 2.2 1.8	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6 2.6-6.2 1.6-4.1 2.3-5.9 1.1-3.4 1.0-3.5 0.8-2.9 0.5-2.2	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256 487 421 447 639
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain Myeloma Liver Pharynx	768 282 193 89 237 228 96 3 11 82 79 71 59 0 50 45 42 40 39 33 33 30 29 27 26	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.8 1.7 1.6 1.4 1.4 1.3 1.2	121.1 43.5 29.0 14.5 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6 5.1 6.3 4.4 4.9	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 7.2-9.6.2	7 20 30 58 25 23 62 1662 559 73 67 81 91 * 152 226 119 168 144 130 161 148 153 199 207 180	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix Stomach Lip, gum & mouth Oesophagus	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22 18 14 14	28.5 12.3 8.6 3.7 9.2 5.1 0.4 4.7 4.1 3.1 2.9 2.7 2.6 2.3 2.2 1.4 0.8 1.7 1.4 1.3 1.1 0.8 0.8	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1 2.2 2.2	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6 2.6-6.2 1.6-4.1 2.3-5.9 1.1-3.4 1.0-3.5 0.8-2.9	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256 487 421 447
Males Prostate Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Pancreas Unknown primary Stomach Oesophagus Lip, gum & mouth Mesothelioma Brain Myeloma Liver Pharynx Thyroid gland Skin (NMSC exc. SCC/BCC)	768 282 193 89 237 228 96 3 11 82 79 71 29 29 0 50 45 42 40 39 33 33 30 29 27 26 22 22	32.1 11.8 8.1 3.7 9.9 9.5 4.0 0.1 0.5 3.4 3.3 3.0 2.5 0.0 1.2 1.2 2.1 1.9 1.6 1.4 1.4 1.3 1.2 1.1	121.1 43.5 29.0 14.5 38.4 15.5 0.5 2.6 12.4 13.5 10.7 10.3 0.1 5.5 4.7 7.5 6.6 6.4 6.3 6.6 5.1 6.3 4.9 4.9 3.0 2.6	112-130 38.2-48.8 24.7-33.3 11.4-17.6 29.7-38.8 33.3-43.5 12.2-18.7 0 - 1.0 1.0-4.1 9.6-15.3 10.4-16.7 8.1-13.3 7.5-13.1 0 - 0.3 3.3-7.7 2.9-6.5 5.4-9.6 4.6-8.7 4.4-8.3 4.3-8.4 4.5-8.8 3.3-6.8 4.0-8.7 2.9-6.2 2.8-6.1 3.1-6.8 3.0-6.8 1.7-4.3	7 20 30 58 25 23 62 1662 559 73 67 81 152 226 119 168 144 130 161 148 153 199 207 180 198 334	Breast Colorectal Colon Rectum Lung Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Uterus Thyroid gland Pancreas Unknown primary Kidney Ovary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Brain Bladder & urinary tract Cervix Stomach Lip, gum & mouth Oesophagus Myelodysplastic diseases	477 205 143 62 162 153 85 1 6 78 68 52 48 45 43 39 37 0 23 14 0 29 24 22 18 14 14 12 12	28.5 12.3 8.6 3.7 9.7 9.2 5.1 0.4 4.7 4.1 3.1 2.7 2.6 2.3 2.2 1.4 0.8 1.7 1.4 1.3 1.1 0.8 0.7	79.7 28.6 19.2 9.3 21.6 24.9 12.7 0.1 1.3 11.4 10.5 6.0 5.1 7.2 6.4 6.2 3.8 2.3 4.4 2.8 4.1 2.2 2.2 1.8 1.4	72.3-87.2 24.3-32.8 15.8-22.6 6.8-11.9 18.0-25.1 20.7-29.0 9.8-15.7 0 - 0.2 0.2-2.4 8.7-14.1 8.1-13.4 7.6-13.4 4.2-7.9 3.4-6.8 4.9-9.5 4.3-8.6 3.8-8.5 1.9-5.7 1.0-3.6 2.6-6.2 1.6-4.1 2.3-5.9 1.1-3.4 1.0-3.5 0.8-2.9 0.5-2.2 0.5-2.2	12 31 47 90 38 40 71 * 1075 76 69 96 153 204 127 141 177 287 458 212 311 256 487 421 447 639 610

//ales						Females					
December	Cases	%	ASR	95%c.i.	Risk	Daniel	Cases	%	ASR	95%c.i.	F
Prostate	1591	32.8	122.8	117-129	7	Breast	1058	29.8	83.3	78.1-88.5	
Colorectal	579	11.9	43.6	39.9-47.3	20	Colorectal	410	11.6	26.7	23.9-29.5	
Colon	375	7.7	27.2	24.4-30.1	32	Colon	284	8.0	17.7	15.5-20.0	
Rectum	203	4.2	16.3	14.0-18.6	50	Rectum	125	3.5	9.0	7.3-10.6	
Melanoma (skin)	480	9.9	38.3	34.8-41.8	22	Lung	313	8.8	20.2	17.8-22.6	
_ung	449	9.3	32.3	29.2-35.4	26	Melanoma (skin)	291	8.2	22.5	19.8-25.2	
_ymphoma	199	4.1	16.1	13.7-18.4	62	Lymphoma	147	4.1	10.4	8.6-12.2	
Lymphoma NOS	8	0.2	8.0	0.2-1.3	1451	Lymphoma NOS	4	0.1	0.1	0.0-0.2	
Hodgkin lymphoma	23	0.5	2.5	1.4-3.5	556	Hodgkin lymphoma	15	0.4	1.6	0.8-2.5	
NHL	168	3.5	12.9	10.9-14.9	73	NHL	128	3.6	8.6	7.0-10.3	
Bladder & urinary tract	147	3.0	10.4	8.7-12.2	89	Uterus	135	3.8	9.9	8.1-11.6	
Kidney	146	3.0	11.9	9.9-13.9	74	Thyroid gland	131	3.7	12.0	9.9-14.1	
_eukaemia	133	2.7	11.6	9.5-13.8	84	Pancreas	103	2.9	6.4	5.0-7.7	
Leukaemia NOS	4	0.1	0.2	0 - 0.5	4889	Ovary	99	2.8	7.9	6.3-9.5	
Lymphoid leukaemia	67	1.4	6.4	4.7-8.0	138	Unknown primary	93	2.6	5.0	3.9-6.1	
Myeloid leukaemia	62	1.3	5.0	3.7-6.4	221	Kidney	83	2.3	6.6	5.1-8.2	
Leukaemia, other	0					Leukaemia	83	2.3	6.7	5.0-8.4	
Jnknown primary	109	2.2	7.8	6.2-9.3	136	Leukaemia NOS	1	0.0	0.1	0 - 0.2	
Pancreas	96	2.0	7.1	5.6-8.5	125	Lymphoid leukaemia	44	1.2	3.6	2.3-4.8	
Stomach	91	1.9	6.6	5.2-8.0	137	Myeloid leukaemia	38	1.1	3.1	2.0-4.2	
_ip, gum & mouth	71	1.5	5.8	4.4-7.2	177	Leukaemia, other	0				
Desophagus	67	1.4	5.0	3.8-6.3	172	Cervix	66	1.9	6.0	4.5-7.5	
Brain	66	1.4	5.7	4.2-7.2	182	Bladder & urinary tract	63	1.8	3.5	2.5-4.4	
Mesothelioma	62	1.3	4.5	3.3-5.6	179	Brain	56	1.6	4.7	3.3-6.1	
_iver	56	1.2	4.5	3.3-5.8	194	Myeloma	43	1.2	2.4	1.6-3.2	
Гestis	56	1.2	5.7	4.2-7.2	225	Stomach	40	1.1	2.6	1.7-3.4	
Γhyroid gland	53	1.1	4.5	3.3-5.8	213	Lip, gum & mouth	29	8.0	2.2	1.3-3.0	
Myeloma	50	1.0	3.7	2.6-4.8	244	Oesophagus	27	8.0	1.4	0.8-2.1	
Pharynx	49	1.0	4.0	2.9-5.2	219	Gallbladder / bile ducts	27	8.0	1.6	1.0-2.3	
		0.0	2.8	1.9-3.8	368	Skin (NMSC exc. SCC/BCC)	26	0.7	1.5	0.9-2.2	
Skin (NMSC exc. SCC/BCC)	39	8.0	2.0	1.5 5.6	300	OKIT (THINGO CXC. GOO/BOO,					
All cancers Il Western Australia	4854	100.0	376.0	365-387	3	All cancers	3545	100.0	259.5	250-269	
All cancers Il Western Australia	4854					,			259.5 ASR	250-269 95%c.i.	
All cancers Il Western Australia	4854	100.0	376.0	365-387	3	All cancers	3545	100.0			
All cancers Ill Western Australia lales Prostate	4854 Cases	% 32.3 11.7	376.0 ASR	365-387 95%c.i.	3 Risk	All cancers Females	3545 Cases	100.0	ASR	95%c.i.	
All cancers Il Western Australia lales Prostate	4854 Cases 2030	100.0 % 32.3	376.0 ASR 121.4	365-387 95%c.i. 116-127	3 Risk 7	All cancers Females Breast	3545 Cases 1313	100.0 % 29.1	ASR 81.7	95%c.i. 77.1-86.3	
All cancers Ill Western Australia lales Prostate Colorectal	Cases 2030 739	% 32.3 11.7	376.0 ASR 121.4 43.2	95%c.i. 116-127 40.0-46.4	3 Risk 7 20	All cancers Females Breast Colorectal	3545 Cases 1313 545	% 29.1 12.1	ASR 81.7 28.8	95%c.i. 77.1-86.3 26.2-31.4	
All cancers III Western Australia lales Prostate Colorectal Colon Rectum	Cases 2030 739 471	% 32.3 11.7 7.5	ASR 121.4 43.2 26.7	95%c.i. 116-127 40.0-46.4 24.2-29.2	Risk 7 20 32	Females Breast Colorectal Colon	3545 Cases 1313 545 379	% 29.1 12.1 8.4	ASR 81.7 28.8 19.3	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4	
All cancers III Western Australia Iales Prostate Colorectal Colon Rectum Melanoma (skin)	Cases 2030 739 471 266	% 32.3 11.7 7.5 4.2	ASR 121.4 43.2 26.7 16.3	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3	Risk 7 20 32 50	Females Breast Colorectal Colon Rectum	3545 Cases 1313 545 379 165	% 29.1 12.1 8.4 3.7	ASR 81.7 28.8 19.3 9.5	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0	
All cancers III Western Australia lales Prostate Colorectal Colon Rectum Melanoma (skin)	Cases 2030 739 471 266 643	% 32.3 11.7 7.5 4.2 10.2	ASR 121.4 43.2 26.7 16.3 39.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7	Risk 7 20 32 50 21	All cancers Females Breast Colorectal Colon Rectum Melanoma (skin)	3545 Cases 1313 545 379 165 400	% 29.1 12.1 8.4 3.7 8.9	ASR 81.7 28.8 19.3 9.5 24.8	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4	
All cancers II Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung	Cases 2030 739 471 266 643 583	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3	ASR 121.4 43.2 26.7 16.3 39.6 32.9	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6	Risk 7 20 32 50 21 25	All cancers Females Breast Colorectal Colon Rectum Melanoma (skin) Lung	3545 Cases 1313 545 379 165 400 393	% 29.1 12.1 8.4 3.7 8.9 8.7	ASR 81.7 28.8 19.3 9.5 24.8 20.5	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7	
All cancers All Western Australia fales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma	Cases 2030 739 471 266 643 583 255	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3	Risk 7 20 32 50 21 25 59	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus	3545 Cases 1313 545 379 165 400 393 176	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9	ASR 81.7 28.8 19.3 9.5 24.8 20.5	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1	
All cancers All Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS	Cases 2030 739 471 266 643 583 255 10	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5	Risk 7 20 32 50 21 25 59 1370	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma	3545 Cases 1313 545 379 165 400 393 176 172	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4	
All cancers All Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	Cases 2030 739 471 266 643 583 255 10 33 212 191	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7	Risk 7 20 32 50 21 25 59 1370 501	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2	
All cancers All Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney	Cases 2030 739 471 266 643 583 255 10 33 212	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2	Risk 7 20 32 50 21 25 59 1370 501 71 90 75	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4	
All cancers All Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney	Cases 2030 739 471 266 643 583 255 10 33 212 191	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9	Risk 7 20 32 50 21 25 59 1370 501 71 90	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4	
All cancers All Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney	Cases 2030 739 471 266 643 583 255 10 33 212 191 183	% 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2	Risk 7 20 32 50 21 25 59 1370 501 71 90 75	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4	
All cancers All Western Australia fales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Sladder & urinary tract Kidney Leukaemia	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas	Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7	
All cancers All Western Australia dales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia Leukaemia, other	Cases 2030 739 471 266 643 583 225 10 33 212 191 183 169 5 91	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.4 0.0-0.4 5.3-8.3	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 6.5 7.3 5.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia Leukaemia, other	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.4 0.0-0.4 5.3-8.3	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia	3545 Cases 1313 545 379 165 400 393 176 4 20 148 159 131 117 115 110	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 7.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5	
All cancers All Western Australia Iales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Jnknown primary	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 9.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 7.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2	
All cancers All Western Australia Iales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Sladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Jnknown primary Pancreas	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 9.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 0.1 3.9	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Sladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Jnknown primary Pancreas Stomach	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 0.1 3.9	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Jinknown primary Pancreas Stomach Lip, gum & mouth	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 128	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7	Risk 7 20 32 50 21 125 59 1370 501 71 90 75 82 6335 127 238 133 127 130	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 7.0 0.1 1.3,9	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Jinknown primary Peancreas Stomach Lip, gum & mouth Desophagus	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.6 0.2 6.8 4.6	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Kidney	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 7.0 0.1 3.9 9.3	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Jinknown primary Pancreas Stomach Lip, gum & mouth Desophagus Brain	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 91 73 0 138 128 121 102 88	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix	3545 Cases 1313 545 379 165 400 393 176 4 20 148 159 131 117 115 110 1 61 48 0 93 92	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 6.5 7.3 5.0 7.0 0.1 3.9 3.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9	
All cancers All Western Australia Iales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Jinknown primary Pancreas Stomach Lip, gum & mouth Desophagus Brain Mesothelioma	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102 88 85	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4 1.4	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1 5.8	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2 4.5-7.1	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161 178	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix Bladder & urinary tract	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93 92 77	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1 2.0 1.7	ASR 81.7 28.8 19.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 0.1 3.9 3.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9	
All cancers All Western Australia Itales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Sladder & urinary tract (idney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Unknown primary Pancreas Stomach Lip, gum & mouth Desophagus Brain Mesothelioma Liver	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102 88 85 81	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 9.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4 1.3	376.0 ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1 5.8 4.7	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2 4.5-7.1 3.6-5.7	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161 178 160	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix Bladder & urinary tract Brain	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93 92 77 72	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1 2.0 1.7 1.6	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 0.1 3.9 3.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9 4.6-7.1 5.3-8.0 2.6-4.3 3.6-6.1	
All cancers All Western Australia Males Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Heukaemia, other Unknown primary Pancreas Stomach Lip, gum & mouth Oesophagus Brain Mesothelioma Liver Testis	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102 88 85 81 76	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4 1.3 1.2	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1 5.8	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2 4.5-7.1 3.6-5.7	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161 178 160 178	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix Bladder & urinary tract Brain Myeloma	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93 92 77 72 62	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1 1.1 1.1 1.1 1.1 1.1 1.1	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 7.0 0.1 3.9 3.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9 4.6-7.1 5.3-8.0 2.6-4.3 3.6-6.1 2.2-3.9	
Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102 88 85 81 76 72	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4 1.3 1.2 1.1	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1 5.1 5.7	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2 4.5-7.1 3.6-5.8 4.3-7.0	Risk 7 20 32 50 21 125 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161 178 160 178 226	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix Bladder & urinary tract Brain Myeloma Stomach	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93 92 77 72 62 46	% 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1 2.0 1.7 1.6 1.4 1.0	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.6 6.5 7.3 5.0 7.0 0.1 3.9 3.0 5.8 6.7 3.0 5.8 6.7 3.0 5.8 6.7 3.0 5.8 6.7 3.0 5.8 6.7 3.0 5.8 6.7 3.0 5.8 6.7 5.8 6.7 5.8 6.7 5.8 6.7 5.8 6.7 5.8 6.7 5.8 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9 4.6-7.1 5.3-8.0 2.6-4.3 3.6-6.1 2.2-3.9 1.7-3.2	•
All cancers All Western Australia Alales Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Unknown primary Pancreas Stomach Lip, gum & mouth Oesophagus Brain Mesothelioma Liver Testis Myeloma Pharynx	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102 88 85 81 76 72 70	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4 1.3 1.2 1.1 1.1	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1 5.7 4.7	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.2 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2 4.5-7.1 3.6-5.7 3.6-5.8 4.3-7.0 3.0-4.9	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161 178 160 178 226 206	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix Bladder & urinary tract Brain Myeloma Stomach Lip, gum & mouth	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93 92 77 72 62 46 43	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 3.8 0.1 0.4 3.3 3.5 2.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1 2.0 1.7 1.6 1.4 1.0 1.0	ASR 81.7 28.8 19.3 9.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.3 5.0 7.0 0.1 13.9 3.0 5.8 6.7 3.5 4.8 3.0 5.2 4.8 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9 4.6-7.1 5.3-8.0 2.6-4.3 3.6-6.1 2.2-3.9 1.7-3.2 1.8-3.5	
All cancers All Western Australia Males Prostate Colorectal Colon Rectum Melanoma (skin) Lung Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Bladder & urinary tract Kidney Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Unknown primary Pancreas Stomach Lip, gum & mouth Oesophagus Brain Mesothelioma Liver Testis Myeloma	Cases 2030 739 471 266 643 583 255 10 33 212 191 183 169 5 91 73 0 138 128 121 102 88 85 81 76 72 70 68 64	100.0 % 32.3 11.7 7.5 4.2 10.2 9.3 4.1 0.2 0.5 3.4 3.0 2.9 2.7 0.1 1.4 1.2 2.2 2.0 1.9 1.6 1.4 1.3 1.2 1.1 1.1	ASR 121.4 43.2 26.7 16.3 39.6 32.9 16.2 0.7 2.7 12.8 10.4 11.4 11.6 0.2 6.8 4.6 7.7 7.3 6.8 6.5 5.1 5.8 4.7 4.0 4.3	95%c.i. 116-127 40.0-46.4 24.2-29.2 14.3-18.3 36.5-42.7 30.1-35.6 14.1-18.3 0.2-1.2 1.8-3.7 11.0-14.5 8.9-11.9 9.7-13.4 0.0-0.4 5.3-8.3 3.5-5.7 6.4-9.1 6.0-8.6 5.6-8.1 5.2-7.7 4.0-6.2 4.5-7.1 3.6-5.7 3.6-5.8 4.3-7.0 3.0-4.9 3.3-5.3	Risk 7 20 32 50 21 25 59 1370 501 71 90 75 82 6335 127 238 133 127 130 152 161 178 160 178 226 206 199	Females Breast Colorectal Colon Rectum Melanoma (skin) Lung Uterus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Thyroid gland Pancreas Ovary Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Kidney Cervix Bladder & urinary tract Brain Myeloma Stomach Lip, gum & mouth Oesophagus	3545 Cases 1313 545 379 165 400 393 176 172 4 20 148 159 131 117 115 110 1 61 48 0 93 92 77 72 62 46 43 38	100.0 % 29.1 12.1 8.4 3.7 8.9 8.7 3.9 8.7 3.9 2.6 2.5 2.4 0.0 1.4 1.1 2.1 2.0 1.7 1.6 1.4 1.0 0.8	ASR 81.7 28.8 19.5 24.8 20.5 10.5 9.8 0.1 1.7 8.0 11.6 6.5 7.0 0.1 3.9 3.0 5.8 6.7 3.5 4.8 3.5 4.8 3.5 4.8 3.5 4.8	95%c.i. 77.1-86.3 26.2-31.4 17.2-21.4 8.0-11.0 22.3-27.4 18.3-22.7 8.9-12.1 8.2-11.4 0.0-0.2 0.9-2.5 6.6-9.4 9.7-13.4 5.3-7.7 5.9-8.7 3.9-6.0 5.5-8.5 0 - 0.2 2.8-5.1 2.0-3.9 4.6-7.1 5.3-8.0 2.6-4.3 3.6-6.1 2.2-3.9 1.7-3.2 1.8-3.5 1.1-2.2	

CHS Kimberley Reg	gion										
Males						Females					
	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Lung	3	15.8	22.5	0 - 48.1	21	Breast	4	20.0	30.0	0 - 60.6	21
Prostate	3	15.8	21.8	0 - 46.5	32	Pancreas	3	15.0	26.9	0 - 58.6	25
Gallbladder / bile ducts	2	10.5	10.5	0 - 25.3	77	Oesophagus	2	10.0	16.6	0 - 40.7	40
Pancreas	2	10.5	10.5	0 - 25.3	77	Lung	2	10.0	11.2	0 - 26.7	258
Mesothelioma	2	10.5	14.8	0 - 35.3	32	Unknown primary	2	10.0	20.4	0 - 48.5	38
Colorectal	1	5.3	6.3	0 - 18.7	127	Colorectal	1	5.0	4.2	0 - 12.4	287
Colon	1	5.3	6.3	0 - 18.7	127	Colon	1	5.0	4.2	0 - 12.4	287
Rectum	0				-	Rectum	0				-
Lip, gum & mouth	1	5.3	4.6	0 - 13.6	262	Liver	1	5.0	9.6	0 - 28.3	*
Oesophagus	1	5.3	4.3	0 - 12.7	234	Cervix	1	5.0	5.3	0 - 15.7	227
Liver	1	5.3	4.3	0 - 12.7	234	Ovary	1	5.0	5.2	0 - 15.4	193
Brain	1	5.3	4.2	0 - 12.3	193	Kidney	1	5.0	5.2	0 - 15.4	193
Unknown primary	1	5.3	7.0	0 - 20.7	*	Leukaemia	1	5.0	7.4	0 - 21.9	244
Lymphoma	1	5.3	4.3	0 - 12.7	234	Leukaemia NOS	0	0.0		0 20	-
Lymphoma NOS	0	0.0		0 .2	-	Lymphoid leukaemia	0				_
Hodgkin lymphoma	0				_	Myeloid leukaemia	1	5.0	7.4	0 - 21.9	244
NHL	1	5.3	4.3	0 - 12.7	234	Leukaemia, other	0	0.0		0 21.0	
MIL	•	0.0	4.5	0 12.7	204	Leakaernia, otrici	·				
All cancer deaths	19	100.0	115.0	62.1-168	6	All cancer deaths	20	100.0	147.8	80.0-216	6
CHS Pilbara Region	n										
Males						Females					
iviales	Deaths	%	ASR	95%c.i.	Risk	remales	Deaths	%	ACD	95%c.i.	Risk
Ossanhagus		17.6				Coloradal			ASR		
Oesophagus	3		14.8	0 - 34.6	34	Colorectal	1	25.0	3.9	0 - 11.6	407
Melanoma (skin)	3	17.6	14.5	0 - 33.5	46	Colon	0				-
Colorectal	2	11.8	7.8	0 - 19.2	116	Rectum	1	25.0	3.9	0 - 11.6	407
Colon	1	5.9	5.1	0 - 15.1	158	Breast	1	25.0	4.3	0 - 12.8	232
Rectum	1	5.9	2.7	0 - 8.1	437	Cervix	1	25.0	20.0	0 - 59.0	21
Unknown primary	2	11.8	11.7	0 - 29.9	55	Leukaemia	1	25.0	20.0	0 - 59.0	21
Tongue	1	5.9	2.8	0 - 8.3	287	Leukaemia NOS	0				-
Stomach	1	5.9	2.8	0 - 8.3	287	Lymphoid leukaemia	0				-
Liver	1	5.9	8.9	0 - 26.2	68	Myeloid leukaemia	1	25.0	20.0	0 - 59.0	21
Pancreas	1	5.9	5.1	0 - 15.1	158	Leukaemia, other	0				-
Larynx	1	5.9	5.1	0 - 15.1	158						
Lung	1	5.9	9.4	0 - 27.9	43						
Mesothelioma	1	5.9	2.8	0 - 8.3	287						
All cancer deaths	47	400.0	05.0	20.4.422	0	All cancer deaths	,	100.0	40.2	0.404	40
All caricer deaths		100.0	85.6	39.4-132	8	All caricel deaths	4	100.0	48.3	0 - 104	10
CHS Midwest Region	on										
Males						Females					
	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Lung	24	33.8	42.6	25.1-60.0	19	Breast	10	22.7	21.4	7.5-35.2	42
Prostate	6	8.5	8.8	1.3-16.2	123	Unknown primary	6	13.6	10.3	1.8-18.9	74
Colorectal	5	7.0	7.5	0.7-14.3	123	Lung	5	11.4	9.9	0.9-18.9	96
Colon	4	5.6	6.5	0 - 13.1	123	Bladder & urinary tract	4	9.1	8.9	0 - 18.0	118
Rectum	1	1.4	0.9	0 - 2.8	*	Pancreas	3	6.8	5.8	0 - 12.7	146
Bladder & urinary tract	4	5.6	8.6	0.2-17.1	111	Uterus	3	6.8	7.3	0 - 15.5	100
Liver	3	4.2	6.2	0.2-17.1	100	Colorectal	2	4.5	3.7	0 - 13.3	
Pancreas	3	4.2	5.4	0 - 13.2	483	Colon	1	2.3	1.1	0 - 9.2	308 *
Lymphoma Lymphoma NOS	3	4.2	6.0	0 - 12.9	113	Rectum	1	2.3	2.6	0 - 7.7	308
, ,	0					Lymphoma NOS	2	4.5	3.8	0 - 9.5	454 -
Hodgkin lymphoma	0	4.0		0 400	-	Lymphoma NOS	0				-
NHL	3	4.2	6.0	0 - 12.9	113	Hodgkin lymphoma	0			0.05	-
Pharynx	2	2.8	3.7	0 - 8.9	215	NHL	2	4.5	3.8	0 - 9.5	454
Gallbladder / bile ducts	2	2.8	3.2	0 - 7.6	215	Liver	1	2.3	2.2	0 - 6.5	183
Melanoma (skin)	2	2.8	4.2	0 - 10.1	210	Gallbladder / bile ducts	1	2.3	1.2	0 - 3.5	*
Brain	2	2.8	4.3	0 - 10.2	231	Melanoma (skin)	1	2.3	1.1	0 - 3.2	*
Unknown primary	2	2.8	4.0	0 - 9.6	136	Skin (NMSC inc. SCC/BCC)	1	2.3	1.2	0 - 3.5	*
All cancer deaths	71	100.0	127.9	97.4-158	7	All cancer deaths	44	100.0	84.9	58.6-111	11

	on					Famala.					
Males	Deaths	%	ASR	95%c.i.	Risk	Females	Deaths	%	ASR	95%c.i.	Ris
Lung	25	24.5	31.8	19.0-44.6	26	Lung	19	22.1	24.8	12.8-36.9	3
Prostate	12	11.8	12.6	5.2-19.9	131	Breast	14	16.3	15.5	6.6-24.3	6
Colorectal	11	10.8	14.5	5.3-23.7	47	Colorectal	9	10.5	12.3	2.3-22.4	ç
Colon	5	4.9	6.0	0.6-11.3	100	Colon	7	8.1	8.9	0.0-17.7	19
Rectum	6	5.9	8.5	1.0-16.0	88	Rectum	2	2.3	3.4	0 - 8.2	17
	7	6.9	7.8	1.9-13.8	156	Unknown primary	7	8.1	9.6	2.1-17.1	6
Unknown primary									6.5		2
Leukaemia	6 0	5.9	7.9	1.4-14.4	147	Pancreas	6	7.0		0.8-12.1	
Leukaemia NOS		4.0	4.0	0 40	-	Ovary	6	7.0	6.6	1.0-12.3	16
Lymphoid leukaemia	1	1.0	1.3	0 - 4.0	300	Lymphoma	5	5.8	6.4	0.4-12.3	1:
Myeloid leukaemia	5	4.9	6.6	0.6-12.5	288	Lymphoma NOS	0				-
Leukaemia, other	0				-	Hodgkin lymphoma	0				-
Oesophagus	5	4.9	5.3	0.5-10.1	191	NHL	5	5.8	6.4	0.4-12.3	1
Brain	4	3.9	6.8	0.1-13.6	144	Oesophagus	2	2.3	1.6	0 - 4.0	*
Stomach	3	2.9	3.8	0 - 8.1	191	Stomach	2	2.3	3.8	0 - 9.1	1
Skin (NMSC inc. SCC/BCC)	3	2.9	5.1	0 - 11.5	214	Brain	2	2.3	1.7	0 - 4.0	*
Kidney	3	2.9	3.5	0 - 7.5	527	Leukaemia	2	2.3	2.3	0 - 5.7	2
Lymphoma	3	2.9	4.2	0 - 9.0	123						
All cancer deaths	102	100.0	128.7	103-155	7	All cancer deaths	86	100.0	106.4	81.5-131	
CHS Goldfields Region	on										
/lales	Dootho	0/	A C D	95%c.i.	Diak	Females	Dootho	0/	A C D	0E9/ a i	D
	Deaths	%	ASR		Risk		Deaths	%	ASR	95%c.i.	Ri
Lung	16	22.9	46.9	23.7-70.1	15	Colorectal	6	21.4	16.9	2.7-31.1	
Prostate	10	14.3	30.3	11.2-49.4	58	Colon	5	17.9	14.4	1.0-27.7	
Mesothelioma	5	7.1	16.2	1.9-30.5	35	Rectum	1	3.6	2.5	0 - 7.5	*
Liver	4	5.7	11.0	0.2-21.8	324	Lung	5	17.9	19.7	2.3-37.1	
Pancreas	4	5.7	12.1	0.1-24.1	56	Breast	4	14.3	12.0	0 - 24.3	
Melanoma (skin)	4	5.7	13.3	0.3-26.3	39	Unknown primary	3	10.7	7.0	0 - 15.1	2
Colorectal	3	4.3	7.1	0 - 15.0	224	Stomach	2	7.1	5.8	0 - 13.8	1
Colon	2	2.9	4.6	0 - 10.9	502	Parotid gland	1	3.6	2.0	0 - 6.0	*
Rectum	1	1.4	2.5	0 - 7.4	402	Small intestine	1	3.6	1.9	0 - 5.7	*
Pharynx	3	4.3	8.0	0 - 17.2	130	Gallbladder / bile ducts	1	3.6	4.1	0 - 12.2	
Stomach	3	4.3	8.5	0 - 18.2	76	Pancreas	1	3.6	2.5	0 - 7.5	*
Bladder & urinary tract	3	4.3	9.6	0 - 20.6	159	Uterus	1	3.6	4.2	0 - 12.4	1
•							1				
Brain	3	4.3	10.3	0 - 21.9	59	Kidney		3.6	4.2	0 - 12.4	1
Leukaemia	3	4.3	9.4	0 - 20.1	49	Bladder & urinary tract Brain	1 1	3.6 3.6	4.1 1.9	0 - 12.2 0 - 5.7	*
All cancer deaths	70	100.0	209.3	160-259	4	All cancer deaths	28	100.0	86.6	53.2-120	
	•				***************************************						
	Regio	n				Famalas					
	rtegio									050/ - :	
Males	_		VGD	Q5% o :	Diek	Females	Deaths	0/	VGD		р:
Males	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Ri
Males Prostate	Deaths 15	% 20.8	21.0	10.0-32.0	67	Lung	13	27.1	26.2	11.5-40.9	:
Males Prostate Lung	Deaths 15 10	% 20.8 13.9	21.0 18.7	10.0-32.0 6.5-30.9	67 52	Lung Breast	13 10	27.1 20.8	26.2 20.7	11.5-40.9 5.5-35.9	
Males Prostate Lung Colorectal	Deaths 15 10 8	% 20.8 13.9 11.1	21.0 18.7 14.0	10.0-32.0 6.5-30.9 3.8-24.3	67 52 67	Lung Breast Colorectal	13 10 5	27.1 20.8 10.4	26.2 20.7 7.7	11.5-40.9 5.5-35.9 0.3-15.0	1
Males Prostate Lung Colorectal Colon	Deaths 15 10 8	% 20.8 13.9 11.1 8.3	21.0 18.7 14.0 9.8	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2	67 52 67 114	Lung Breast Colorectal Colon	13 10 5 5	27.1 20.8	26.2 20.7	11.5-40.9 5.5-35.9	1
Males Prostate Lung Colorectal	Deaths 15 10 8 6	% 20.8 13.9 11.1 8.3 2.8	21.0 18.7 14.0	10.0-32.0 6.5-30.9 3.8-24.3	67 52 67	Lung Breast Colorectal	13 10 5	27.1 20.8 10.4	26.2 20.7 7.7	11.5-40.9 5.5-35.9 0.3-15.0	1
Males Prostate Lung Colorectal Colon Rectum	Deaths 15 10 8	% 20.8 13.9 11.1 8.3	21.0 18.7 14.0 9.8	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2	67 52 67 114	Lung Breast Colorectal Colon	13 10 5 5	27.1 20.8 10.4	26.2 20.7 7.7	11.5-40.9 5.5-35.9 0.3-15.0	1 1
Males Prostate Lung Colorectal Colon Rectum Kidney	Deaths 15 10 8 6	% 20.8 13.9 11.1 8.3 2.8	21.0 18.7 14.0 9.8 4.2	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1	67 52 67 114 162	Lung Breast Colorectal Colon Rectum	13 10 5 5	27.1 20.8 10.4 10.4	26.2 20.7 7.7 7.7	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0	1 1 - 3
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract	Deaths 15 10 8 6 2 5	% 20.8 13.9 11.1 8.3 2.8 6.9	21.0 18.7 14.0 9.8 4.2 6.8	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1	67 52 67 114 162 363	Lung Breast Colorectal Colon Rectum Pancreas Brain	13 10 5 5 0 4	27.1 20.8 10.4 10.4	26.2 20.7 7.7 7.7 4.9	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0	1 1 - 3 1
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus	Deaths 15 10 8 6 2 5 3	% 20.8 13.9 11.1 8.3 2.8 6.9 6.9 4.2	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6	67 52 67 114 162 363 125	Lung Breast Colorectal Colon Rectum Pancreas	13 10 5 5 0 4 3	27.1 20.8 10.4 10.4 8.3 6.3 6.3	26.2 20.7 7.7 7.7 4.9 7.6 3.7	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6	1 1 - 3 1 4
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary	Deaths 15 10 8 6 2 5 3 3	% 20.8 13.9 11.1 8.3 2.8 6.9 6.9 4.2 4.2	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2	67 52 67 114 162 363 125 *	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia	13 10 5 5 0 4 3 3	27.1 20.8 10.4 10.4 8.3 6.3	26.2 20.7 7.7 7.7 4.9 7.6	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4	1 1 - 3 1 4
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach	Deaths 15 10 8 6 2 5 3 3 2	% 20.8 13.9 11.1 8.3 2.8 6.9 6.9 4.2 4.2 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8	67 52 67 114 162 363 125 * *	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS	13 10 5 5 0 4 3 3 2	27.1 20.8 10.4 10.4 8.3 6.3 6.3	26.2 20.7 7.7 7.7 4.9 7.6 3.7	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6	1 1 - 3 1 4 3
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver	Deaths 15 10 8 6 2 5 3 3 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4	67 52 67 114 162 363 125 * * 363 143	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia	13 10 5 5 0 4 3 3 2 0	27.1 20.8 10.4 10.4 8.3 6.3 6.3 4.2	26.2 20.7 7.7 7.7 4.9 7.6 3.7 3.1	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6 0 - 8.0	11 11 33 11 44 33
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver Pancreas	Deaths 15 10 8 6 2 5 3 3 2 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1 3.9 2.5	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4 0 - 5.9	67 52 67 114 162 363 125 * * 363 143 *	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	13 10 5 5 0 4 3 3 2 0 0	27.1 20.8 10.4 10.4 8.3 6.3 6.3	26.2 20.7 7.7 7.7 4.9 7.6 3.7	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6	11 11 33 11 44 33
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver Pancreas Pleura	Deaths 15 10 8 6 2 5 3 3 2 2 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1 3.9 2.5 7.4	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4 0 - 5.9 0 - 18.1	67 52 67 114 162 363 125 * * 363 143 *	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	13 10 5 5 0 4 3 3 2 0 0	27.1 20.8 10.4 10.4 8.3 6.3 4.2	26.2 20.7 7.7 7.7 4.9 7.6 3.7 3.1	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6 0 - 8.0	1 1 - 3 1 4 3 -
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver Pancreas Pleura Melanoma (skin)	Deaths 15 10 8 6 2 5 5 3 3 2 2 2 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8 2.8 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1 3.9 2.5 7.4 3.6	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4 0 - 5.9 0 - 18.1 0 - 9.1	67 52 67 114 162 363 125 * * 363 143 * 219 453	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Oesophagus	13 10 5 5 0 4 3 3 2 0 0 0 2	27.1 20.8 10.4 10.4 8.3 6.3 4.2 4.2	26.2 20.7 7.7 7.7 4.9 7.6 3.7 3.1	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6 0 - 8.0 0 - 8.0	1 1 3 1 4 3 3 - 3 3
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver Pancreas Pleura Melanoma (skin) Skin (NMSC inc. SCC/BCC)	Deaths 15 10 8 6 2 5 5 3 3 2 2 2 2 2 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1 3.9 2.5 7.4	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4 0 - 5.9 0 - 18.1	67 52 67 114 162 363 125 * * 363 143 * 219 453 *	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Oesophagus Melanoma (skin)	13 10 5 5 0 4 3 3 2 0 0	27.1 20.8 10.4 10.4 8.3 6.3 4.2	26.2 20.7 7.7 7.7 4.9 7.6 3.7 3.1	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6 0 - 8.0	1 1 - 3 1 4 3 3 - - 3
Males Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver Pancreas Pleura Melanoma (skin)	Deaths 15 10 8 6 2 5 5 3 3 2 2 2 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8 2.8 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1 3.9 2.5 7.4 3.6	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4 0 - 5.9 0 - 18.1 0 - 9.1	67 52 67 114 162 363 125 * * 363 143 * 219 453	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Oesophagus	13 10 5 5 0 4 3 3 2 0 0 0 2	27.1 20.8 10.4 10.4 8.3 6.3 4.2 4.2	26.2 20.7 7.7 7.7 4.9 7.6 3.7 3.1	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6 0 - 8.0 0 - 8.0	1 1 - 3 1 4 3 - - 3 3 - *
Prostate Lung Colorectal Colon Rectum Kidney Bladder & urinary tract Oesophagus Unknown primary Stomach Liver Pancreas Pleura Melanoma (skin) Skin (NMSC inc. SCC/BCC)	Deaths 15 10 8 6 2 5 5 3 3 2 2 2 2 2 2 2	% 20.8 13.9 11.1 8.3 2.8 6.9 4.2 4.2 2.8 2.8 2.8 2.8 2.8	21.0 18.7 14.0 9.8 4.2 6.8 7.7 3.1 3.4 3.1 3.9 2.5 7.4 3.6 2.4	10.0-32.0 6.5-30.9 3.8-24.3 1.4-18.2 0 - 10.1 0.6-13.1 0.7-14.6 0 - 6.6 0 - 7.2 0 - 7.8 0 - 9.4 0 - 5.9 0 - 18.1 0 - 9.1 0 - 5.8	67 52 67 114 162 363 125 * * 363 143 * 219 453 *	Lung Breast Colorectal Colon Rectum Pancreas Brain Unknown primary Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Oesophagus Melanoma (skin)	13 10 5 5 0 4 3 3 2 0 0 0	27.1 20.8 10.4 10.4 8.3 6.3 4.2 4.2 2.1 2.1	26.2 20.7 7.7 7.7 4.9 7.6 3.7 3.1	11.5-40.9 5.5-35.9 0.3-15.0 0.3-15.0 0 - 10.1 0 - 16.4 0 - 8.6 0 - 8.0 0 - 8.0 0 - 2.1 0 - 3.3	1 1 - 3 1 4 3 3 - - 3

CHS South West Reg	gion										
Males			400	0=0/	D: 1	Females	5	٠,	400	0=0/ :	D : 1
	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Lung	34	25.2	23.1	15.0-31.2	37	Lung	26	22.0	17.6	10.5-24.7	46
Prostate	21	15.6	12.4	7.0-17.9 5.7-17.8	150 49	Breast	16	13.6	12.5	6.1-18.9	72
Colorectal Colon	15 11	11.1 8.1	11.7 8.7	3.5-13.9	63	Colorectal Colon	14 11	11.9 9.3	9.9 8.2	4.4-15.5 3.1-13.4	117 129
Rectum	4	3.0	3.0	0 - 6.0	215	Rectum	3	2.5	1.7	0 - 3.9	1214
Bladder & urinary tract	9	6.7	5.7	1.9-9.5	280	Pancreas	10	8.5	6.1	2.0-10.1	161
Stomach	7	5.2	5.3	1.3-9.3	201	Gallbladder / bile ducts	7	5.9	3.6	0.7-6.4	242
Pancreas	7	5.2	4.7	1.1-8.4	270	Brain	6	5.1	6.1	0.9-11.4	173
Melanoma (skin)	7	5.2	4.6	1.0-8.1	197	Uterus	5	4.2	4.1	0.4-7.8	201
Mesothelioma	6	4.4	4.4	0.8-8.0	163	Lymphoma	5	4.2	4.4	0.5-8.3	196
Kidney	4	3.0	3.1	0.0-6.2	178	Lymphoma NOS	Ō				-
Unknown primary	3	2.2	2.6	0 - 5.6	215	Hodgkin lymphoma	1	0.8	0.9	0 - 2.8	646
Lymphoma	3	2.2	2.5	0 - 5.3	195	NHL	4	3.4	3.4	0 - 6.9	280
Lymphoma NOS	0				-	Myelodysplastic diseases	4	3.4	1.6	0.0-3.2	*
Hodgkin lymphoma	1	0.7	0.8	0 - 2.4	492	Melanoma (skin)	3	2.5	2.8	0 - 6.0	346
NHL	2	1.5	1.7	0 - 4.0	321	Ovary	3	2.5	1.8	0 - 4.1	855
Myeloma	3	2.2	2.2	0 - 4.8	321	Oesophagus	2	1.7	1.2	0 - 3.1	1115
Oesophagus	2	1.5	1.7	0 - 4.0	345	Bone	2	1.7	2.6	0 - 6.4	476
Small intestine	2	1.5	1.7	0 - 4.2	280	Unknown primary	2	1.7	1.1	0 - 2.5	*
Skin (NMSC inc. SCC/BCC)	2	1.5	1.2	0 - 3.0	492	Tongue	1	0.8	0.5	0 - 1.6	*
Leukaemia	2	1.5	1.9	0 - 4.4	323	Pharynx	1	0.8	0.9	0 - 2.8	858
Leukaemia NOS	0				-	Anus	1	0.8	0.4	0 - 1.1	*
Lymphoid leukaemia	1	0.7	0.9	0 - 2.7	646	Liver	1	0.8	8.0	0 - 2.5	483
Myeloid leukaemia	1	0.7	0.9	0 - 2.7	646	Peritoneum/retro-p.	1	0.8	8.0	0 - 2.5	483
Leukaemia, other	0				-	Cervix	1	0.8	0.3	0 - 1.0	*
Lip, gum & mouth	1	0.7	0.8	0 - 2.4	492	Female genital, other	1	0.8	0.9	0 - 2.8	646
Tongue	1	0.7	0.9	0 - 2.7	646	Kidney	1	0.8	0.5	0 - 1.6	*
Pharynx	1	0.7	0.8	0 - 2.4	492	Bladder & urinary tract	1	0.8	0.9	0 - 2.8	646
Liver	1	0.7	0.9	0 - 2.7	646	Eye & lacrimal gland	1	0.8	0.5	0 - 1.6	*
	1	0.7	0.9	0 - 2.7	646	Leukaemia	1	0.8	0.4	0 - 1.1	*
Larynx											
All cancer deaths	135	100.0	95.4	78.9-112	9	All cancer deaths	118	100.0	83.8	67.5-100	12
All cancer deaths WA Country - all Males	135 Deaths	%	ASR	95%c.i.	9 Risk	Females	Deaths	%	ASR	95%c.i.	Risk
All cancer deaths WA Country - all Males Lung	135 Deaths 113	% 23.3	ASR 28.1	95%c.i. 22.8-33.4	9 Risk 29	Females Lung	Deaths 70	% 20.1	ASR 18.5	95%c.i. 14.0-23.1	Risk 43
All cancer deaths WA Country - all Males Lung Prostate	135 Deaths 113 67	% 23.3 13.8	ASR 28.1 15.0	95%c.i. 22.8-33.4 11.3-18.6	9 Risk 29 99	Females Lung Breast	Deaths 70 59	% 20.1 17.0	ASR 18.5 15.7	95%c.i. 14.0-23.1 11.5-20.0	Risk 43 60
All cancer deaths WA Country - all Males Lung Prostate Colorectal	135 Deaths 113 67 45	% 23.3 13.8 9.3	ASR 28.1 15.0 11.4	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8	9 Risk 29 99 64	Females Lung Breast Colorectal	Deaths 70 59 38	% 20.1 17.0 10.9	ASR 18.5 15.7 9.5	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8	Risk 43 60 115
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon	Deaths 113 67 45 30	% 23.3 13.8 9.3 6.2	ASR 28.1 15.0 11.4 7.5	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3	9 Risk 29 99 64 93	Females Lung Breast Colorectal Colon	Deaths 70 59 38 30	% 20.1 17.0 10.9 8.6	ASR 18.5 15.7 9.5 7.2	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0	Risk 43 60 115
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum	Deaths 113 67 45 30 15	% 23.3 13.8 9.3 6.2 3.1	ASR 28.1 15.0 11.4 7.5 3.8	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8	Risk 29 99 64 93 197	Females Lung Breast Colorectal Colon Rectum	Deaths 70 59 38 30 8	% 20.1 17.0 10.9 8.6 2.3	ASR 18.5 15.7 9.5 7.2 2.3	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0	Risk 43 60 115 152
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract	Deaths 113 67 45 30 15 22	% 23.3 13.8 9.3 6.2 3.1 4.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7	9 Risk 29 99 64 93 197 232	Females Lung Breast Colorectal Colon Rectum Pancreas	Deaths 70 59 38 30 8 27	% 20.1 17.0 10.9 8.6 2.3 7.8	ASR 18.5 15.7 9.5 7.2 2.3 6.2	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7	Risk 43 60 115 152 474
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas	135 Deaths 113 67 45 30 15 22 21	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3	9 Risk 29 99 64 93 197 232 208	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary	Deaths 70 59 38 30 8 27 23	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6	Risk 43 60 115 152 474 170
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin)	135 Deaths 113 67 45 30 15 22 21 20	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1	Risk 29 99 64 93 197 232 208 155	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain	Deaths 70 59 38 30 8 27 23	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9	Risk 43 60 115 152 474 170 158 246
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary	Deaths 113 67 45 30 15 22 21 20 18	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5	9 Risk 29 99 64 93 197 232 208 155 210	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma	Deaths 70 59 38 30 8 27 23 13 13	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6	Risk 43 60 115 152 474 170 158 246
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus	Deaths 113 67 45 30 15 22 21 20 18 17	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4	9 Risk 29 99 64 93 197 232 208 155 210 282	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS	Deaths 70 59 38 30 8 27 23 13 13 0	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4	Risk 43 60 115 152 474 170 158 246 267
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach	Deaths 113 67 45 30 15 22 21 20 18 17	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4	9 Risk 29 99 64 93 197 232 208 155 210 282 208	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma Hodgkin lymphoma	Deaths 70 59 38 30 8 27 23 13 13 0 1	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9	Risk 43 60 115 152 472 170 158 246 267
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma	Deaths 113 67 45 30 15 22 21 20 18 17 17	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0	9 Risk 29 99 64 93 197 232 208 155 210 282 208 128	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	Deaths 70 59 38 30 8 27 23 13 13 0 0 1 12	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9	Risk 43 60 115 152 472 170 158 246 267 - 1752 312
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach	Deaths 113 67 45 30 15 22 21 20 18 17	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 3.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0	9 Risk 29 99 64 93 197 232 208 155 210 282 208	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary	Deaths 70 59 38 30 8 27 23 13 13 0 1	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6	Risk 43 60 115 152 472 170 158 246 267 - 1752 312
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS	Deaths 113 67 45 30 15 22 21 20 18 17 17 15	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 0 - 0.4	9 Risk 29 99 64 93 197 232 208 155 210 282 208 128 188	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.4 0.3 3.1 2.9	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3	Risk 43 60 115 472 170 158 246 267 - 1754 314 398 426
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia	Deaths 113 67 45 30 15 22 21 20 18 17 17 15	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 3.5 3.1	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 *	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 3.4 2.9	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6	Risk 43 60 115 152 47 177 155 246 267 - 175 314 398 426 242
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia	Deaths 113 67 45 30 15 22 21 20 18 17 17 17 15 1	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 3.1 0.2 0.8	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 0 - 0.4 0.0-2.2	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 *	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.9	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3	Risk 43 60 115 152 47 ² 170 155 246 267 - 175 ² 314 398 426 242 813
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	Deaths 113 67 45 30 15 22 21 18 17 17 17 15 1 4	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 3.1 0.2 0.8	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 0 - 0.4 0.0-2.2	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 *	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.9 2.0	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7	Risk 43 60 115 152 47 ² 170 155 246 267 - 175 ² 314 398 426 242 813
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	Deaths 113 67 45 30 15 22 21 120 18 17 17 15 1 4 10 0	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.5 3.5 3.5 3.1 0.2 0.8 2.1	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.3 4.7 3.9 0.1 1.1 2.7	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4	Risk 29 99 64 93 197 232 208 128 128 128 454 321 -	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.9 2.0	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7	Riskl 44 66 115 47-4 170 155 246 - 175-3 31-398 426 242 813
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver	Deaths 113 67 45 30 15 22 21 20 18 17 17 15 1 4 10 0 14	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 3.1 0.2 0.8 2.1 2.9	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4	Risk 29 99 64 93 197 232 208 128 128 128 454 321 - 197	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.9 2.0	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5	Risk 45 60 118 152 474 177 158 244 267 - 1754 314 328 426 247 438 15 438 - *
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney	Deaths 113 67 45 30 155 22 21 20 18 17 17 15 1 4 10 0 14 13	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.1 0.2 0.8 2.1 2.9 2.7	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.7 3.0	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 * 454 321 - 197 341	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 0 1	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.9 2.0	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5	Risl 4: 60 11! 15: 47- 17: 15: 24! 26: - 175- 31: 39: 420 24: 43:
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma	Deaths 113 67 45 30 15 22 21 20 18 17 17 17 15 1 4 10 0 14 13 13	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.1 0.2 0.8 2.1 2.9 2.7	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.7 3.0	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4	Risk 29 99 64 93 197 232 208 155 210 282 208 128 128 128 188 *	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia Nyeloid leukaemia Myeloid leukaemia	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7 0 1 6	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.9 2.0	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5	Risk 43 66 118 152 47-17 175 246 - 175-4 314 398 426 244 811 438 - *
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma NOS	Deaths 113 67 45 30 15 22 21 20 18 17 17 17 15 1 4 10 0 14 13 13	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 3.1 0.2 0.8 2.1 2.9 2.7 2.7	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.7 3.0 3.5	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4	Risk 29 99 64 93 197 232 208 155 210 282 208 128 128 128 188 * 454 321 - 197 341 182 -	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7 0 1 6 0	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3	Risl 43 60 11! 152 477 177 158 244 267 - 1755 311 438 421 438 - * * * * * * * * * * * * * * * * * *
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma	Deaths 113 67 45 30 15 22 21 18 17 17 15 1 4 10 0 14 13 13 0 1	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.1 0.2 0.8 2.1 2.9 2.7 2.7 0.2	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.7 3.0 3.5 0.3	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 * 454 321 - 197 341 182 - 1446	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Melanoma (skin)	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7 0 1 6 0 6	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3	Risil 44 66 611 152 474 177 155 246 267 314 399 426 244 438 - + 438 500 500 500 500 500 500 500 500 500 50
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	Deaths 113 67 45 30 15 22 21 18 17 17 15 1 4 10 0 14 13 13 0 1 12	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.5 3.5 3.5 3.5 2.1 0.2 0.8 2.1 2.9 2.7 2.7 0.2 2.5	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.3 4.7 3.9 0.1 1.1 2.7 3.7 3.0 3.5 0.3 3.2	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8 1.4-5.1	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 * 454 321 - 197 341 182 - 1446 208	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Melanoma (skin) Cervix Bladder & urinary tract Kidney	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7 0 1 6 0 6 6 6 5	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5	Risl 4: 66 11! 15:24 17:0 15:4 17:0 15:4 17:5 17:5 17:5 17:5 17:5 17:5 17:5 17:5
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Skin (NMSC inc. SCC/BCC) Larynx	Deaths 113 67 45 30 15 22 21 20 18 17 17 15 1 4 10 0 11 13 13 0 1 12 12 10 8	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.1 0.2 0.8 2.1 2.9 2.7 2.7 0.2 2.5 2.1 1.6	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.5 0.3 3.5 0.3 3.5 2.6 2.3	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8 1.4-5.1 1.5-5.5 0.9-4.2 0.7-3.9	Risk 29 99 64 93 197 232 208 155 210 282 208 128 128 188 * 454 321 - 197 341 182 - 1446 208 221 328 321	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Melanoma (skin) Cervix Bladder & urinary tract Kidney Myeloma	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7 0 1 6 0 6 6 5 5	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.4 2.9 2.0 2.0 0.3 1.7 1.7 1.7 1.7	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9 0.1 1.8	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3 0.2-2.7 0.2-2.8 0.3-3.3 0.2-2.7 0.1-2.8	Risil 43 66 11! 15:2 44:4 17:1 15:4 15:4 15:4 15:4 15:4 15:4 15:4 15
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Skin (NMSC inc. SCC/BCC) Larynx Pharynx	Deaths 113 67 45 30 15 22 21 20 18 17 17 17 15 1 4 10 0 14 13 0 1 12 12 10 8 7	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.1 0.2 0.8 2.1 2.9 2.7 2.7 0.2 2.5 2.5 2.1 1.6 1.4	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.5 0.3 3.5 0.3 3.2 3.5 2.6 2.3 1.8	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8 1.4-5.1 1.5-5.5 0.9-4.2 0.7-3.9 0.4-3.2	Risk 29 99 64 93 197 232 208 155 210 282 208 128 128 188 * 454 321 - 197 341 182 - 1446 208 221 328 321 387	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Melanoma (skin) Cervix Bladder & urinary tract Kidney Myeloma Stomach	Deaths 70 59 38 30 8 27 23 13 13 0 1 12 12 10 10 7 7 0 1 6 0 6 6 5 5 4	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7 1.7 1.7 1.7 1.7 1.4 1.4	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9 0.1 1.8 1.4 1.5 1.8 1.4	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3 0.2-2.7 0.2-2.8 0.3-3.3 0.2-2.7 0.1-2.8 0.0-2.6	Risl 4: 66 11! 152 47: 177 158 244 26: - 175-31: 398 426 24: 81: 438 - 988 500 65: 566: 598
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Skin (NMSC inc. SCC/BCC) Larynx Pharynx Gallbladder / bile ducts	Deaths 113 67 45 30 15 22 21 20 18 17 17 17 15 1 4 10 0 14 13 13 0 1 12 12 10 0 8 7	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 2.7 2.7 0.2 2.5 2.5 2.1 1.6 1.4 1.4	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.5 0.3 3.5 2.6 2.3 1.8 1.8	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8 1.4-5.1 1.5-5.5 0.9-4.2 0.7-3.9 0.4-3.2 0.5-3.2	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 * 454 321 - 197 341 182 - 1446 208 221 328 321 387 367	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloid leukaemia Cervix Bladder & urinary tract Kidney Myeloma Stomach Myelodysplastic diseases	Deaths 70 59 38 30 8 27 23 13 13 10 11 12 12 10 10 10 6 6 6 6 5 5 4 4	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7 1.7 1.7 1.7 1.7 1.4 1.1	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9 0.1 1.8 1.4 1.5 1.8 1.4 1.5 1.8	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3 0.2-2.7 0.1-2.8 0.3-3.3 0.2-2.7 0.1-2.8 0.0-1.2	Risk 43 66 118 152 474 177 158 248 267 - 1754 314 388 500 400 652 5665 598 *
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma Lymphoma NHL Brain Skin (NMSC inc. SCC/BCC) Larynx Pharynx Gallbladder / bile ducts Tongue	Deaths 113 67 45 30 15 22 21 10 18 17 17 17 15 1 4 10 0 14 13 13 0 1 12 12 10 8 7 7 6	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 2.1 2.9 2.7 2.7 0.2 2.5 2.5 2.1 1.6 1.4 1.2	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.3 4.7 3.9 0.1 1.1 2.7 3.5 2.6 2.3 5.5 2.6 2.3 1.8 1.7	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8 1.4-5.1 1.5-5.5 0.9-4.2 0.7-3.9 0.4-3.2 0.5-3.2 0.3-3.0	Risk 29 99 64 93 197 232 208 155 210 282 208 128 * 454 321 - 197 341 182 - 1446 208 221 328 321 387 367 508	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Cervix Bladder & urinary tract Kidney Myeloma Stomach Myelodysplastic diseases Liver	Deaths 70 59 38 30 8 27 23 13 13 10 11 12 10 10 7 7 0 1 6 6 6 6 5 5 4 4 3	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7 1.7 1.7 1.7 1.4 1.4 1.1	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.8 3.4 0.3 3.1 1.5 1.9 0.1 1.8 1.4 1.5 1.8 1.4 1.5 1.8 0.8	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3 0.2-2.7 0.2-2.8 0.3-3.3 0.2-2.7 0.1-2.8 0.0-1.2 0 - 1.7	Risk 434 60 1152 474 1770 1552 246 2677 - 1754 314 398 4262 242 813 438 - * * * * * * * * * * * * * * * * * *
All cancer deaths WA Country - all Males Lung Prostate Colorectal Colon Rectum Bladder & urinary tract Pancreas Melanoma (skin) Unknown primary Oesophagus Stomach Mesothelioma Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Kidney Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Skin (NMSC inc. SCC/BCC) Larynx Pharynx Gallbladder / bile ducts	Deaths 113 67 45 30 15 22 21 20 18 17 17 17 15 1 4 10 0 14 13 13 0 1 12 12 10 0 8 7	% 23.3 13.8 9.3 6.2 3.1 4.5 4.3 4.1 3.7 3.5 3.5 3.5 2.7 2.7 0.2 2.5 2.5 2.1 1.6 1.4 1.4	ASR 28.1 15.0 11.4 7.5 3.8 5.4 5.1 4.9 4.4 3.6 4.3 4.7 3.9 0.1 1.1 2.7 3.5 0.3 3.5 2.6 2.3 1.8 1.8	95%c.i. 22.8-33.4 11.3-18.6 8.0-14.8 4.8-10.3 1.8-5.8 3.1-7.7 2.8-7.3 2.7-7.1 2.3-6.5 1.8-5.4 2.3-6.4 2.5-7.0 1.9-6.0 0 - 0.4 0.0-2.2 1.0-4.4 1.7-5.6 1.3-4.7 1.6-5.4 0 - 0.8 1.4-5.1 1.5-5.5 0.9-4.2 0.7-3.9 0.4-3.2 0.5-3.2	Risk 29 99 64 93 197 232 208 155 210 282 208 128 188 * 454 321 - 197 341 182 - 1446 208 221 328 321 387 367	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Brain Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Ovary Gallbladder / bile ducts Uterus Oesophagus Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloid leukaemia Cervix Bladder & urinary tract Kidney Myeloma Stomach Myelodysplastic diseases	Deaths 70 59 38 30 8 27 23 13 13 10 11 12 12 10 10 10 6 6 6 6 5 5 4 4	% 20.1 17.0 10.9 8.6 2.3 7.8 6.6 3.7 0.3 3.4 2.9 2.0 2.0 0.3 1.7 1.7 1.7 1.7 1.7 1.4 1.1	ASR 18.5 15.7 9.5 7.2 2.3 6.2 5.3 3.4 0.3 3.1 2.9 2.0 3.1 1.5 1.9 0.1 1.8 1.4 1.5 1.8 1.4 1.5 1.8	95%c.i. 14.0-23.1 11.5-20.0 6.2-12.8 4.4-10.0 0.6-4.0 3.7-8.7 3.0-7.6 1.6-5.9 1.5-5.4 0 - 1.0 1.2-4.9 1.1-4.6 0.7-3.3 1.1-5.0 0.3-2.7 0.3-3.5 0 - 0.4 0.2-3.3 0.2-2.7 0.1-2.8 0.3-3.3 0.2-2.7 0.1-2.8 0.0-1.2	438 - 989 503 403 652 562 598

/lales	_				_	Females	_				
Lucia	Deaths	%	ASR	95%c.i.	Risk	Loren	Deaths	%	ASR	95%c.i.	R
Lung	167	20.3	23.0	19.4-26.6	38	Lung	129	18.4	15.4	12.6-18.3	
Colorectal	96 50	11.7	13.2	10.5-15.9	71	Breast	100 89	14.2	13.6	10.8-16.5 7.8-12.4	
Colon Rectum	58 38	7.1 4.6	7.4 5.8	5.4-9.4 3.9-7.7	146 138	Colorectal Colon	66	12.7 9.4	10.1 7.4	7.8-12.4 5.4-9.3	
Prostate	95	11.6	11.2	8.9-13.6	123	Rectum	23	3.3	2.7	1.5-4.0	
Melanoma (skin)	40	4.9	5.5	3.7-7.4	189	Unknown primary	40	5.7	3.9	2.5-5.3	
Bladder & urinary tract	39	4.8	5.0	3.3-6.6	212	Pancreas	31	4.4	3.6	2.2-4.9	
Stomach	35	4.3	4.6	3.0-6.1	262	Brain	26	3.7	3.6	2.2-5.0	
Pancreas	33	4.0	4.6	3.0-6.2	182	Leukaemia	25	3.6	2.9	1.7-4.1	
Jnknown primary	33	4.0	4.2	2.7-5.7	258	Leukaemia NOS	2	0.3	0.2	0 - 0.5	2
_ymphoma	30	3.7	4.0	2.5-5.5	259	Lymphoid leukaemia	7	1.0	0.6	0.1-1.2	2
Lymphoma NOS	1	0.1	0.2	0 - 0.5	6051	Myeloid leukaemia	16	2.3	2.1	1.0-3.1	•
Hodgkin lymphoma	1	0.1	0.2	0 - 0.5	7170	Leukaemia, other	0	2.0			
NHL	28	3.4	3.7	2.3-5.1	281	Ovary	23	3.3	3.3	1.8-4.7	
Mesothelioma	29	3.5	4.1	2.6-5.7	216	Lymphoma	23	3.3	2.1	1.1-3.1	
_eukaemia	26	3.2	3.8	2.3-5.3	235	Lymphoma NOS	2	0.3	0.1	0 - 0.3	
Leukaemia NOS	1	0.1	0.2	0 - 0.5	2458	Hodgkin lymphoma	1	0.1	0.2	0 - 0.7	(
Lymphoid leukaemia	7	0.9	1.1	0.2-2.0	934	NHL	20	2.8	1.8	0.9-2.6	
Myeloid leukaemia	18	2.2	2.5	1.3-3.7	360	Melanoma (skin)	19	2.7	2.6	1.3-3.8	
Leukaemia, other	0			1.0 0.7	-	Bladder & urinary tract	18	2.6	1.3	0.7-1.9	
Desophagus	25	3.0	3.5	2.1-5.0	249	Stomach	16	2.3	1.4	0.6-2.2	•
Brain	24	2.9	3.8	2.1-5.0	244	Myeloma	16	2.3	1.7	0.7-2.6	
iver	21	2.6	3.4	1.8-4.9	242	Liver	14	2.0	1.4	0.6-2.2	
Myeloma	19	2.3	2.6	1.4-3.8	320	Gallbladder / bile ducts	13	1.9	1.6	0.7-2.6	
Gallbladder / bile ducts	18	2.2	2.3	1.2-3.4	434	Skin (NMSC inc. SCC/BCC)	13	1.9	1.1	0.4-1.8	
Kidney	15	1.8	1.9	0.9-2.9	684	Kidney	13	1.9	1.4	0.5-2.2	
Skin (NMSC inc. SCC/BCC)		1.6	1.7	0.8-2.7	593	Cervix	12	1.7	1.8	0.7-2.8	
_arynx	9	1.1	1.4	0.5-2.7	583	Oesophagus	10	1.4	1.0	0.7-2.8	
ip, gum & mouth	7	0.9	1.0	0.2-1.8	769	Uterus	10	1.4	1.3	0.4-2.2	
⊒ip, guiπ α πουιπ			0.8	0.2-1.6	1229		10	1.4	0.7	0.4-2.2	;
Avalodvenlastic diseases	7										•
all cancer deaths	7 821	100.0	111.2	103-119	9	Myelodysplastic diseases All cancer deaths Females	702	100.0	82.4	75.7-89.0	
outh Metro AHS lales	821 Deaths	100.0	111.2 ASR	103-119 95%c.i.	9 Risk	All cancer deaths Females	702 Deaths	100.0	82.4 ASR	75.7-89.0 95%c.i.	
All cancer deaths South Metro AHS lales	821 Deaths 202	100.0 % 23.8	111.2 ASR 28.9	95%c.i. 24.7-33.0	9 Risk 30	All cancer deaths Females Lung	702 Deaths 121	100.0 % 18.5	82.4 ASR 15.6	75.7-89.0 95%c.i. 12.6-18.6	
South Metro AHS lales	821 Deaths 202 93	100.0 % 23.8 11.0	111.2 ASR 28.9 11.3	95%c.i. 24.7-33.0 8.9-13.7	9 Risk 30 120	All cancer deaths Females Lung Breast	702 Deaths 121 89	100.0 % 18.5 13.6	ASR 15.6 12.6	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5	
South Metro AHS lales	821 Deaths 202 93 87	% 23.8 11.0 10.2	ASR 28.9 11.3 12.3	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0	9 Risk 30 120 84	All cancer deaths Females Lung Breast Colorectal	702 Deaths 121 89 82	% 18.5 13.6 12.5	ASR 15.6 12.6 10.6	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1	
All cancer deaths South Metro AHS lales Lung Prostate Colorectal Colon	821 Deaths 202 93 87 58	% 23.8 11.0 10.2 6.8	ASR 28.9 11.3 12.3 8.3	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5	9 Risk 30 120 84 130	All cancer deaths Females Lung Breast Colorectal Colon	702 Deaths 121 89 82 58	% 18.5 13.6 12.5 8.9	ASR 15.6 12.6 10.6 7.3	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4	
All cancer deaths South Metro AHS lales Lung Prostate Colorectal Colon Rectum	821 Deaths 202 93 87 58 29	% 23.8 11.0 10.2 6.8 3.4	ASR 28.9 11.3 12.3 8.3 4.0	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6	Risk 30 120 84 130 236	All cancer deaths Females Lung Breast Colorectal Colon Rectum	702 Deaths 121 89 82 58 24	100.0 % 18.5 13.6 12.5 8.9 3.7	ASR 15.6 12.6 10.6 7.3 3.2	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6	
All cancer deaths South Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas	821 Deaths 202 93 87 58 29 38	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5	ASR 28.9 11.3 12.3 8.3 4.0 5.8	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6	9 Risk 30 120 84 130 236 146	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas	702 Deaths 121 89 82 58 24 54	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3	ASR 15.6 12.6 10.6 7.3 3.2 6.2	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1	
couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jnknown primary	821 Deaths 202 93 87 58 29 38 37	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.8	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4	Risk 30 120 84 130 236 146 239	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary	702 Deaths 121 89 82 58 24 54 31	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3	95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Unknown primary Mesothelioma	821 Deaths 202 93 87 58 29 38 37 33	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.8 4.9	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7	Risk 30 120 84 130 236 146 239 180	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary	702 Deaths 121 89 82 58 24 54 31 28	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus	Deaths 202 93 87 58 29 38 37 33 31	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.8 4.9	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1	Risk 30 120 84 130 236 146 239 180 207	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma	702 Deaths 121 89 82 58 24 54 31 28 27	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Junknown primary Mesothelioma Desophagus Stomach	Deaths 202 93 87 58 29 38 37 33 31 29	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8	Risk 30 120 84 130 236 146 239 180 207 224	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS	702 Deaths 121 89 82 58 24 54 31 28 27	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Junknown primary Mesothelioma Desophagus Stomach Melanoma (skin)	Deaths 202 93 87 58 29 38 37 33 31 29 29	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.4 3.9	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9	9 Risk 30 120 84 130 236 146 239 180 207 224 223	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma	702 Deaths 121 89 82 58 24 54 31 28 27 1	% 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6	
couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin)	Deaths 202 93 87 58 29 38 37 33 31 29 29 27	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8	9 Risk 30 120 84 130 236 146 239 180 207 224 223 245	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	702 Deaths 121 89 82 58 24 54 31 28 27 1 2	% 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3 3.7	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS	Deaths 202 93 87 58 29 38 37 33 31 29 27 0	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.4 3.9	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9	Risk 30 120 84 130 236 146 239 180 207 224 223 245	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin)	702 Deaths 121 89 82 58 24 27 1 2 24 23	% 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4	95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma Lymphoma Lymphoma Lymphoma	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3	Risk 30 120 84 130 236 146 239 180 207 224 223 245 -	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 2 44 23 23	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 3.5	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0	
Couth Metro AHS dales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 16	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 3.5 2.4	ASR 15.6 12.6 10.6 7.3 3.2 6.2 2.7 0.1 0.2 2.4 3.4 3.4 2.0	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0	
All cancer deaths South Metro AHS Itales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney	Deaths 202 93 87 58 29 38 37 33 31 29 27 0 0 27 26	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 31 16 16	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 3.5	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4	95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0	
All cancer deaths South Metro AHS Itales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract	821 Deaths 202 93 87 58 29 38 37 33 31 29 27 0 0 27 26 25	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.8 3.6	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1	9 Risk 30 120 84 130 236 146 239 180 207 224 223 245 245 277 261	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 23 166 0	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4	ASR 15.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7	
All cancer deaths South Metro AHS Iales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver	Deaths 202 93 87 58 29 38 37 33 31 29 27 0 0 27 26 25 24	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9 2.8	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.8 3.8 3.6 3.4	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 23 166 0 5	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 3.5 2.4 2.4	ASR 15.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6	
Couth Metro AHS Islates Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Gidney Bladder & urinary tract Liver Leukaemia	Deaths 202 93 87 58 29 38 37 33 31 29 27 0 0 27 26 25 24 24	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.8 3.6	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1	9 Risk 30 120 84 130 236 146 239 180 207 224 223 245 245 277 261	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 23 16 16 0 5	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4	ASR 15.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7	
Couth Metro AHS clales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 0	% 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.1 2.9 2.8 2.8	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.8 3.8 3.8 3.4 3.4 3.4	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 -	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 2 44 23 3 16 16 0 5 5 11	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liever Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6	% 23.8 11.0 10.2 6.8 3.4 4.5 5 4.4 3.9 3.7 3.4 3.2 3.1 2.9 2.8 2.8 0.7	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 0.8	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Myeloma	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 16 16 0 5 11 0 15	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1	
All cancer deaths South Metro AHS Itales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia Leukaemia Myeloid leukaemia Myeloid leukaemia	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6 18	% 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.1 2.9 2.8 2.8	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.8 3.8 3.8 3.4 3.4 3.4	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9	Risk 30 120 84 130 236 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 16 16 0 5 11 0 15	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 2.0	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6	
Couth Metro AHS lales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6 18	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.1 2.9 2.8 2.8 0.7 2.1	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9 2.0-4.9	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 -	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 316 16 0 5 11 0 15 14	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8	ASR 15.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 1.6 1.4	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2	
All cancer deaths Gouth Metro AHS Iales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Skin (NMSC inc. SCC/BCC)	Deaths 202 93 87 58 29 38 37 33 31 29 27 0 0 27 26 25 24 24 0 6 18 0 21	3.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9 2.8 0.7 2.1	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2	Risk 30 120 84 130 236 146 239 180 207 224 5 - 245 277 261 318 368 - 1180 534 - 381	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus Cervix	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 23 16 0 5 11 0 15 14 12 12	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8	82.4 ASR 15.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 1.6 1.4 2.1	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4	
All cancer deaths Gouth Metro AHS Iales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL (idiney) Bladder & urinary tract Liver Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Skin (NMSC inc. SCC/BCC) Brain	Deaths 202 93 87 58 29 38 37 33 31 29 27 0 0 27 26 25 24 0 6 18 0 0 21 20	3.2 3.2 3.2 3.2 3.1 2.8 2.8 0.7 2.1 2.5 2.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9 3.3	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2 1.8-4.8	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 - 381 244	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus Cervix Uterus	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 23 16 16 0 5 11 0 15 14 12 12 12	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8	ASR 15.6 12.6 10.6 7.3 3.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 2.0 1.6 1.4 2.1	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2 0.9-3.3 0.5-2.2	
All cancer deaths Gouth Metro AHS Itales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloma Myeloma	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6 18 0 21 20 20	3.2 3.2 3.1 2.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 2.8 0.7 2.1 2.5 2.4 2.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9 3.3 3.1	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2 1.8-4.8 1.7-4.5	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 - 381 244 265	All cancer deaths Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus Cervix Uterus Kidney	702 Deaths 121 89 82 58 24 54 54 128 27 1 2 24 23 16 16 0 5 11 0 15 14 12 12 12 12	100.0 % 18.5 13.6 12.5 8.9 3.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8 1.8	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 1.6 1.4 1.4 1.6	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2 0.9-3.3 0.5-2.2 0.6-2.6	
All cancer deaths South Metro AHS Males Lung Prostate Colorectal Colon Rectum Pancreas Unknown primary Mesothelioma Oesophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Skin (NMSC inc. SCC/BCC) Brain Myeloma Gallbladder / bile ducts	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 0 6 18 0 21 20 20 12	3.2 3.2 3.1 2.9 2.8 0.7 2.1 2.5 2.4 2.4 1.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9 3.3 3.1 1.9	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2 1.8-4.8 1.7-4.5 0.8-3.0	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 - 381 244 265 353	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus Cervix Uterus Kidney Gallbladder / bile ducts	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 16 16 0 5 11 0 15 14 12 12 12 12 11	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3 3.5 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8 1.8 1.7	ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.3 0.3 2.0 2.3 0.3 2.0 1.6 1.4 1.6 1.4	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2 0.9-3.3 0.5-2.2 0.6-2.6 0.5-2.3	
All cancer deaths South Metro AHS Males Lung Prostate Colorectal Colon Rectum Pancreas Unknown primary Mesothelioma Oesophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liever Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Skin (NMSC inc. SCC/BCC) Brain Myeloma Gallbladder / bile ducts Myelodysplastic diseases	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6 18 0 21 20 20 12 12	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9 2.8 0.7 2.1 2.5 2.4 2.4 1.4 1.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9 3.3 3.1 1.9 1.3	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2 1.8-4.8 1.7-4.5 0.8-3.0 0.5-2.0	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 - 381 244 265 353 1374	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus Cervix Uterus Kidney Gallbladder / bile ducts Liver	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 316 16 0 5 11 0 15 14 12 12 12 11 7	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8 1.8 1.8 1.7 1.1	82.4 ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 1.6 1.4 1.6 1.4 1.0	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2 0.9-3.3 0.5-2.2 0.6-2.6 0.5-2.3 0.2-1.9	
Rectum Pancreas Unknown primary Mesothelioma Oesophagus Stomach Melanoma (skin) Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liver Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Skin (NMSC inc. SCC/BCC) Brain Myelodader / bile ducts Myelodysplastic diseases Pharynx	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6 18 0 21 20 20 12	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9 2.8 2.8 0.7 2.1 2.5 2.4 1.4 1.4 1.1	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9 3.3 3.1 1.9 1.3 1.5	95%c.i. 24,7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2 1.8-4.8 1.7-4.5 0.8-3.0 0.5-2.0 0.5-2.6	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 - 381 244 265 353 1374 472	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloma Bladder & urinary tract Oesophagus Cervix Uterus Kidney Gallbladder / bile ducts Liver Peritoneum/retro-p.	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 16 16 0 5 11 1 12 12 12 12 11 7 6	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3 3.7 3.5 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8 1.8 1.8 1.7 1.1 0.9	82.4 ASR 15.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 2.0 1.6 1.4 1.4 1.6 0.8	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2 0.9-3.3 0.5-2.2 0.6-2.6 0.5-2.3 0.2-1.9 0.1-1.6	2
All cancer deaths South Metro AHS Itales Lung Prostate Colorectal Colon Rectum Pancreas Jinknown primary Mesothelioma Desophagus Stomach Melanoma (skin) Lymphoma Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Kidney Bladder & urinary tract Liever Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Skin (NMSC inc. SCC/BCC) Brain Myeloma Gallbladder / bile ducts Myelodysplastic diseases	Deaths 202 93 87 58 29 38 37 33 31 29 29 27 0 0 27 26 25 24 24 0 6 18 0 21 20 20 12 12	100.0 % 23.8 11.0 10.2 6.8 3.4 4.5 4.4 3.9 3.7 3.4 3.2 3.2 3.1 2.9 2.8 0.7 2.1 2.5 2.4 2.4 1.4 1.4	ASR 28.9 11.3 12.3 8.3 4.0 5.8 4.9 4.5 4.2 4.2 3.8 3.6 3.4 3.4 0.8 2.6 2.9 3.3 3.1 1.9 1.3	95%c.i. 24.7-33.0 8.9-13.7 9.6-15.0 6.0-10.5 2.5-5.6 3.9-7.6 3.2-6.4 3.2-6.7 2.8-6.1 2.6-5.8 2.6-5.9 2.3-5.3 2.1-5.1 2.0-4.9 0.1-1.5 1.3-3.9 1.6-4.2 1.8-4.8 1.7-4.5 0.8-3.0 0.5-2.0	Risk 30 120 84 130 236 146 239 180 207 224 223 245 - 245 277 261 318 368 - 1180 534 - 381 244 265 353 1374	Females Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Melanoma (skin) Brain Stomach Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Myeloid leukaemia Myeloid leukaemia Leukaemia, other Myeloma Bladder & urinary tract Oesophagus Cervix Uterus Kidney Gallbladder / bile ducts Liver	702 Deaths 121 89 82 58 24 54 31 28 27 1 2 24 23 316 16 0 5 11 0 15 14 12 12 12 11 7	100.0 % 18.5 13.6 12.5 8.9 3.7 8.3 4.7 4.3 4.1 0.2 0.3 3.7 3.5 2.4 2.4 0.8 1.7 2.3 2.1 1.8 1.8 1.8 1.8 1.7 1.1	82.4 ASR 15.6 12.6 10.6 7.3 3.2 6.2 3.3 4.2 2.7 0.1 0.2 2.4 3.4 2.0 2.3 0.3 2.0 1.6 1.4 1.6 1.4 1.0	75.7-89.0 95%c.i. 12.6-18.6 9.8-15.5 8.0-13.1 5.3-9.4 1.8-4.6 4.4-8.1 2.0-4.7 2.5-5.8 1.6-3.9 0 - 0.2 0 - 0.6 1.3-3.5 1.9-4.9 1.8-5.0 0.9-3.0 1.0-3.7 0.0-0.6 0.7-3.4 0.9-3.1 0.7-2.6 0.5-2.2 0.9-3.3 0.5-2.2 0.6-2.6 0.5-2.3 0.2-1.9	

Males	Deste	0/	400	050/ - 1	D'-I	Females	Death	0/	400	050/ - 1	Dist
Luna	Deaths	%	ASR	95%c.i.	Risk	Lung	Deaths	% 10.4	ASR	95%c.i.	Risk
Lung Prostate	369 188	22.1 11.3	25.9 11.3	23.1-28.6 9.6-13.0	33 121	Lung Breast	250 189	18.4 13.9	15.5 13.2	13.4-17.6 11.2-15.2	56 68
Colorectal	183	11.0	12.8	10.8-14.7	77	Colorectal	171	12.6	10.3	8.6-12.0	85
Colon	116	6.9	7.8	6.3-9.3	138	Colon	124	9.1	7.3	5.9-8.7	127
Rectum	67	4.0	5.0	3.7-6.2	173	Rectum	47	3.5	3.0	2.0-3.9	256
Pancreas	71	4.3	5.1	3.9-6.4	163	Pancreas	85	6.3	4.8	3.7-6.0	192
Unknown primary	70	4.2	4.5	3.4-5.6	248	Unknown primary	71	5.2	3.6	2.7-4.6	312
Melanoma (skin)	69	4.1	4.9	3.7-6.1	204	Ovary	51	3.8	3.7	2.6-4.8	232
Stomach	64	3.8	4.4	3.3-5.5	241	Lymphoma	50	3.7	2.4	1.7-3.2	526
Bladder & urinary tract	64	3.8	4.3	3.2-5.4	234	Lymphoma NOS	3	0.2	0.1	0 - 0.2	*
Mesothelioma	62	3.7	4.5	3.3-5.7	197	Hodgkin lymphoma	3	0.2	0.2	0 - 0.6	3741
Lymphoma	57	3.4	3.9	2.9-5.0	251	NHL	44	3.2	2.1	1.4-2.8	612
Lymphoma NOS	1	0.1	0.1	0 - 0.3	*	Brain	49	3.6	3.5	2.4-4.5	219
Hodgkin lymphoma	1	0.1	0.1	0 - 0.3	*	Melanoma (skin)	42	3.1	2.9	2.0-3.9	305
NHL	55	3.3	3.7	2.7-4.8	262	Leukaemia	41	3.0	2.6	1.7-3.5	428
Oesophagus	56	3.4	4.0	2.9-5.1	226	Leukaemia NOS	2	0.1	0.1	0 - 0.3	5317
Leukaemia	50	3.0	3.6	2.5-4.7	286	Lymphoid leukaemia	12	0.9	0.5	0.2-0.8	5033
Leukaemia NOS	1	0.1	0.1	0 - 0.2	4889	Myeloid leukaemia	27	2.0	2.0	1.2-2.9	513
Lymphoid leukaemia	13	0.8	1.0	0.4-1.5	1031	Leukaemia, other	0		. –		-
Myeloid leukaemia	36	2.2	2.6	1.7-3.4	429	Stomach	32	2.4	1.7	1.0-2.3	663
Leukaemia, other	0	_			-	Bladder & urinary tract	32	2.4	1.5	0.9-2.0	765
Liver	45	2.7	3.4	2.3-4.5	275	Myeloma	31	2.3	1.8	1.1-2.5	532
Brain	44	2.6	3.6	2.5-4.7	242	Kidney	25	1.8	1.5	0.8-2.1	578
Kidney	41	2.5	2.8	1.9-3.7	400	Gallbladder / bile ducts	24	1.8	1.5	0.9-2.2	709
Myeloma	39	2.3	2.8	1.9-3.7	292	Cervix	24	1.8	1.9	1.1-2.7	497
Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts	34	2.0	2.3	1.5-3.1	467	Oesophagus Uterus	22	1.6	1.2	0.6-1.8	788
Myelodysplastic diseases	30 19	1.8 1.1	2.1 1.0	1.3-2.9	390 1302	Liver	22 21	1.6 1.5	1.3 1.2	0.7-1.9 0.6-1.8	615 833
Lip, gum & mouth	15	0.9	1.1	0.5-1.5 0.5-1.7	625	Skin (NMSC inc. SCC/BCC)	17	1.3	0.7	0.8-1.6	2034
Pharynx	15	0.9	1.3	0.6-1.9	531	Myelodysplastic diseases	16	1.2	0.7	0.3-1.1	6510
•	13	0.5	1.5	0.0-1.3	551	, , ,	10	1.2	0.0	0.5-0.9	0310
All cancer deaths	1670	100.0	115.6	110-121	9	All cancer deaths	1356	100.0	83.3	78.4-88.1	12
All Western Australia Males											
	Deaths	%	ASR	95%c.i.	Risk	Females	Deaths	%	ASR	95%c.i.	Risk
Lung	483	22.4	26.5	24.0-28.9	32	Lung	320	18.8	16.2	14.3-18.1	53
Prostate	483 255	22.4 11.8	26.5 12.1	24.0-28.9 10.5-13.6	32 115	Lung Breast	320 248	18.8 14.6	16.2 13.7	14.3-18.1 11.8-15.5	53 66
Prostate Colorectal	483 255 228	22.4 11.8 10.6	26.5 12.1 12.5	24.0-28.9 10.5-13.6 10.8-14.2	32 115 73	Lung Breast Colorectal	320 248 209	18.8 14.6 12.3	16.2 13.7 10.1	14.3-18.1 11.8-15.5 8.6-11.6	53 66 90
Prostate Colorectal Colon	483 255 228 146	22.4 11.8 10.6 6.8	26.5 12.1 12.5 7.8	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1	32 115 73 124	Lung Breast Colorectal Colon	320 248 209 154	18.8 14.6 12.3 9.0	16.2 13.7 10.1 7.3	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6	53 66 90 131
Prostate Colorectal Colon Rectum	483 255 228 146 82	22.4 11.8 10.6 6.8 3.8	26.5 12.1 12.5 7.8 4.7	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8	32 115 73 124 178	Lung Breast Colorectal Colon Rectum	320 248 209 154 55	18.8 14.6 12.3 9.0 3.2	16.2 13.7 10.1 7.3 2.8	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6	53 66 90 131 283
Prostate Colorectal Colon Rectum Pancreas	483 255 228 146 82 92	22.4 11.8 10.6 6.8 3.8 4.3	26.5 12.1 12.5 7.8 4.7 5.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2	32 115 73 124 178 172	Lung Breast Colorectal Colon Rectum Pancreas	320 248 209 154 55 112	18.8 14.6 12.3 9.0 3.2 6.6	16.2 13.7 10.1 7.3 2.8 5.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1	53 66 90 131 283 186
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin)	483 255 228 146 82 92 89	22.4 11.8 10.6 6.8 3.8 4.3 4.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0	32 115 73 124 178 172 190	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary	320 248 209 154 55 112 94	18.8 14.6 12.3 9.0 3.2 6.6 5.5	16.2 13.7 10.1 7.3 2.8 5.1 4.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9	53 66 90 131 283 186 262
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary	483 255 228 146 82 92 89 88	22.4 11.8 10.6 6.8 3.8 4.3 4.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5	32 115 73 124 178 172 190 238	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary	320 248 209 154 55 112 94 63	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4	53 66 90 131 283 186 262 255
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin)	483 255 228 146 82 92 89	22.4 11.8 10.6 6.8 3.8 4.3 4.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0	32 115 73 124 178 172 190	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma	320 248 209 154 55 112 94	18.8 14.6 12.3 9.0 3.2 6.6 5.5	16.2 13.7 10.1 7.3 2.8 5.1 4.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9	53 66 90 131 283 186 262
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract	483 255 228 146 82 92 89 88	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5	32 115 73 124 178 172 190 238 233	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary	320 248 209 154 55 112 94 63 63	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4	53 66 90 131 283 186 262 255 435
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach	483 255 228 146 82 92 89 88 86 81	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0 3.8	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4	32 115 73 124 178 172 190 238 233 232	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS	320 248 209 154 55 112 94 63 63	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2	53 66 90 131 283 186 262 255 435
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma	483 255 228 146 82 92 89 88 86 81	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0 3.8 3.7	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4	32 115 73 124 178 172 190 238 233 232 176	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma	320 248 209 154 55 112 94 63 63 3	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6	53 66 90 131 283 186 262 255 435 *
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus	483 255 228 146 82 92 89 88 86 81 79	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8	32 115 73 124 178 172 190 238 233 232 176 237	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL	320 248 209 154 55 112 94 63 63 3 4	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 3.7 0.2 0.2 3.3	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0	53 66 90 131 283 186 262 255 435 * 2976 509
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma	483 255 228 146 82 92 89 88 86 81 79 73	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9 3.8	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8	32 115 73 124 178 172 190 238 233 232 176 237 231	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain	320 248 209 154 55 112 94 63 63 3 4 56	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5	53 66 90 131 283 186 262 255 435 * 2976 509 224
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma	483 255 228 146 82 92 89 88 86 81 79 73 70	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9 3.8 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 0 - 0.2 0 - 0.3 2.7-4.6	32 115 73 124 178 172 190 238 233 232 176 237 231	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin)	320 248 209 154 55 112 94 63 63 3 4 56 62 48	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4	53 66 90 131 283 186 262 255 435 * 2976 509 224 356
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3	32 115 73 124 178 172 190 238 233 232 176 237 231 *	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia	320 248 209 154 55 112 94 63 63 3 4 56 62 48	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 2.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 2.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia Leukaemia Lymphoid leukaemia	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.0 0.1 0.8	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5	32 115 73 124 178 190 238 233 232 176 237 231 * 4622 248 255 6335 799	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2	32 115 73 124 178 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 -
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other	483 255 228 146 82 92 89 88 86 81 79 73 1 2 67 65 2 17	22.4 11.8 10.6 6.8 4.3 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.1 0.1 0.1 0.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 0 38 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	32 115 73 124 178 172 190 238 233 232 176 237 * 4622 248 255 6335 799 397 - 252	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 83 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.6 2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	32 115 73 124 178 172 190 238 233 232 176 237 * 4622 248 255 6335 799 397 - 252 236	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 33 63 34	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 6.2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 2 17 46 0 59 56 54	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1 2.7 2.6 2.5	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 33 44 56	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.8 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma	483 255 228 146 82 89 88 86 81 79 73 70 1 2 67 52 17 46 0 59 56 54 45	22.4 11.8 10.6 6.8 3.8 4.3 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.1 0.1 0.2 2.1	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 33 33 0	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 0.1 0.1 0.1 9.0 1.9	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.3 1.1-2.3 1.1-2.5	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6491 - 641 647 534 639 463 502
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC)	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.2 2.7 2.6 2.5 2.1 2.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.5 3.6 2.8 2.5 2.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4	32 115 73 124 178 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 36 36 37 38 38 36 30 30 30 30 30 30 30 30 30 30 30 30 30	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 3.6 2.8 2.8 0.1 0.8 1.9 2.1 2.1 2.1 2.0 1.9 1.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.6 1.8 1.6 1.7 1.8	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6401 499 - 641 647 534 639 463 463 463 502 586
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts	483 255 228 146 82 92 89 88 86 81 79 73 65 2 67 65 2 17 46 0 59 56 54 44 37	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 2.7 2.6 2.5 2.1 2.0 1.7	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.6 2.5 2.4 2.0	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.4-5.4 3.5-5.6 3.0-4.8 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 36 36 37 38 38 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.2 8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.8	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.6 1.8 1.6 1.7 1.8	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.1 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1 0.8-1.8	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts Pharynx	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 44 37 22	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 2.1 2.7 2.6 2.5 2.1 2.0 1.7	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5 2.4 2.0	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7 0.8-2.0	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384 488	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus Liver	320 248 209 154 55 112 94 63 63 3 4 566 2 48 48 2 13 33 0 38 36 36 36 36 36 36 37 38 38 36 36 36 36 36 36 36 36 36 36 36 36 36	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.7 1.4	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.6 1.7 1.8 1.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1 0.8-1.8 0.6-1.6	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786 797
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts Pharynx Larynx	483 255 228 146 82 92 92 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 45 44 43 72 22	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 0.8 2.1 2.7 2.6 2.5 2.1 2.0 1.7 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.9 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 2.8 2.5 2.4 2.0 1.4	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7 0.8-2.0 0.8-1.9	32 115 73 124 178 172 190 238 233 232 176 237 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384 488 656	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus Liver Myelodysplastic diseases	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 31 32 30 30 30 30 30 30 30 30 30 30 30 30 30	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.2 8 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.7 1.4	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 2.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.6 1.8 1.6 1.7 1.8 1.5 1.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1 0.8-1.8 0.6-1.6 0.3-0.9	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 797 8264
Prostate Colorectal Colon Rectum Pancreas Melanoma (skin) Unknown primary Bladder & urinary tract Stomach Mesothelioma Oesophagus Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Liver Brain Kidney Myeloma Skin (NMSC inc. SCC/BCC) Gallbladder / bile ducts Pharynx	483 255 228 146 82 92 89 88 86 81 79 73 70 1 2 67 65 2 17 46 0 59 56 54 44 37 22	22.4 11.8 10.6 6.8 3.8 4.1 4.1 4.0 3.8 3.7 3.4 3.2 0.0 0.1 3.1 3.0 0.1 2.7 2.6 2.5 2.1 2.0 1.7 1.0 1.0	26.5 12.1 12.5 7.8 4.7 5.1 4.9 4.5 4.4 4.6 3.8 0.1 0.1 3.6 3.7 0.1 1.0 2.6 3.5 3.6 2.8 2.5 2.4 2.0	24.0-28.9 10.5-13.6 10.8-14.2 6.5-9.1 3.7-5.8 4.0-6.2 3.9-6.0 3.5-5.5 3.5-5.5 3.4-5.4 3.5-5.6 2.9-4.8 0 - 0.2 0 - 0.3 2.7-4.6 0 - 0.2 0.5-1.5 1.8-3.4 2.5-4.4 2.6-4.5 2.1-3.6 1.8-3.3 1.6-3.1 1.4-2.7 0.8-2.0	32 115 73 124 178 172 190 238 233 232 176 237 231 * 4622 248 255 6335 799 397 - 252 236 386 317 426 384 488	Lung Breast Colorectal Colon Rectum Pancreas Unknown primary Ovary Lymphoma Lymphoma NOS Hodgkin lymphoma NHL Brain Melanoma (skin) Leukaemia Leukaemia NOS Lymphoid leukaemia Myeloid leukaemia Leukaemia, other Bladder & urinary tract Stomach Myeloma Gallbladder / bile ducts Uterus Cervix Kidney Oesophagus Liver	320 248 209 154 55 112 94 63 63 3 4 56 62 48 48 2 13 33 0 38 36 36 36 36 36 37 30 29 24 20 19	18.8 14.6 12.3 9.0 3.2 6.6 5.5 3.7 0.2 0.2 3.3 6.6 2.8 0.1 0.8 1.9 2.2 2.1 2.0 1.9 1.8 1.7 1.4	16.2 13.7 10.1 7.3 2.8 5.1 4.0 3.5 2.7 0.1 0.3 3.5 2.6 2.5 0.1 0.4 2.0 1.6 1.8 1.6 1.7 1.8 1.1	14.3-18.1 11.8-15.5 8.6-11.6 6.0-8.6 2.0-3.6 4.1-6.1 3.1-4.9 2.6-4.4 1.9-3.4 0 - 0.2 0 - 0.6 1.6-3.0 2.6-4.5 1.8-3.4 1.7-3.3 0 - 0.2 0.2-0.7 1.2-2.7 1.0-2.2 1.1-2.4 1.0-2.2 1.1-2.3 1.1-2.5 0.9-2.1 0.8-1.8 0.6-1.6	53 66 90 131 283 186 262 255 435 * 2976 509 224 356 433 6593 6401 499 - 641 647 534 639 463 502 586 786 797